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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) are endemic in UK hospitals. Treatment 
options for the infections caused by these multiresistant strains include vancomycin, teicoplanin 
and linezolid. Mutational resistance to these antibiotics, although rare in the clinic, has been 
detected. Resistance to linezolid requires at least one chromosomal mutation followed by 
subsequent internal recombination. The hypothesis tested was that resistance to linezolid or 
glycopeptides could emerge in hypermutable strains and that hypermutability could be co-selected 
with resistance to linezolid or glycopeptides. Accordingly, this work studied linezolid and 
teicoplanin-resistant clinical isolates and laboratory-selected linezolid-resistant S. aureus mutants 
for evidence of hypermutability.
Mutation frequencies to a range of antibiotics were determined to evaluate the occurrence of 
hypermutability. Linezolid-resistant mutants were selected by serial passage in the presence of 
increasing concentrations of linezolid. Mutations conferring linezolid resistance were 
characterized by PCR-RFLP and sequencing. Pyrosequencing and hybridization were used to 
detect and quantify six mutations known to confer linezolid resistance.
Pre-existing hypermutability increased the ability of a laboratory strain to generate linezolid 
resistant mutants. However, few clinical linezolid or teicoplanin-resistant isolates or mutants were 
found to be hypermutable, indicating that stable hypermutability is not a prerequisite for the 
emergence of these resistances. Likewise, no laboratory-selected linezolid-resistant mutants were 
hypermutable, demonstrating the lack of co-selection of linezolid resistance with hypermutability. 
Most linezolid-resistant laboratory-selected mutants were unstable. There was a direct correlation 
between the number of mutated 23 S rRNA genes and linezolid MIC in clinical and laboratory 
mutants, although analysis was complicated by the fact that the 23 S rRNA gene copy number was 
variable among the laboratory mutants. Cross-resistance between linezolid and chloramphenicol 
was detected in some laboratory mutants.
In conclusion, there was no evidence for the co-selection of hypermutability and linezolid or 
teicoplanin resistance, and hypermutability was not found to be a prerequisite for the emergence of 
linezolid resistance.
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1.1 Staphylococcus
1.1.1 Description
Staphylococci were first described by Sir Alexander Ogsten in 1880, after he observed them in 
pus from human abscesses. He named the organisms after the Greek words for grape (staphyle) 
and berry (kokkos) due to their appearance (Figure 1). In 1884 staphylococci were isolated from a 
wound and grown for the first time in pure culture by Rosenbach (Baird-Parker, 1990).
Staphylococci are non-motile, gram-positive, catalase-positive, chemoorganotrophic, facultative 
anaerobes that are non-spore forming. Staphylococcal colony colour varies with species, ranging 
from opaque to orange (Holt, 1994). The natural habitat of staphylococci is the skin and mucous 
membranes of warm-blooded animals (Kloos, 1990). Problems associated with staphylococcal 
species arise when the natural, cutaneous barrier between bacterium and host is breached through 
trauma, surgery or indwelling surgical devices (Kloos, 1980).
In terms of classification, staphylococci belong to the Order Bacillales, Bacterial family 
Staphylococcaceae, genus Staphylococcus (http://141.150.157.80/bergeysoutline/outline/bergeys 
outline _5_2004.pdf). As of January 2006, there are 40 species and 24 sub-species within the 
genus Staphylococcus (http://www.bacterio.cict.fr/s/staphylococcus.html). The best-known and 
most clinically important of these is Staphylococcus aureus (S. aureus) (Holt, 1994). The genus 
Staphylococcus is traditionally divided into two broad categories based on the ability of some 
species to coagulate blood plasma. Coagulase-positive species, include S. aureus (principally), 
Staphylococcus intermedius and Staphylococcus delphini', coagulase-negative species (CNS) 
includes Staphylococcus epidermidis (S. epidermidis) (Kloos, 1990).
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Figure 1. Scanning electron microscopy image of S. aureus on epithelial cells. (From 
http://www.microbiology.med.umn.edu/microbiology/seminars/mmpc.html)
S-4700 1 2kV  12 0mm xlS.Ck S£(M ) S/7/03 3 OOum
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1.1.2 Delineation o f species
1.1.2.1 Phenotypic identification
The coagulase test was introduced in 1925 by Von Daranyi and is still an important tool to 
discriminate S. aureus from less pathogenic CNS species (Kloos, 1980). Commercial phenotypic 
identification systems, such as API Staph and ID 32 Staph (bioMerieux), provide identification to 
species level within 24 hours. Nevertheless, they are less than fully reliable for some more obscure 
species, such as Staphylococcus vitulinus, which are not included in the reference databases of 
these systems, possibly resulting in mis-identification (Stepanovic et al., 2005). Automated 
identification systems, such as the Vitek system (bioMerieux) and the BD (Becton-Dickinson) 
Phoenix system, are a more recent development and also perform susceptibility testing. Reports on 
the accuracy of these systems are conflicting (Heikens et al., 2005, Ligozzi et al., 2002). 
Ultimately, phenotypic characterizations are marred by the fact that they depend on the expression 
of metabolic or morphological features which may vary between strains (Becker et al., 2004). 
With the introduction of molecular techniques, genotypic identification has proved superior.
1.1.2.2 Genotypic identification
Deoxyribonucleotide genetic divergence (DNA-DNA homology) is now the ‘gold standard’ for 
the definition of new staphylococcal species and subspecies, with dissimilar species having relative 
hybridization values of less than 70% (Kloos, 1980). Nevertheless, this method is lengthy and 
more rapid methods have been introduced. Amplification and partial sequencing of gene targets 
has been assessed as a technique for staphylococcal species identification. Within a genus, highly- 
conserved regions of an essential gene are amplified, followed by partial DNA sequencing 
(Heikens et al., 2005). In the search for a suitable molecular target, a variety of genes have been 
assessed, e.g., 16S rRNA (ribosomal ribonucleic acid) (Heikens et al., 2005), superoxidase 
dismutase A (sodA) (Poyart et al., 2001), RNA polymerase B (rpoB) (Drancourt and Raoult, 2002), 
elongation factor Tu (tuf) (Martineau et a l, 2001) and heatshock protein 60 (hsp60) (Kwok et al.,
1999). In a comparison of these techniques, Mellman et al., (2006) found that using rpoB as a
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molecular target provided the greatest differentiation between species, enabling successful 
identification of 38 staphylococcal species and subspecies. Similarly, Khamis et al., (2005) found 
partial rpoB sequencing a simple and efficient means of identifying species of Corynebacterium. 
However, the drawback to using rpoB as a target gene is the generally poor availability of 
published sequences, as compared with 16S rRNA (Mellmann et al., 2006).
Ribotyping is a technique that allows subtype differentiation beyond species and subspecies level. 
It is utilised for both species identification and also as an epidemiological tool for strain typing. A 
fingerprint, based on a restriction pattern, is produced by hybridizing digested chromosomal DNA 
with a complementary DNA (cDNA) probe derived from rRNA. Differences within rRNA genes 
and their flanking regions result in fingerprint variations. Izard et al., (1992) found ribotyping of 
little use for differentiating strains of coagulase-negative staphylococci and concluded that 
similarities in ribotypes between species interfered with interspecies variation. In this instance, the 
epidemiological value of ribotyping outweighs its capacity as a taxonomic tool.
PCR (polymerase chain reaction) -amplified tDNA (transfer DNA) intergenic spacer length 
polymorphism (tDNA-ILP) was evaluated as a tool for species identification by Welsh et al., 
(1992). Conserved tDNA genes are used as a basis for designing genus-specific primers to amplify 
variable spacer regions. The resulting PCR products are species-specific in size. Maes et al., 
(1997) used tDNA-ILP to identify, successfully, 15 staphylococcal species with 99% accuracy, 
whilst Welsh et al., (1992) proposed that intergenic spacer regions between 16S and 23S or 23S 
and 5S rRNA genes could also be used as a means of identifying staphylococci to species level, a 
technique Mendoza et al., (1998) and Couto et al., (2001) found to be successful. To enable 
greater discrimination between species it is possible to use restriction fragment length 
polymorphism (RFLP) analysis of the intergenic 16-23S rRNA PCR product (Mendoza et al., 
1998, Sudagidan et al., 2005). A comparison of DNA-ILP identification techniques revealed both 
tDNA-ILP and 16-23S rRNA-ILP RFLP to be potentially important techniques for quick and 
precise staphylococcal species identification (Lee and Park, 2001). However, the lack of variation 
within species means the identification of subspecies is difficult (Mendoza et al., 1998).
PCR still remains the quickest and most economical technique for identification of the most 
common staphylococcal species. Gribaldo et al., (1997) designed a PCR assay, based on three
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variable regions in the 16S rRNA gene, to identify eight common staphylococcal species. More 
recently, Sabat et al., (2004) described a single-tube multiplex-PCR for the discrimination of 
eleven Staphylococcus species, based on the amplification of regions of genes encoding 
metalloproteinases from the thermolysin family, the results of which were in agreement with partial 
sequencing of 16S rRNA and rpoB.
1.1.3 Clinical role o f staphylococci
Staphylococci, particularly S. aureus, are common causes of bloodstream and other infections in 
hospitalised patients. CNS live naturally on the skin and mucous membranes of humans and are 
therefore often found in clinical specimens (O'Gara and Humphreys, 2001, von Eiff et al., 2001). 
Distinguishing clinically significant, pathogenic CNS from contaminants is therefore difficult and it 
is often thought that the isolation of CNS species from blood samples is due to contamination when 
the specimen is taken (O'Gara and Humphreys, 2001, von Eiff et al., 2002). Nevertheless, CNS are 
by far the most common causes of bacteraemia related to indwelling devices (Huebner and 
Goldmann, 1999).
Outbreaks of both S. aureus and CNS infections in hospitals are often the result of nosocomial 
transmission of clones, which are often multi-resistant (see section 1.2) (Boyce et al., 1993, 
Huebner and Goldmann, 1999). To distinguish these clones from sporadic isolates, molecular 
epidemiological typing techniques are required (Aber and Mackel, 1981). These techniques rely on 
the fact that epidemiologically-related isolates, being descendants of a common ancestor, have 
relatively similar genomic fingerprints (Maslow et al., 1993, Shopsin and Kreiswirth, 2001). As a 
result of typing, measures can be put into place to interrupt and control strain transmission (Weller,
2000). In the face of increasing MRSA bacteraemia rates, political pressure and media interest, 
typing techniques have become more important than ever in the battle to control the spread of 
MRSA.
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1.1.4 Methods for typing staphylococci
Typing systems need to be broadly applicable, reproducible, discriminatory, based on a stable 
property, inexpensive, readily available, standardized and field-tested (Aber and Mackel, 1981). 
Very few meet all of these criteria.
Bacterial phage typing has been the mainstay of S. aureus typing techniques for many years. The 
realization that S. aureus contained phages which could lyse some bacteria of the same species led 
to the development of a technique enabling strain discrimination based on their phage susceptibility 
(Wentworth, 1963). An agar plate, covered with the test organism, is inoculated with 23 standard 
phages and the degree of lysis produced by each phage is recorded, resulting in the production of a 
phage pattern or type (Weller, 2000, Wentworth, 1963). The procedure relies on the propagation of 
phage stocks and has low reproducibility (Weller, 2000). A further disadvantage is the non- 
typability of many strains (Weller, 2000). Bannerman et al., (1995) and Schlichting et al., (1993) 
found 32% and 30% of strains, respectively, were not typeable by phage analysis. Owing to these 
disadvantages, phage typing is being replaced by more discriminatory techniques.
Adaptation of a pulsed-field gel electrophoresis (PFGE) procedure, first utilized in yeasts, has led 
to the production of one of the most widely used strain discrimination techniques (Chu et a l, 
1986). This technique involves the interpretation of profiles that arise as a result of the macro- 
restriction of DNA with an enzyme that cuts infrequently, producing few, large DNA fragments 
(50-700 Kb) (Tenover et al., 1994). The patterns produced show distinct, well-separated fragments 
and are highly reproducible (Maslow et al., 1993). All isolates are typeable and the discriminatory 
ability of the technique is high (Tenover et al., 1997). Conversely, the technique is expensive to set 
up, technically demanding and time-consuming, with the procedure taking four days (Bannerman et 
al., 1995, Maslow et al., 1993). A further major disadvantage is the lack of standardized 
interpretative criteria (Tenover et al., 1994, Weller, 2000), although guidelines have been published 
by the National Centre for Infectious Diseases (USA) (Tenover et al., 1995) and HARMONY 
(Europe) (http://www.harmony-microbe.net/microtyping.htm). Recent advances in computer 
programming have assisted with the analysis of PFGE profiles, but inter-laboratory comparison 
still proves difficult (Cookson et al., 1996, van Belkum et al., 1998). Nevertheless, PFGE proved 
superior when compared to phage typing (Bannerman et al., 1995), capsular typing (Schlichting et
30
al., 1993), ribotyping (Prevost et al., 1992) and RAPD (Saulnier et al., 1993) and remains th e ‘gold 
standard’ for defining local outbreaks of S. aureus infection.
Recently, spa typing has been developed for S. aureus. This involves the amplification and 
subsequent sequencing of the spa gene, which encodes for protein A (Koreen et al., 2004). The 
technique relies on diversity within this gene, arising from the deletion and duplication of 24 bp 
repetitive units and point mutations (Frenay et a l, 1996). The existence of well-conserved regions 
flanking the spa gene allows amplification and sequence typing (Shopsin et al., 1999). Shopsin et 
al., (1999) and Koreen et al., (2004) evaluated spa typing and found it comparable with other 
techniques such as PFGE and RFLP typing. All isolates were typeable, interpretation is easy, the 
process is rapid and the technique allows database creation and interlaboratory reproducibility, as 
shown by Aires-de-Sousa et al., (2006). These advantages probably outweigh the fact that spa 
typing does not have the discriminatory power of PFGE when analysing subtypes (Shopsin et al., 
1999).
More recently, multilocus sequence typing (MLST) was proposed as a means for strain 
differentiation and, additionally, for determining the evolutionary history of clones (Enright et al., 
2000, Enright et al., 2002). The technique involves sequencing approximately 450 bp of each of 
seven housekeeping genes. The sequence for each gene is assigned a distinct allele number and, in 
combination, the seven alleles make up an allelic profile or sequence type (Enright et al., 2000). 
Isolates with the same sequence type are assumed to belong to the same clone (Maiden et al., 
1998). The method is highly discriminatory and the inter-laboratory exchange of sequence data is 
straightforward (Enright et al., 2000). As well as using MLST to investigate recent clonal 
outbreaks, the technology has been used in combination with SCCmec {staphylococcal cassette 
chromosome) type (see section 1.2.3) as a population tool to gain insight into the long-term 
evolutionary history of MRSA clones (Crisostomo et a l, 2001, Enright et a l, 2002).
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1.2 Antibiotic resistance in Staphylococcus aureus
1.2.1 Emergence of antibiotic resistance in S. aureus (pre-MRSA)
Long before MRSA became a problem, strains of S. aureus were already emerging as multi- 
resistant. The 1940s saw the emergence of S. aureus strains resistant to penicillin. This was 
quickly followed by resistance to tetracycline, erythromycin and streptomycin in the 1950s and 
60s. All the time these multi-resistant strains were becoming more prevalent in hospitals and, later 
on, in the community too. This section discusses the emergence of these early resistance 
mechanisms in more detail.
1.2.1.1 Penicillin resistance
Penicillin acts by inactivating the penicillin-binding proteins (PBPs) which catalyse the last steps 
in cell wall synthesis, resulting in reduced cell wall crosslinking. Penicillin was introduced into 
clinical use in the 1940s, however, resistant strains of S. aureus emerged shortly afterwards. 
Research by Kirby (1944) demonstrated that penicillin-resistant strains of S. aureus were able to 
inactivate penicillin. Further work by Bondi et al., (1945) identified that the enzyme penicillinase 
was responsible for this inactivation. It has since been elucidated that resistance to penicillin is 
mediated by the blaZ gene which encodes the P-lactamase enzyme (also referred to as 
penicillinase) (Barber and Rozwadowska-Dowzenko, 1948). The enzyme hydrolyses the (3-lactam 
ring, rendering the antibiotic inactive (Bush, 1988). The blaZ gene is usually plasmid-mediated, 
although chromosomal integration is frequent (Bush, 1989). In 1948 a survey of a UK hospital 
revealed 59% of S. aureus infections were penicillin-resistant (Barber and Rozwadowska- 
Dowzenko, 1948, Rammelkamp and Maxon, 1942). A survey conducted in the UK in 2004 
revealed 90% of S. aureus strains isolated from bacteraemias, were resistant to penicillin 
(http://www.bsacsurv.org/mrsweb /bacteraemia). It is thought that the spread of penicillin-resistant 
strains could be attributed to the horizontal transfer of plasmids encoding the P-lactamase enzyme 
by bacteriophages, or by strain dissemination (Berger-Bachi, 2002, Lowy, 2003). Fortunately, in 
the years following the emergence of penicillin-resistant strains new antibiotics were introduced,
including erythromycin, tetracycline and streptomycin which were used to combat S. aureus.
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1.2.1.2 Streptomycin
Streptomycin, introduced in 1944, was the first aminoglycoside antibiotic to be used in clinical 
practice. It targets protein synthesis and impairs the proof-reading process by binding to the 30S 
ribosomal subunit, resulting in the production of defective proteins (Mingeot-Leclercq et al., 1999). 
Subsequent incorporation of these proteins into the cell wall results in altered permeability and 
enables increased access of the antibiotic to the cell (Busse et al., 1992). In 1948 resistance to 
streptomycin was selected in vitro by passaging S. aureus strains in the presence of increasing drug 
concentrations and, by 1951, resistance had emerged in clinical isolates of penicillin-resistant S. 
aureus in Australia (Demerec, 1948, Rountree and Barbour, 1951). The mechanism of resistance 
was proposed to be via an antibiotic modifying nucleotidyltransferase (ANT) enzyme (also known 
as adenylyltransferase (AAD) enzyme), which impairs the binding of the drug to the ribosome by 
modifying the streptomycin molecule (Shaw et al., 1993, Suzuki et al., 1975). The aadE gene (also 
known as ant6 and ant(6)-Id), encoding this adenylyltransferase enzyme, has been associated with 
streptomycin resistance in staphylococci (Derbise et al., 1996, Shaw et al., 1993). An aadA gene 
(also known as aad(3 ”) (9) and ant(3 ”-Ia)) has also been found in S. aureus (Courvalin and Fiandt, 
1980, Shaw et al., 1993). The str gene, thought to encode for an antibiotic modifying 
phosphotransferase enzyme, is also associated with streptomycin resistance in staphylococci 
(Ohnuki et al., 1985, Projan et al., 1988). The fact that these resistance genes are associated with 
plasmids means rapid transfer of resistance occurs and hence the most common form of resistance 
in S. aureus seems to be via enzymatic modification of the drug. However, Lacey et al., (1972) 
proposed resistance to streptomycin in S. aureus could also be due to chromosomal mutations 
rather than enzymatic inactivation.
1.2.1.3 Chloramphenicol
Chloramphenicol was discovered in 1947 and used soon after for the treatment of infections due 
to penicillin-resistant S. aureus. It is an antibiotic that inhibits bacterial protein synthesis by 
binding to the peptidyltransferase centre of the 50S subunit of the 70S ribosome (Schwarz et al., 
2004). Preliminary work on the resistance mechanism of staphylococci to chloramphenicol
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determined that the antibiotic was inactivated in cultures of chloramphenicol-resistant 
staphylococci (Miyamura, 1964). Suzuki et al., (1966) proposed that chloramphenicol-resistant 
strains produced an enzyme, which inactivated chloramphenicol through acetylation and 
furthermore, that acetyl coenzyme A (CoA) was necessary. These findings were later confirmed by 
Kono et al., (1968) and Shaw et al., (1968). Limited evidence suggested the chloramphenicol 
acetyltransferase {cat) gene was plasmid-mediated (Shaw and Brodsky, 1968). In staphylococci, 
seven different types of cat genes have since been isolated, all of which were present on different 
plasmids (Schwarz et al., 2004). Ettayebi et al., (1985) demonstrated that resistance to 
chloramphenicol in a laboratory strain of E. coli {Escherichia coli) could occur via mutations in the 
genes encoding 23 S rRNA, although this type of resistance mechanism is rarely seen in clinical 
isolates of S. aureus. The toxic effects of chloramphenicol, such as reversible bone marrow 
suppression and aplastic anaemia, lead to low usage and in a survey carried out in 14 UK hospitals 
in the early 1970s less than 1% of strains were resistant (Lowbury and Ayliffe, 1974, Yunis, 1989).
1.2.1.4 Tetracycline
The first tetracycline to be discovered was chlortetracycline in 1947, closely followed by
oxytetracycline (Roberts, 1996). Tetracycline itself was discovered in 1948 and introduced into
clinical use in 1952 (Chopra and Roberts, 2001). It proved to be a useful antibiotic due to its low-
cost, broad spectrum and the fact that it can be taken orally (Roberts, 2003, Speer et a l, 1992).
Tetracycline is a protein synthesis inhibitor. It has been shown to bind strongly to the 30S bacterial
ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome (Epe et al., 1987,
Goldman et al., 1983). Although effective for a short while, resistance to tetracycline had emerged
by 1953, and by the late 1950s S. aureus resistant to both tetracycline and penicillin were common
(Watanabe, 1963, Williams, 1959). The mechanism of resistance to tetracycline was determined to
be as a result of the acquisition of resistance determinants rather than chromosomal mutations
(Roberts, 1996). Resistance is mediated by tet (tetracycline) or otr (oxytetracycline) genes which
encode either efflux pumps, ribosomal protection proteins or modifying enzymes (Roberts, 2003).
Thirty-eight tet and otr genes characterized were recently reviewed (Roberts, 2005).
Staphylococcus species most commonly carry tet{K) and tet{L), encoding efflux proteins that
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export tetracycline from the cytoplasm, reducing the concentration within the cell. The tet{M) and 
tet{O) genes are also commonly found in staphylococci and encode ribosomal protection proteins 
(Chopra and Roberts, 2001, Roberts, 2005). These bind to the ribosome and block the tetracycline 
binding site, causing the release of the tetracycline molecule (Roberts, 2005). Efflux genes are 
usually present on small plasmids, whereas ribosomal protection genes are often present on 
transposons, which can be integrated into the chromosome, allowing for inter- and intra-species 
spread by conjugation (Roberts, 2003). The use of tetracycline and oxytetracycline in animal and 
plant agriculture is thought to have assisted the selection and dissemination of resistance genes 
(S p eers  al., 1992).
1.2.1.5 Macrolides, lincosamides and streptogramins
The macrolides were first introduced in 1952 with the launch of erythromycin. Its lack of cross­
resistance with penicillin and the tetracyclines and its activity against gram-positive cocci meant 
erythromycin was a good antistaphylococcal antibiotic (Thabaut et al., 1985). However, due to the 
emergence of erythromycin-resistant staphylococci in the United States after extensive use, calls 
were made for the use of erythromycin in the UK to be restricted to delay the emergence of 
resistance and preserve the effectiveness of the antibiotic (Anon, 1956, Garrod, 1957, Lepper et al., 
1953). Due to this limited-use policy, resistance to erythromycin in staphylococci took slightly 
longer to emerge than originally anticipated; nevertheless it had occurred in the UK by the late 
1950s (Forfar, 1977, Garrod, 1957). Studies on the mechanism of action of erythromycin revealed 
that it targeted bacterial protein synthesis by binding to the 50S subunit of the ribosome (Vazquez, 
1966). Initially, resistance to erythromycin was thought to be via a simple mechanism, however 
the subsequent introduction of other macrolide antibiotics, spiramycin and oleandomycin, the 
lincosamide antibiotic, lincosamine, and the streptogramin antibiotics revealed unusual cross­
resistance between these groups (Weisblum and Demohn, 1969). All three of these classes of 
antibiotics, now called the MLSB (macrolide, lincosamide, streptograminB) group, share a similar 
mode of action, spectrum of activity and are affected by a common mechanism of resistance (in 
addition to mechanisms that affect one class only) (Le Goffic, 1985). This cross-resistance to
MLSb antibiotics is via erythromycin ribosomal methylation (erm) genes, which encode an enzyme
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that methylates a single residue, A2058, in the 23S rRNA, resulting in reduced binding for MLS 
antibiotics to the ribosome (Skinner et al., 1983, Weisblum, 1995a). Resistance can be constitutive 
or inducible. When resistance is inducible, the Erm protein is synthesised only in the presence of a 
stimulating macrolide, i.e., erythromycin (Fiebelkorn et al., 2003). This results in resistance to 14- 
and 15-member lactone macrolides, such as erythromycin and azithromycin which are strong 
inducers, but not to weak inducers, such as 16-member macrolides, such as spiramycin, 
lincosamides and type B streptogramins (Weisblum, 1995b). When resistance is constitutive, the 
Erm protein is synthesised constantly, resulting in resistance to all macrolides, lincosamides and 
type B streptogramins (Weisblum, 1995b). Constitutive resistance is conferred, in staphylococci, 
by the presence of mutations in the promoter region of the erm gene, allowing the production of a 
methylase without an inducer. Inducible resistance can become constitutive with the emergence of 
these mutations and with consequent resistance to 16-member macrolides and streptograminB 
antibiotics (Weisblum, 1995b). Both constitutive and inducible strains remain susceptible to type 
A streptogramins due to their binding at a different site on the ribosome (Vazquez, 1966). Erm 
genes are plasmid mediated, enabling transfer between strains and species (Engel et al., 1980).
Independent mechanisms of resistance to the MLSB antibiotics have been detected in 
staphylococci. These include the nucleotidylation gene, lnu(A), conferring resistance to 
lincosamides, the v<2/(A)(B)(C) acetyltransferase genes and the vg6(A)(B) hydrolase genes 
conferring resistance to streptogramins and lincosamides, also the msr(A) gene conferring 
resistance to macrolides and streptogramins via active efflux (Leclercq et al., 1987, Leclercq and 
Courvalin, 1991, Roberts et al., 1999, Ross et al., 1990, Woodford, 2005).
1.2.2 Emergence of MRSA
This section describes the antibiotic evolution of MRSA and how it has managed to acquire or 
generate antibiotic resistance mechanisms against nearly all classes of antibiotics. It goes on to 
discuss the origins of MRSA, their dissemination worldwide, the infections caused by MRSA and 
the treatment options currently available.
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1.2.3 Methicillin resistance in S. aureus
In the early 1960s, in an attempt to combat penicillin-resistant strains, semi-synthetic penicillin 
derivatives such as methicillin, oxacillin, cloxacillin, dicloxacillin and flucloxacillin were 
manufactured. These antibiotics are not susceptible to the activity of the staphylococcal P- 
lactamase enzyme (Rolinson, 1998). Nevertheless, the first methicillin-resistant strains were 
isolated in the UK in 1961, one year after the antibiotic had been introduced (Jevons, 1961). 
Hartman et al., (1984) discovered the presence of an extra PBP in MRSA, in addition to the three 
usually found in susceptible S. aureus. PBP-2a or -2’, as it was named, had a low affinity for 
methicillin. It was proposed that PBP-2a allowed continued cell wall synthesis in the presence of 
P-lactam antibiotics (Hartman and Tomasz, 1984). Ubukata et al., (1989) demonstrated that PBP- 
2a was encoded by the mecA gene and suggested accessory genes were involved in its induction. 
Further work by Ito et al., (1999) and Katayama et al., (2000) determined the mecA gene and its 
accessory genes were located on a staphylococcal cassette chromosome (SCCmec). SCCmec is a 
mobile genetic element which is integrated into the chromosome at a specific site, attBscc within 
orfX  (Hiramatsu et al., 2001). There are five SCC mec variants, Types I to V, which vary in size 
(21-67 Kb) and are classified according to the type of cassette chromosome recombinase gene (<ccr) 
present and the organisation of the mec complex (Hanssen and Ericson Sollid, 2006).
1.2.4 Origins of MRSA
The origins of MRSA have been much disputed. Lacey et al., (1973) proposed that MRSA 
evolved from the single acquisition of mecA, followed by clonal expansion and diversification. 
Kreisworth et al., (1993) investigated the presence of the mecA gene in 472 MRSA isolates. They 
concluded that horizontal transfer of mec A after its initial acquisition in S. aureus is rare 
(Kreiswirth et al., 1993). Musser et al., (1992), after studying 254 MRSA isolates from nine 
countries using multilocus enzyme electrophoresis, also concluded that linear descent was 
probable. Although, subsequent horizontal transfer and recombination events has enabled the 
distribution of mecA to methicillin-susceptible S. aureus strains, creating divergent clonal lineages 
(Musser and Kapur, 1992). More recently, Enright et al., (2002) analysed a collection of 359
MRSA isolates, spanning 38 years and 20 countries, using MLST and SCC mec typing to try to 
determine the origins of MRSA. They found evidence to suggest that successful methicillin- 
susceptible S. aureus (MSSA) clones have acquired the mecA gene on more than one occasion, as 
many isolates had the same sequence type yet different SCC mec types. Furthermore, they 
concluded that MRSA have not evolved from a single clone, but have evolved in relatively few 
lineages via the horizontal transfer of the mecA gene (Enright et al., 2002). Crisostomo et al., 
(2001) proposed that extensive horizontal transfer, possibly by homologous gene transfer, resulted 
in the spread of mec A. Moreover, it was suggested that the mecA gene was acquired before the first 
reported finding of MRSA in the UK (Crisostomo et al., 2001). The origin of SCCmec is not 
known as it has not been discovered in other genera, however, there is evidence that type I SCC mec 
could have been transferred from Staphylococcus haemolyticus (S. haemolyticus) (Archer et al., 
1996). Additionally, a mecA homologue has been identified in Staphylococcus sciuri (S. sciuri). 
This does not confer methicillin resistance in S. sciuri but does so when transferred into S. aureus 
(Severin et al., 2005, Wu et al., 1996).
1.2.5 Epidemic strains of MRSA
Epidemic strains of MRSA (EMRSA) were defined as those which have been identified in two or 
more patients in two or more hospitals (Marples et al, 1986). The first UK epidemic MRSA strain, 
EMRSA-1, was isolated in Essex in 1983, spreading to London in 1984 (Marples et al., 1986). A 
six month survey by Kerr et al., (1990) confirmed EMRSA-1 had spread to 50 hospitals. A further 
13 epidemic strains, EMRSA-2 to -14 were also identified, however, only EMRSA-3 and 12 
became widespread in the 1980s and early 1990s (Kerr et al., 1990). Subsequently, two further 
strains EMRSA-15 and -16 have become dominant. EMRSA-15 emerged in 1991 and is now 
widespread in most hospitals in the UK. Additionally, it has caused outbreaks in Australia, New 
Zealand, Germany, Sweden and Finland (Anon, 1992, O'Neill et al., 2001). The emergence of 
EMRSA-16, in 1992, can be traced back to a single hospital in Northamptonshire (Anon, 1993). 
By 1994 it had spread to 136 hospitals (Murchan et al., 2004). EMRSA-15 and EMRSA-16 
accounted for 96% of MRSA from cases of bacteraemia between 1998 and 2000 (Johnson et al.,
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2001). There has only been one report of a new epidemic strain since the emergence of EMRSA- 
15 and -16. Specifically, a study by Aucken et al., (2002) characterized 69 strains isolated between 
1997 and 2000 and determined the presence of an epidemic strain, designated EMRSA-17. 
However, this strain has not proved to be as successful as EMRSA-15 and -16 and remains rare.
1.2.6 Global spread of MRSA
Figures for MRSA bacteraemias are usually presented as a percentage of all S. aureus 
bacteraemias, however, this does not give an indication of the burden of disease. Alternatively, 
MRSA rates are calculated as the number of MRSA bacteraemias per 1000 bed days. This takes 
into account the size of the hospital but not whether the hospital has more vulnerable patients nor 
whether there are infection control measures in place. In the UK, the most recent figures state that 
38.9% of S. aureus from bacteraemias are due to MRSA (Johnson et al., 2005), whilst the MRSA 
incidence rate was 0.17 MRSA bacteraemias per 1000 bed days (Johnson et al., 2005). In Europe 
as a whole, the European Antimicrobial Resistance Surveillance System (EARSS) compared 
MRSA bacteraemia rates from hospitals across Europe. Results in 2004 and showed MRSA rates 
were under 10% for The Netherlands, Estonia, Sweden, Finland, Denmark, Iceland and Norway 
(Figure 2). The highest MRSA rate was seen in Bulgaria at 73%, and 11 European countries had 
MRSA rates between 25 and 50%. However, the MRSA rates per 1000 bed days for these 
countries shows a rather different picture (Table 1). Not all of the countries with a high percentage 
of bacteraemias due to MRSA have a high MRSA rate, e.g., Bulgaria. These data highlight a rough 
divide between north and south Europe, with a low incidence of MRSA in Scandinavia, when 
compared with countries like Italy. Further afield, a national survey of 17 Australian hospitals 
revealed MRSA rates are not as high as in some European countries, with 25% of all bloodstream 
infections being caused by MRSA (Collignon et al., 2005). A survey of 300 clinical microbiology 
laboratories in the USA revealed MRSA rates have continued to climb since 1998 with current 
MRSA bacteraemia rates standing at 49% of all S. aureus bacteraemias (Styers et al., 2006). Based 
on MLST data, Oliveira et al., (2002) identified five major MRSA clones, which accounted for 
70% of 3000 isolates from southern and eastern Europe, South America and the USA (Figure 3).
Figure 2. Proportion of invasive S. aureus isolates resistant to oxacillin (and equivalents) in 
2004 (EARSS data) (Luxembourg (LT), Malta (MT)). (From http://www.rivm.nl/earss 
/Images/EARSS%20annual%20report%202004%20webversie_tcm6 l-25345.pdf).
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Table 1. Incidence of MRSA bacteraemia per 1000 bed days specified per country in 2004.
(From http://www.rivm.nl/earss/Images/EARSS%20annual%20report%202004%20webversie_ 
tcmtcm61-25345.pdf)
Country Incidence of MRSA bacteraemia per 1000 bed days
Belgium 0.078
Bulgaria 0.015
Cyprus 0.079
Czech Republic 0.010
Greece 0.033
Estonia 0.003
Spain 0.060
Finland 0.008
France 0.118
Greece 0.074
Croatia 0.061
Hungary 0.013
Ireland 0.120
Israel 0.122
Iceland 0.009
Italy 0.064
Latvia 0.017
Malta 0.193
Netherlands 0.004
Norway 0.001
Poland 0.011
Portugal 0.176
Romania 0.019
Sweden 0.003
Slovenia 0.020
Slovakia 0.020
United Kingdom 0.096
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From MLST data they concluded these five pandemic clones, Iberian, Brazilian, Hungarian, New 
York/Japan and Paediatric, evolved from two genetic backgrounds. EMRSA-15 and -16 do not 
belong to any of these international clones, however, EMRSA-15 is now spreading in central 
Europe and may become an international problem. It was proposed that EMRSA-15 and -16 
evolved from another two separate lineages (Oliveira et al., 2002).
1.2.7 Infections caused by MRSA
There is no specific ‘MRSA disease’. MRSA can infect a range of tissues and organ systems and 
the range of infections it causes are not matched by any other pathogen. Infection usually begins 
with colonisation, sometimes followed by local infection, then systemic dissemination usually 
accompanied by toxinosis (Archer, 1998). Healthy individuals can be colonised by MRSA, usually 
in the anterior nares or on the skin, without any obvious signs or symptoms of disease, just as with 
other S. aureus strains. Colonisation is thought to precede infection and after the transfer of the 
bacterium on to the skin, infection can occur through a break in the skin. The infection can remain 
local causing, for example, cellulitis, wound infection, or can spread to the bloodstream causing 
bacteraemia or septicaemia (Table 2) (Boyce, 1997). The success of the organism and its ability to 
cause such a wide range of infections is as a result of its extensive virulence factors which, for 
example, enable it to thwart phagocytosis, form abscesses, infect tissue from the bloodstream and 
to invade through tissue from the site of infection (Archer, 1998).
1.2.8 MRSA and nosocomial infection
Infections linked to MRSA as the causative agent have historically been hospital-associated. The
transmission of strains between hospitals, cities and countries is usually via colonized or infected
patients or by colonised health workers (Boyce et al., 1993). Colonising strains can serve as an
endogenous source from which the patient can develop an infection once immunocompromised by
surgery or illness. Most transmission is via staff hands although it can be airborne or as a result of
direct or indirect contact, for example, environmental surfaces can serve as a reservoir for MRSA
strains (Boyce et al., 2005, Shanson and McSwiggan, 1980). Infection control measures are put in
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Table 2. Infections for which MRSA is a prominent pathogen (Adapted from Archer, 1998).
Infection Syndrome
Cellulitis Inflammation of subcutaneous tissue or muscle
Surgical wound infection Usually caused by indwelling surgical devices
Pyomyositis Deep muscle abscesses
Bacteraemia Presence of bacteria in the bloodstream
Endocarditis Infection of the inner lining of the heart chambers and/or a heart valve
Osteomyelitis Inflammation of bone as a result of infection
Empyema Accumulation of pus in a body cavity, usually thoracic cavity
Septicaemia Dissemination of infection throughout the body, causing septic shock
Scalded skin syndrome A side effect of infection, sloughing of the skin, blistering
Toxic shock syndrome Blood-borne bacterial infection
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place to reduce the risk of transmission, including the eradication of nasal carriage pre-hospital 
admission or pre-surgery, i.e., use of mupirocin, use of alcohol hand rubs, isolation of contaminated 
patients and screening of staff and patients. However, these control measures rely on the 
availability of isolation rooms and the compliance of hospital staff, patients and visitors (Coia et 
al., 2006). The use of mupirocin to eradicate nasal colonisation has resulted in increased resistance 
to this antibiotic (Marples et al., 1995). Epidemic strains, such as EMRSA-15 and -16, are still 
commonplace in many of Britain’s hospitals, despite the introduction of national control measures 
(Coia et al., 2006).
1.2.9 Multi-resistant MRSA
Many strains of MRSA are resistant to other antibiotics, not just methicillin. The next section 
focuses on the antibiotics these strains are resistant to and the mechanisms involved. Most 
EMRSA-15 and -16 strains are only resistant to (3-lactam, fluoroquinolones and macrolide 
antibiotics, however some MRSA strains are resistant to other classes of antibiotics as well.
1.2.9.1 Gentamicin
Gentamicin, introduced in the 1958, was the fourth antibiotic to be introduced from the
aminoglycoside family; streptomycin, neomycin and kanamycin were already in use. Treatment of
MRSA infections with gentamicin was initially successful and may have been the cause of a
decline in MRSA rates in the mid-1970s (Johnson et al., 2005). Nevertheless, resistance to
gentamicin had been observed as early as 1969 and, by the mid-1980s, resistance was widespread
(Graham, 1981, King et al., 1981, Lacey and Mitchell, 1969). Gentamicin differs in its molecular
structure from streptomycin and, although they have a similar mode of action and resistance is
mediated by modifying enzymes in both cases, there is no cross-resistance between the two
antibiotics (Phillips and Shannon, 1984, Shaw et al., 1993). Gentamicin resistance is primarily
mediated by inactivating enzymes that modify amino and hydroxyl groups at different sites of the
antibiotic. There are three classes of these aminoglycoside-modifying enzymes; N-
acetyltransferases (ACC) which modify amino residues, O-nucleotidyltransferases (ANT) and O-
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phosphotransferases (APH) which modify hydroxyl sites (Mingeot-Leclercq et a l, 1999, Phillips 
and Shannon, 1984). Antibiotic modification results in a drug that binds poorly to the ribosome. 
The genes encoding the drug modification enzymes are plasmid-encoded, but are associated with 
transposable elements, facilitating rapid transfer (Mingeot-Leclercq et a l, 1999). Jaffe et al., 
(1980) showed interspecies transfer of gentamicin-resistance plasmids between S. aureus and S. 
epidermidis.
Gentamicin resistance rates in MRSA strains have declined, possibly due to clone replacement. A 
British Society for Antimicrobial Chemotherapy (BSAC) survey in 2004 revealed only 5% of 
MRSA strains isolated from bacteraemias were resistant to gentamicin (http:// www.bsacsurv.org/ 
mrsweb/bacteraemia).
1.2.9.2 Fluoroquinolones
A new antibiotic class was discovered in the early 1960s with the introduction of the first 
synthetic quinolone, naladixic acid (Wolfson and Hooper, 1989). Quinolones were made more 
potent by fluorination of the 6-position, producing the fluoroquinolones. The first fluoroquinolone, 
flumequine, was short-lived due to toxicity problems, however a second-generation 
fluoroquinolone, ciprofloxacin, was developed via modification of side chains in the early 1980s 
(Ball, 2000). Other second-generation fluoroquinolones, norfloxacin and ofloxacin, were 
developed soon after. Ciprofloxacin showed good activity against MRSA and was launched in the 
mid-1980s (Smith and Eng, 1985). However, resistance to ciprofloxacin in staphylococci occurred 
almost immediately and calls were made for discretion when using the antibiotic to avoid the rapid 
development of resistance (Smith et al., 1985). New, more potent, fluoroquinolones have been 
developed including levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin, gemifloxacin and more 
recently, sitafloxacin, garenoxacin and fandofloxacin (Ball, 2000, Woodford, 2005).
Fluoroquinolones target two essential enzymes; DNA gyrase and DNA topoisomerase IV; the
latter is the main target in S. aureus (Ferrero et al., 1994). Mutations in the genes encoding these
enzymes result in amino acid substitutions and consequently modification of the target site.
Mutations in the genes encoding DNA gyrase, gyrA and gyrB, and the genes encoding subunits of
DNA topoisomerase IV, grlA and grlB, have been detected in staphylococci (Ferrero et al., 1995,
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Fournier and Hooper, 1998, Ito et al., 1994). These mutations can be present singularly or in 
combination, with certain double combinations conferring high-level resistance (Wang et al., 
1998). In the UK, in 2004, a BSAC survey showed all MRSA isolates, from bacteraemias, were 
resistant to ciprofloxacin (http://www.bsacsurv.org/ mrsweb/bacteraemia).
1.2.9.3 Rifampicin
The discovery of the rifamycin class of antibiotics in 1957 led to the development of a semi­
synthetic derivative called rifampicin (also known as rifampin, rimactane and rifadin) (Wehrli and 
Staehelin, 1971). It showed particular promise against strains of S. aureus and, additionally, its 
novel mechanism of action meant there is no cross-resistance with any other class of antibiotic 
(Dixson et al., 1984, Kunin et al., 1969). Rifampicin works by binding to RNA polymerase, 
specifically to the p subunit, preventing the initiation of messenger RNA (mRNA) synthesis 
(Morrow and Harmon, 1979). In staphylococci, resistance to rifampicin is via mutations in the 
rpoB gene, which encodes the RNA polymerase p subunit. This results in the antibiotic binding to 
the mutated enzyme with less affinity (Morrow and Harmon, 1979). Levels of resistance depend 
upon both the location and the nature of the amino acid substitution (Aubry-Damon et al., 1998). 
In-vitro studies warned of the ease with which rifampicin-resistant mutants of S. aureus arose (at a 
frequency of 10'7-10‘8) and advised using this antibiotic in combination with another agent (Kunin 
et al., 1969, Morrow and Harmon, 1979). This finding was echoed in the clinic where resistance 
occurred rapidly when large numbers of bacteria (>106) were present (Kapusnik et al., 1984). 
Rifampicin was not widely used for the treatment of staphylococcal infections when it was first 
introduced due to the availability of other, more widely used antibiotics (Dixson et al., 1984). 
However, despite its use in combination with other antibiotics resistance still emerged in the clinic 
(Simon et al., 1983). Today the use of rifampicin is still advocated, however, only in combination 
with glycopeptide antibiotics, fusidic acid, fluoroquinolones or trimethoprim (Gemmell et al., 
2006).
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1.2.9.4 Fusidic Acid
Fusidic acid is an antibiotic that inhibits bacterial protein synthesis. It binds to the elongation 
factor G and prevents the binding of transfer RNA (tRNA) to the ribosome, thereby preventing 
elongation of the peptide chain (Tanaka et al., 1968). Fusidic acid was launched in 1962 for use as 
a topical agent as well as a systemic antibiotic. It showed particularly good activity against 
staphylococci and only had cross-resistance with one other antibiotic, cephalosporin Pi (an 
antibiotic structurally related to fusidic acid, not traditional cephalosporins) (Godtfredsen et al., 
1962). S. aureus mutants resistant to fusidic acid were easily selected in vitro (at frequencies of 10' 
6-10'8) (Barber and Waterworth, 1962, Evans and Waterworth, 1966, Hilson, 1962, Lacey and 
Grinsted, 1972). Resistant S. aureus strains were encountered in the clinic almost immediately 
(Lowbury et al., 1962). Resistance has been attributed to mutations in the fusA  gene, which 
encodes for the elongation factor G. Different mutations are thought to confer different levels of 
resistance and multiple mutations within the same region can occur (Besier et al., 2003). Lacey et 
al., (1974) proposed fusidic acid resistance could also occur via a plasmid-mediated mechanism. 
Recent investigations have confirmed that a plasmid-mediated gene, fusB, confers resistance in 
clinical isolates of S. aureus, however the mode of action of this gene is still to be elucidated. 
O’Neill et al., (2006) suggested that the binding of FusB to the target site protects the translational 
apparatus from inhibition by fusidic acid. Lacey et al., (1972) suggested plasmid-mediated 
resistance was a more predominant mechanism of resistance than chromosomal mutation in clinical 
isolates, a finding confirmed by O’Neill et al., (2004). It has been proposed that these two 
mechanisms of resistance are incompatible as they have not yet been discovered within the same 
isolate (O'Neill and Chopra, 2006). Additionally, other mechanisms of resistance may also be 
possible as proved by the isolation of clinical specimens with neither fusA  mutations or a fusB  gene 
(O'Neill et al., 2004). Resistance to fusidic acid, in MRSA bacteraemias, has remained relatively 
low, given the rapid emergence of resistant mutants in vitro and in the clinic. This could be 
attributed to the limited use of fusidic acid, given the ease with which resistance occurs, or the fact 
that it is usually used in combination therapy with other antibiotics to delay the emergence of 
resistance (Besier et a l, 2003). Current guidelines for the treatment of MRSA advise fusidic acid 
only to be used in combination with other antibiotics (Gemmell et al., 2006). Resistance rates
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show 8% of MRSA strains isolated from bacteraemias to be resistant to fusidic acid 
(http://www.bsacsurv.org/mrsweb /bacteraemia). However, although resistance is infrequent in 
bacteraemia isolates, widespread use of fusidic acid as a topical agent to combat clones causing 
dermatological conditions, such as impetigo bullosa, has resulted in increased resistance rates 
(Brown and Thomas, 2002, O'Neill et al., 2004).
1.2.9.5 Vancomycin
Vancomycin, a glycopeptide antibiotic, is one of the mainstays of current anti-MRSA therapy. 
Discovered in 1951, unlike other antibiotics launched at the same time, it still remains almost 
universally effective against MRSA. Vancomycin exerts its action by preventing the attachment of 
precursors into a nascent peptidoglycan chain, thus preventing successful cell wall synthesis 
(Reynolds, 1989).
The first clinical cases of vancomycin-resistant enterococci (VRE) were described in 1988 (Uttley 
et al., 1988). In enterococci, resistance is associated with the presence of operons that encode a 
series of Van enzymes which, firstly, are responsible for the synthesis of low-affinity precursors 
resulting in a modified target, and secondly, eliminate the un-modified precursors, which have a 
high affinity for vancomycin (Arthur et al., 1996). Six Van variants have been identified in 
enterococci one of which, vanA, is associated with providing high level inducible resistance to both 
vancomycin and teicoplanin, however not all van systems confer resistance to both vancomycin 
and teicoplanin. Five of the six Van variants (A, B, D, E  and G) are plasmid-mediated, whereas 
vanC is intrinsic to certain enterococcal species (Courvalin, 2006).
The transfer of Van genes from enterococci to staphylococci has long been feared. This was
proved possible in vitro by Noble et al., (1992) who managed to transfer high-level resistance from
a strain of Enterococcus faecalis (E. faecalis) to S. aureus. It was also implied that transfer was
transposon-mediated (Noble et al., 1992). However, this became a reality in the clinic with the
emergence of vancomycin-resistant strains. Within a four month period in 2002, two unrelated
isolates, fully vancomycin-resistant MRSA (minimum inhibitory concentrations (MICs) 1028 mg/L
and 32 mg/L) were isolated from patients in hospitals in Michigan and Pennsylvania, USA (Anon,
2002a, Anon, 2002b, Clark et al., 2005). A third vancomycin-resistant S. aureus (VRSA) strain
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occurred in 2004 in a hospital in New York and a fourth was isolated in Michigan in 2005 (Anon, 
2004, Appelbaum and Jacobs, 2005). Two more have since been isolated in Michigan, bringing the 
total to six (http://www.cdc.gov/ ncidod/dhqp/ar_visavrsa_FAQ.html).
Investigation of the clinical isolates from Michigan and Pennsylvania revealed the presence of 
vanA genes identical to that found in VRE (Clark et a l, 2005, Tenover et a l, 2004, Weigel et al,
2003). The Michigan strain harboured a plasmid that contained genetic sequence identical to 
Tn1546, the transposon containing the vanA gene found in enterococci (Weigel et a l, 2003). The 
Pennsylvania strain harboured a large plasmid with some sequence homology to Tn1546, although 
not to the same extent as the first Michigan strain. The size of this plasmid and the level of 
expression of the vanA gene could be a reason for the relatively low MIC encountered in this strain 
when compared with that of the Michigan strain (32 mg/L cf. 1024 mg/L) (Tenover et a l, 2004). 
In the Michigan isolate, vancomycin resistance seemed to be due to in vivo transfer from 
enterococci to staphylococci in a mixed infection (Weigel et al, 2003). It was proposed that the 
Van genes had transferred to a resident staphylococcal plasmid (Weigel et al., 2003). The degree 
with which these two plasmids differed both from each other and from Tn1546 indicates that the 
acquisition of the vanA genes occurred independently in the two strains (Clark et a l, 2005). These 
strains were epidemiologically unlinked, although both were USA 100 (via PFGE typing), one of 
the predominant MRS A types in the USA (also known as the New York/Japan clone) (Tenover et 
al, 2004, Weigel et al, 2003). Following the isolation of these two strains, the main cause for 
concern is the dissemination of vancomycin resistance among clones of the predominant epidemic 
MRSA strains. Worryingly, the Pennsylvania strain was isolated from a patient not on vancomycin 
therapy, indicating resistance can be selected for in the absence of vancomycin (Whitener et a l,
2004).
Vancomycin intermediate-resistant S. aureus (VISA) strains are associated with heteroresistance 
in the clinic, although homoresistance does also occur (Hiramatsu et a l, 1997, Kim et a l, 2002, 
Sng et a l, 2005). Heteroresistant strains appear susceptible, but contain subpopulations that are 
able to grow at vancomycin concentrations of 4 mg/L or greater (Hiramatsu et a l, 1997). In both 
hetero- and fully-resistant strains resistance has been attributed to significantly increased cell wall 
synthesis, which serves as a physical barrier against the penetration of vancomycin molecules (Cui
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et al., 2000). It has been proposed that cell wall thickening is associated with the increased 
production of high-affinity peptidoglycan subunits, which capture and immobilise vancomycin 
molecules before they reach the sites of cell-wall synthesis (Sieradzki and Tomasz, 1999). 
However, the exact mechanism that leads to this cell wall thickening has still to be elucidated. 
VISAs are rare and there are few reports of VISAs occurring in the UK (Howe et al., 1998). None 
were isolated in the UK 2004 BSAC bacteraemia survey (http://www.bsacsurv.org/mrsweb 
/bacteraemia).
1.2.9.6 Teicoplanin
Teicoplanin was the second glycopeptide antibiotic to be introduced. It is structurally related to
vancomycin and has similar properties, although its mode of action differs slightly. Like
vancomycin, teicoplanin binds to the cell wall precursors and inhibits their incorporation into a
nascent peptidoglycan chain, thus preventing successful cell wall synthesis (Greenwood, 1988).
Unlike vancomycin, teicoplanin has a hydrophobic tail which anchors it to the cell membrane,
close to its target (Van Bambeke, 2004). Resistance to teicoplanin was first recognised in 1986, six
years after the discovery of the compound, in a clinical isolate of S. haemolyticus (Wilson et al.,
1986). Resistance to teicoplanin in S. aureus emerged in 1990 (Kaatz et al., 1990). Resistance to
teicoplanin in staphylococci is thought to be via a shift in cell wall composition, providing cell wall
precursors with an increased capacity for binding teicoplanin molecules. These sequestered
antibiotic molecules may sterically hinder the access of incoming molecules (Sieradzki and
Tomasz, 1998). In addition Sieradzki et al., (1998) and Bischoff et al., (2001, 2001) have
associated teicoplanin resistance with the sigmaB factor, which is involved in transcription, though
its exact role in resistance is still unclear. It has been proposed that multiple alterations in the cell
wall structure and synthetic machinery, acquired through sequential mutational steps, may be
required (Bischoff et al., 2001, Sieradzki and Tomasz, 1998). Resistance to teicoplanin provides
no cross-resistance to any other antibiotics, however, the VanA phenotype does provide resistance
to both vancomycin and teicoplanin (Courvalin, 2006, Wilson et al., 1986). Currently, resistance to
teicoplanin in clinical isolates of S. aureus in the UK is rare, for example, no isolates with
intermediate or full resistance were found in the 2004 BSAC bacteraemia survey, although many
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isolates of EMRSA-17 are teicoplanin-resistant (Manuel et a l, 2002). Resistance is more 
commonly associated with coagulase-negative staphylococci. BSAC data from 2004 revealed 5% 
of S. epidermidis and 30% of S. haemolyticus bacteraemia isolates from the UK showed 
intermediate resistance to teicoplanin (http://www.bsacsurv.org/mrsweb/bacteraemia). Why CNS 
resistance rates are higher than S. aureus is unknown, it is possibly due to intrinsic resistance 
(Lallemand et al., 2002).
1.2.9.7 Mupirocin
Mupirocin, previously known as pseudomonic acid, was first isolated in 1971 but was not
introduced into the UK until 1985 (Cookson et al., 1990, Fuller et al., 1971). It has an unique
mechanism of action, is highly active against staphylococci and is used as a topical agent (Casewell
and Hill, 1985, Sutherland et al., 1985). Mupirocin binds to the isoleucyl tRNA synthetase and
prevents the incorporation of isoleucine into a nascent peptide chain, thereby halting protein
synthesis (Casewell and Hill, 1987). Additionally, the absence of protein synthesis, and in
particular of tRNA charging, results in the initiation of the stringent response, (a mechanism by
which bacteria can regulate transcription during amino acid starvation) and the shutdown of RNA
synthesis (Cassels et al., 1995, Hughes and Mellows, 1978). Mupirocin is used for the topical
treatment of bacterial skin infections and for the eradication of nasal carriage of MRSA (Dacre et
al., 1983, Sutherland et al., 1985). Although resistance was encountered in laboratory studies,
mupirocin-resistant staphylococci did not emerge in the clinic until 1987 (Rahman et al., 1987,
Sutherland et al., 1985). Low-level mupirocin resistance (MICs 8-256 mg/L) is associated with
chromosomal mutations in the ileS gene which encodes for isoleucyl tRNA synthetase (Antonio et
al., 2002). High-level resistance (MICs > 5 1 2  mg/L) is via the mupA gene, which encodes an
alternative mupirocin-resistant isoleucyl tRNA synthetase, which replaces the native isoleucyl
tRNA synthetase (Gilbart et al., 1993, Woodford et al., 1998). The mupA gene, previously referred
to as the ileS or ileS2 gene, is plasmid-mediated, enabling inter-strain and -species spread (Antonio
et al., 2002, Bradley et al., 1995, Hodgson et al., 1994). It has only 52% identity with the native
ileS gene of S. aureus, indicating that it has not arisen by mutations to the native gene; rather it has
probably been acquired from another organism (Hodgson et al., 1994). Evidence for the
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transmission of the mupA gene between species is provided by Hurdle et al., (2005) and Leski et 
al., (1999), who showed that transfer between S. epidermidis and S. aureus in the clinic was 
possible.
1.2.9.8 Fosfomycin
Fosfomycin is a broad-spectrum antimicrobial, derived from several species of Streptomyces (S. 
fradiae, S. viridochromogenes and S. wedmorensis), which inhibits cell wall synthesis at an early 
stage (Stapley et al., 1969). Fosfomycin is taken into the cytoplasm by the L-a-glycerolphosphate 
pathway or the hexose phosphate uptake (Uhp) system, which are active transport systems induced 
by glycerol-6-phosphate (G-6-P) (Kahan et al., 1974). Resistance to fosfomycin is determined by 
the plasmid-mediated fosB  gene in gram-positive organisms (Etienne et al., 1989, Etienne et al., 
1991). The exact mechanism of resistance conferred by fosB  is unclear, but is thought to be similar 
to fosA, the resistance gene in gram-negative species, which modifies the antibiotic by opening the 
epoxide group (Area et al., 1988). Additionally, chromosomal mutations in glpT  or its regulatory 
genes result in modifications to the L-a-glycerolphosphate pathway and resistance to fosfomycin 
(Nilsson et al., 2003). Resistant mutants can be made more susceptible in vitro in the presence of 
G-6-P which induces the secondary transport system, the Uhp pathway, and hence the uptake of 
fosfomycin (Kahan et al., 1974). Similarly, mutations in the uhpT gene and its regulatory proteins 
also confer resistance to fosfomycin. Fosfomycin is licensed for clinical use in the UK but is not 
marketed. It has been used more widely abroad (Etienne et al., 1991).
1.2.10 New agents for the treatment of MRSA
Linezolid (see section 1.3), vancomycin and teicoplanin are currently the antibiotics of choice for 
the treatment of MRSA bacteraemias, pneumonias, serious soft tissue infections, bone and joint 
infections and, occasionally, in surgical site prophylaxis either singularly or in combination with 
other antibiotics (Gemmell et al., 2006). However, due to the steady emergence of antibiotic- 
resistant pathogens, the development of new antimicrobials to target MRSA essential.
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Dalbavancin, oritavancin and telavancin are all new glycopeptide antibiotics (Table 3). 
Dalbavancin is a semi-synthetic teicoplanin derivative. It shows activity against MRSA, VISA, 
glycopeptide-susceptible strains and glycopeptide-resistant enterococci (GRE) strains, however is 
not effective against GRE strains with VanA (Candiani et al., 1999, Lin et a l, 2005). As a result it 
probably would not be effective against VRSA strains with a vanA genotype. Dalbavancin is most 
notable for having a serum half-life of over one week, enabling flexible and, possibly, once weekly 
dosing regimens (Woodford, 2005). Oritavancin is a semi-synthetic glycopeptide with activity 
against MRSA and GRE strains (Garcia-Garrote et al., 1998, Schwalbe et al., 1996). However, 
questions concerning its longevity in the clinic have been made after oritavancin-resistant 
enterococci were selected in vitro (Arthur et al., 1999). Telavancin is a lipoglycopeptide antibiotic 
that is proposed to have two mechanisms of action. It inhibits cell wall synthesis and also interacts 
with the bacterial membrane, dissipating the membrane potential and causing changes in cell 
permeability (Higgins et al., 2005). Resistance should be slower to emerge as multiple 
mechanisms of action may mean multiple resistance mechanisms are necessary (Krause et al., 
2003). Both telavancin and oritavancin show activity against strains of MRSA, glycopeptide- 
intermediate S. aureus, VRSA and VRE (Higgins et al., 2005, King et al., 2004). Telavancin is 
currently in phase III clinical trials.
Tigecycline is a glycylcycline, structurally related to the tetracyclines. It is effective against 
highly-resistant gram-positive bacteria, including MRSA, and is not subject to the same resistance 
mechanisms affecting existing tetracyclines (Livermore, 2005). However, serial passage of S. 
aureus in the presence of increasing concentrations of tigecycline resulted in resistant mutants due 
to the over expression of a efflux pump, mepA (McAleese et al., 2005). Additionally, reports of 
variant tet genes, able to confer resistance to glycylcyclines, being isolated in veterinary isolates of 
Salmonella (Tuckman et al., 1998) and the discovery of resistance to glycylcyclines in Salmonella 
and Shigella isolates from Africa is of concern (Chopra and Roberts, 2001). Daptomycin (Cubicin) 
is the first member of a new class of bactericidal antibiotics called the lipopeptides and is effective 
against nearly all clinically relevant gram-positive bacteria (Steenbergen et al., 2005). Daptomycin 
inserts itself into the cell membrane, causing depolarisation. This itself is not lethal, but the 
secondary effects are. This mechanism of action is unique from all other drugs currently available,
54
Ta
bl
e 
3. 
A 
co
m
pa
ri
so
n 
of 
new
 
an
ti-
M
RS
A 
an
tib
io
tic
s.
R
ef
er
en
ce
(B
og
da
no
vi
ch
 
et 
al.
, 
20
05
)
(L
in 
et 
al.
,  
20
05
)
(L
in 
et 
al.
, 
20
05
)
(L
in 
et 
al.
, 
20
05
)
(K
ing
 
et 
al.
, 
20
04
)
(R
ey
no
ld
s 
et 
al.
, 
20
04
)
(B
aj
ak
so
uz
ia
n 
et 
al.
, 
20
02
)
N
/A
/ • s
"Sfe
E
N * /
o
ON
Ui—<
S
0.
5-
2
0.
06 0.
5 i
<N
0.2
5 
- 0
.5
0.2
5 
-1
0.5
 
- >
32
N
/A
"wD
E
' w '
U
H H
2
0.
12
5-
2
0.0
3 
- 0
.0
6
0.2
5 
- 0
.5
<N
0.2
5 
- 0
.5
0.2
5 
- 0
.5
0.
12
-0
.2
5
N
/A
No
. 
of 
st
ap
hy
lo
co
cc
i 
te
st
ed
A
30
3
14
6
14
6
14
6
1—H 89
2
10
0
N
/A
A
nt
ib
io
tic
 
cl
as
s
C
ep
ha
lo
sp
or
in
Li
po
gl
yc
op
ep
tid
e
Cy
cli
c 
lip
op
ep
tid
e
G
ly
co
pe
pt
id
e
Li
po
gl
yc
op
ep
tid
e
G
ly
cy
lc
yc
lin
e
D
ih
yd
ro
fo
la
te
 
re
du
cta
se
 
(D
H
FR
)
C
ep
ha
lo
sp
or
in
A
nt
ib
io
tic
Ce
fto
bi
pr
ol
e
D
al
ba
va
nc
in
D
ap
to
m
yc
in
O
rit
av
an
ci
n
Te
la
va
nc
in
Ti
ge
cy
cl
in
e
Ic
la
pr
im
C
ef
ta
ro
lin
e
»0»o
ato
P .t/3
<D>
15bfl<uc
Ioo
T3
§
<dc/)CO
CO
<u
and consequently daptomycin may be able to circumvent existing resistance mechanisms 
(Silverman et a l, 2003). Resistance to daptomycin in S. aureus nevertheless can be selected by 
serial passage in vitro, although the mechanism of resistance is unknown (Silverman et a l, 2001). 
Furthermore, daptomycin is a natural product, isolated from S. roseosporus, and therefore there is 
the possibility that resistance genes could exist in this species and transfer to clinically-significant 
species (D'Costa et al, 2006, Woodford, 2003).
Ceftobiprole is a new “fifth-generation” cephalosporin. Unlike other cephalosporins, so far 
marketed, it shows good activity against MRSA due to its increased affinity for PBP2a, which it 
binds and inactivates (Bogdanovich et a l, 2005, Hebeisen et a l, 2001, Jones et a l, 2002). It is 
possible to generate low-level resistance in staphylococci in vitro via serial passage in the presence 
of ceftobiprole, however the mechanism by which this occurs is unknown (Bogdanovich et a l,
2005). Another new cephalosporin which is active against strains of MRSA is ceftaroline (PPI- 
0903) (Andes and Craig, 2006). It has recently entered phase III trials and the USA Food and Drug 
Administration (FDA) granted it fast-track designation for the treatment of cSSSI (complicated 
skin and skin structure infections) caused by MRSA (http://www.cerexa.com/press/040506pr.html).
A new antibiotic currently in the pipeline is iclaprim. Iclaprim is a novel, synthetic inhibitor of 
DHFR which shows activity against MRSA (Bajaksouzian et a l, 2002, Then et a l, 2002). 
Nevertheless, its usefulness against MRSA strains is potentially impaired by the fact that there is a 
degree of cross-resistance between trimethoprim (another DHFR inhibitor) and iclaprim (Then et 
al, 2002). Iclaprim is currently undergoing phase III trials for the treatment of cSSSI also after 
being granted fast track status by the USA FDA (http://iclaprim.com/).
Several new oxazolidinones were investigated after the launch of linezolid in the hope of 
increasing their activity and spectrum. Those currently in development include VIC-105535 
(Pfizer), RWJ-416457 (Johnson & Johnson), Rx-01 (Rib-X Pharmaceuticals) and DA-7157 (Dong- 
A Pharm). These new compounds show activity comparable to or slightly greater than that of 
linezolid (Choi et a l, 2005, Foleno et a l, 2005, Lawrence et a l, 2005, Luehr et a l, 2005).
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1.2.11 Community-acquired MRSA
The deaths of four healthy children in Dakota and Minnesota (USA) in 1999 reflected the 
emergence of community-acquired MRSA (CA-MRSA) capable of causing severe infections 
(Anon, 1999). Early CA-MRSA strains in the USA were recognised as being only resistant to 
methicillin and other P-lactam antibiotics due to the presence of the SCCmec type IV element. 
This element is smaller and may be more mobile than its counterparts, SCCmec types I-III. It does 
not carry resistant determinants to non-P-lactam antibiotics (Daum et al., 2002). Multiply resistant, 
highly-virulent and invasive CA-MRSA epidemic clones, such as the USA 300 strain, have since 
emerged (Diep et al., 2006, Vandenesch et al., 2003). Lina et al., (1999a) made the connection 
between CA-MRSA and the Panton-Valentine leukocidin (PVL) virulence factor, detecting PVL 
genes in 23 of 27 CA-MRSA isolates. CA-MRSA strains with PVL genes were subsequently 
associated with necrotic lesions of the skin and subcutaneous tissues and with severe community- 
acquired necrotic pneumonia (Lina et al., 1999a). Vandenesch et al., (2003) investigated 117 CA- 
MRSA isolates in three continents and were able to elucidate that both SCCmec type IV element 
and the PVL locus were prevalent in (but not exclusive to) CA-MRSA isolates. Additionally, they 
proposed that the emergence of CA-MRSA strains did not reflect the dissemination of one clone 
but was due to the independent worldwide evolution of multiple CA-MRSA strains, not related to 
local hospital MRSA strains. The significance and genetic advantage conferred by the presence of 
the PVL genes and the SCC mec type IV element has not yet been proved or disproved 
(Vandenesch et al., 2003). Although these CA-MRSA strains seem to be well suited to the 
community environment, the detection of CA-MRSA strains with PVL genes and that are related to 
the two major clones in UK hospitals, EMRSA-15 and EMRSA-16, is a major cause for concern 
and presents a real and potential threat (Holmes et al., 2005).
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1.3 Oxazolidinones
1.3.1 Background
Researchers at E.I. du Pont de Nemours & Co. originally developed oxazolidinones as 
monoamine oxidase inhibitors for the treatment of depression. It was subsequently discovered that 
they had antimicrobial activity and they were developed for use in the control of bacterial plant 
diseases in the late 1970s (Brickner, 1996). In 1987, improvement of these initial compounds 
resulted in the development of the first two oxazolidinone analogues for use against human 
pathogens, DuP 721 and DuP 105 (Slee et a l, 1987). These analogues showed promise in vitro but 
lethal toxicity in animals prevented their development (Brickner, 1996, Slee et al., 1987).
Preliminary research showed oxazolidinones to be active against problem gram-positive bacteria, 
including MRSA and enterococci and mutant generation was difficult. They were water-soluble 
and had a novel mechanism of action, unlike existing antibiotic classes (Brumfitt and Hamilton- 
Miller, 1988, Daly et a l, 1988, Slee et a l, 1987). These promising attributes ensured work 
continued on these compounds by researchers at Upjohn Laboratories. In 1996 their perseverance 
was rewarded with the development of two non-toxic derivatives, linezolid (UP-100176) and 
eperezolid (UP-100592) (Figure 4) (Brickner et al, 1996). Linezolid was preferred for clinical use 
due to its better pharmacokinetic and safety profile (Barrett, 2000). Following FDA approval, 
linezolid was launched in the USA in May 2000 (Hamel et a l, 2000). Subsequently, it was 
launched in the UK in January 2001 and is currently being marketed under the trade name Zyvox. 
It is licensed for the treatment of VRE infections, nosocomial infections caused by S. aureus or 
penicillin-susceptible Streptococcus pneumoniae (S. pneumoniae), cSSSIs caused by S. aureus, 
Streptococcus pyogenes or Streptococcus agalactiae and community-acquired pneumonia due to S. 
aureus (MSSA only) or penicillin-susceptible S. pneumoniae (Barrett, 2000).
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Figure 4. Chemical structures of linezolid and eperezolid. (A) Linezolid (B) Eperezolid (From 
Shinabarger et al., 1997).
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1.3.2 M echanism o f action o f linezolid
Bacterial protein synthesis involves, firstly, the assembly of a functional ribosome on an mRNA 
ready to commence protein synthesis (initiation). Next the correct amino acid is brought to the 
ribosome (via tRNA), joined to the nascent polypeptide chain and the entire assembly translocates 
along the mRNA (elongation). When a stop codon is reached the newly-synthesized polypeptide is 
released from the ribosome (termination). The ribosome releases mRNA and tRNA and is 
recycled.
The initiation stage of protein synthesis requires the assembly of several components (the 70S 
ribosome, three initiation factors (IF 1, IF2, IF3) and initiator tRNA (N-formyl-methionyl-tRNA 
(tRNAfMet)) into a functionally competent ribosome on an mRNA strand ready to commence 
protein synthesis (Figure 5). The 70S subunit is comprised of 50S and 30S subunits and has three 
tRNA binding sites, aminoacyl (A), peptidyl (P) and exit (E) (Laursen et a l, 2005). Binding of IF3 
to the ribosome promotes dissociation into its two component subunits, the 30S (comprised of 16S 
rRNA and 21 proteins) and 50S (comprised of 5S, 23S rRNA and 34 proteins) subunits (Petrelli et 
al., 2001). IF 1 guides the initiator tRNA to its correct binding site, the peptidyltransferase P site, 
on the 3OS subunit, forming a complex comprising of the 3OS subunit, three initiation factors, 
mRNA and tRNAfMet. Initiation factors IF1 and IF3 dissociate and IF2 promotes the incorporation 
of the 50S subunit into the complex. As the 50S subunit of the ribosome associates with the 
30Sinitiation complex, hydrolysis of GTP bound to IF2 occurs. Subsequent dissociation of IF2 
leaves a 70S initiation complex and translation can proceed (Laursen et al., 2005). Initial studies 
on oxazolidinones concluded that their target site was protein synthesis, however, conflicting 
research emerged as to the exact mechanism of action (Slee et al., 1987). Eustice et al., (1988) 
determined that oxazolidinones must inhibit an early event in initiation, preceeding the interaction 
between tRNAfMet and the 30S subunit (Eustice et al., 1988). Later research by Lin et al., (1997) 
found that eperezolid bound to the 50S subunit near to the interface with the 30S subunit, possibly 
preventing the formation of a functional 70S initiation complex whilst Swaney et al., (1998a) 
determined that oxazolidinones inhibited development of the initiation complex by preventing 
formation of the tRNAfMet-70S and 30S subunit-mRNA complex.
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Figure 5. Translation initiation pathway in bacteria. The 30S and 50S subunits are shown in 
light and dark grey respectively. Translation factors IF 1, IF2 and IF3, mRNA and fMet-tRNAfMet 
are shown in red, blue, green, yellow and purple, respectively (Diagram from Laursen et al., 2005).
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Continued research led to the finding that oxazolidinones bound to domain V, the 2100-2180 
region, of the 50S ribosomal subunit. Other antibiotics targeting the ribosome have not been 
associated with binding to this region, indicating why the mechanism of action of oxazolidinones 
was unique (Matassova et al., 1999). Confirmation of the interaction of oxazolidinones with the 
50S subunit was provided by the discovery of mutations in the peptidyl transferase domain of the 
genes encoding 23 S rRNA in a laboratory-selected linezolid-resistant strain of S. aureus (Swaney 
et al., 1998b). This finding was confirmed by Kloss et al., (1999) who selected linezolid-resistant 
Halobacterium halobium (H. halobium) mutants, all of which had mutations within the central loop 
of domain V of their single 23 S rRNA gene copy. This finding led the authors to propose that 
oxazolidinones inhibit the incorporation of tRNAfMet-ribosome-mRNA complex. Mutations in 
laboratory-selected linezolid-resistant E. coli isolates were also clustered in domain V (Xiong et 
al., 2000). Bobkova et a l, (2003) proposed that oxazolidinones prevent binding of the initiator 
tRNA to the peptidyltransferase P site on the 50S subunit and hence the formation of the first 
peptide bond. It has been suggested that oxazolidinones may bind to a ribosomal protein and that 
mutations in the rRNA genes would therefore alter the protein conformation, affecting interactions 
between the drug and target (Kloss et al., 1999). However, Kloss et al., (1999) went on to suggest 
that if ribosomal proteins were directly involved in binding of oxazolidinones, resistance would 
arise at a greater frequency in these proteins. More recently, it was suggested that oxazolidinones 
bind to tRNA, proteins L27 and Lep and to nucleotides A2603 or G2608 (situated in the peptidyl 
transferase centre) of the genes encoding 23S rRNA (Colca et al., 2003, Xu et al., 2005). It was 
suggested that the tRNAfMet-ribosome-mRNA complex optimally exposes the ribosome to drug 
binding (Colca et al., 2003, Xu et al., 2005). Drug binding may “lock” the ribosome and prevent 
further conformational change (Colca et al., 2003) or may block the exit tunnel between P and A 
sites (Xu et al., 2005).
In short, whilst the evidence for binding of oxazolidinones in the peptidyltransferase region is 
conclusive, the exact binding site or sites remain elusive. Additionally, there is the possibility of 
interactions between oxazolidinones and ribosomal proteins.
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1.3.3 Linezolid resistance
1.3.3.1 The emergence of resistance
It was thought that resistance to linezolid would be rare, firstly due to its unique mechanism of 
action, without known cross-resistance with any other classes of antibiotic and, secondly, due to 
gram-positive species having multiple copies of the 23S rRNA genes and spontaneous mutations 
being necessary in more than one of these gene copies before phenotypic resistance emerged. The 
difficulty in generating linezolid-resistant mutants of S. aureus and enterococci in vitro supported 
this hypothesis (Zurenko et al., 1996). Nevertheless, the first linezolid-resistant mutants of S. 
aureus and E. faecalis were selected by Swaney et al., (1998b) via a spiral gradient technique. 
Further reports of resistance in the laboratory followed (Table 4). In 1999, the first clinical 
linezolid-resistant strains were described (Zurenko et al., 1999); resistance emerged in 
Enterococcus faecium (E. faecium) strains from two patients prescribed linezolid under the 
compassionate use programme. Resistance in clinical S. aureus isolate took slightly longer to 
emerge, but did so in the USA (Tsiodras et al., 2001). Two years later the first clinical linezolid- 
resistant S. aureus was isolated in the UK (Wilson et al., 2003). Reports of linezolid resistance in 
clinical isolates of CNS and streptococci have also emerged; the SENTRY and PROTEKT surveys 
reported linezolid-resistant S. epidermidis, Streptococcus oralis (S. oralis) and S. pneumoniae 
(Farrell et al., 2004, Mutnick et al., 2002). More recently, Fraimow et al., (2005) and Potoski et 
al., (2006) have reported linezolid-resistant Staphylococcus lugdunensis, S. epidermidis and S. 
haemolyticus and isolates from the clinic. Linezolid-resistant CNS from Ireland have also been 
reported to ARMRL (Neil Woodford, personal communication).
Resistance to linezolid in clinical strains of S. aureus is still infrequent, however, more 
occurrences are being reported (Gales et al., 2006, Hill et al., 2005, Machado et al., 2003, Meka et 
al., 2004a, Meka et al., 2004b, Paterson et al., 2003, Pillai et al., 2002, Roberts et al., 2006, 
Tsiodras et al., 2001, Wilson et al., 2003). In the majority of cases, linezolid resistance evolved 
during long-term therapy with linezolid. For example, early E. faecium  isolates resistant to 
linezolid arose after 21 and 40 days treatment with linezolid (Gonzales et al., 2001, Johnson et al., 
2002, Zurenko et al., 1999). A linezolid-resistant E. faecalis was isolated after 25 days treatment
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(Johnson et al., 2002), and three independent linezolid-resistant S. aureus isolates emerged after 21 
days, one month and 20 months treatment, respectively (Meka et a l, 2004b, Tsiodras et al., 2001, 
Wilson et al., 2003). Long-term, low-dose treatment may facilitate selection of resistance (Hill et 
al., 2005).
1.3.3.2 Mechanism of resistance
Sequencing of the 23S rRNA genes of the first mutants selected in vitro by Swaney et al., (1998b) 
revealed a G to T change at position 2447 in S. aureus mutants and a G to T change at position 
2528 in both S. aureus and E. faecalis. Subsequent clinical isolates of S. aureus, E. faecium  and E. 
faecalis all had a G to T change at position 2576 (Johnson et al., 2002, Tsiodras et al., 2001, 
Zurenko et al., 1999). Meka et al., (2004b) characterized the only exception to this pattern; a 
clinical linezolid-resistant S. aureus with a T2500A mutation in three of its six 23S rRNA gene 
copies. Despite investigation, the reason for the repeated selection of the G2576T mutation in the 
clinic, independent of species, has not been determined (Lobritz et al., 2003, Pillai et al., 2002). 
Although this one mutation predominates clinically, a variety of mutations have been characterized 
in laboratory-selected mutants of several species (Table 4). Additionally, it is possible to generate 
the G2576T mutation in the laboratory (Bryskier, 1999). The location of these mutations, within 
the peptidyltransferase centre and in close proximity to A, P and E sites, serves to reinforce theories 
that linezolid binds to the 50S ribosomal subunit (Xiong et al., 2000).
1.3.3.3 Genetic recombination of resistance
S. aureus typically has five or six 23S rRNA gene copies, E. faecalis has four and E. faecium  has 
six (Klappenbach et al., 2001). It was thought that a mutation conferring resistance to linezolid in 
one gene copy would be masked by the remaining wild-type gene copies and therefore that 
independent mutations would be required in at least two genes to convey phenotypic resistance 
(Willems et al., 2003, Xiong et al., 2000). The possibility of such spontaneous mutations occurring 
in two or more of the 23 S rRNA genes was thought to be rare, however resistance still emerged as 
noted above. Lobritz et al., (2003) proposed that a spontaneous mutation in one gene copy,
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followed by homologous recombination events with wild-type copies enabled the proliferation of 
the mutation to other gene copies. This phenomenon has previously been implicated in increasing 
levels of resistance to aminoglycosides in Mycobacterium smegmatis (Prammananan et a l, 1999) 
and to evernimicin in S. pneumoniae (Adrian et al., 2000). Experiments with recA-negative E. 
faecalis and S. aureus mutants confirmed that homologous recombination is the primary 
mechanism of spread of a mutation to multiple gene copies (Lobritz et al., 2003, Miller et al.,
2005). Marshall et al., (2002) proved a direct correlation between the linezolid MIC and the 
number of mutated gene copies in enterococci. So as long as a linezolid-resistant isolate retained at 
least one wild-type copy, reversion to susceptibility could occur via reversal of the same route. 
Meka et al., (2004a) reported that in the continued absence of selection pressure, a linezolid- 
resistant S. aureus isolate from the clinic reverted to susceptibility. However, a linezolid-resistant 
mutant with all 23S rRNA gene copies mutated might not revert back to susceptibility via this 
mechanism and would need a spontaneous mutation at the original mutated base or wild-type DNA 
from a foreign source to revert to susceptibility, a finding confirmed by Pillai et al., (Pillai et al., 
2002).
1.3.3.4 Other linezolid resistance mechanisms, not involving 23S rRNA
Although the main mechanism of resistance seems to be mutations in the peptidyltransferase
region of the 23 S rRNA genes, reports have emerged of cases where no mutation could be detected
in this region in clinical isolates and laboratory mutants of staphylococci, enterococci and
streptococci (Carsenti-Dellamonica et a l, 2005, Fraimow et al., 2005, Prystowsky et al., 2001).
Furthermore, Wolter et al., (2005) found mutations in the ribosomal protein L4 of pneumococci
with resistance to oxazolidinones, macrolides and chloramphenicol, and Farrell et al., (2004) found
a combination of 23 S rRNA and L4 mutations conferred resistance to linezolid in a clinical S.
pneumoniae isolate. There have been no reports to date of similar mutations in the ribosomal
proteins conferring resistance to linezolid in staphylococci or enterococci. More recently a RNA
methyltransferase, encoded by the cfr gene, has been shown to methylate position A2503 of the
23 S rRNA genes, conferring resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins
and streptogramin A antibiotics in E. coli and S. aureus (Long et al., 2006). This is the first
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reported mechanism, so far, of linezolid resistance that is transferable. It has been detected in very 
few staphylococcal strains, although it is probably not widely looked for (Kehrenberg and Schwarz, 
2006).
1.3.3.5 Unstable linezolid resistance
There have been reports of unstable linezolid resistance, especially when selected in vitro.
Prystowsky et al., (2001) found a two-fold reduction in the linezolid MIC (32 to 16 mg/L) for a 
resistant mutant of eneterococci after one month of growth on drug-free media. Similarly, Xiong et 
al., (2000) used a laboratory strain of E. coli (growth was suppressed at high concentrations) to 
raise linezolid-resistant mutants. Only two of 12 E. coli mutants maintained a highly resistant 
phenotype after one passage in the absence of linezolid.
1.3.3.6 Cross-resistance between linezolid and other antibiotic classes
Although oxazolidinones are marketed as having no cross-resistance with any other class of 
antibiotic, studies designed to determine the binding site of linezolid, revealed partial cross­
resistance between linezolid and other antibiotics when mechanisms other than G2576T are
involved. Bobkova et al., (2003) and Lin et al., (1997) discovered that chloramphenicol and
linezolid compete for binding sites, and that mutations G2032A and G2447A in the 23S rRNA 
genes resulted in reduced sensitivity to both these agents conferring partial cross-resistance. 
Likewise mutations at positions 2062 and 2452 in laboratory-selected linezolid-resistant mutants of 
Halobacterium halobium conferred resistance to both linezolid and chloramphenicol (Kloss et al., 
1999, Mankin and Garrett, 1991). In this context, some of the nucleotides that chloramphenicol 
interacts with most strongly have also been implicated in linezolid resistance, e.g., 2061, 2452, 
2500, 2504, 2505, 2506 (Table 4) (Schlunzen et al., 2001).
Howe et al., (2002) first noticed that the emergence of linezolid resistance was associated with 
loss of erythromycin resistance in laboratory-selected mutants of S. aureus. Wilson et al., (2003) 
confirmed this finding for a clinical isolate of S. aureus, and the relationship was also found in S. 
pneumoniae mutants (Carsenti et a l, 2003). However, the emergence of linezolid resistance does
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not always result in the loss of erythromycin resistance (Meka et a l, 2004b). To determine 
whether linezolid resistance and the G2576T mutation were incompatible with erythromycin 
resistance Sakoulas et al., (2003) tried to restore susceptibility in a linezolid-resistant S. aureus 
strain by introducing an erm{C) determinant. The successful incorporation of erm(C) did not result 
in linezolid susceptibility. It is not known why linezolid resistance causes loss of erythromycin 
determinants in some strains.
1.3.3.7 Detection of the molecular mechanism of linezolid resistance
Initial identification of a linezolid resistance mechanism was made by amplifying a region of the 
23S rRNA genes, followed by DNA sequencing (Swaney et al., 1998b). This enabled the detection 
of single nucleotide polymorphisms and gave a rough indication as to the ratios of wild-type versus 
mutated 23S rRNA gene copies (Swaney et a l, 1998b). The realization that most linezolid- 
resistant clinical isolates had the same mutation, G2576T, led to the development of a more rapid 
detection assay. Amplification of the 23S rRNA genes, followed by digestion with a restriction 
endonuclease NheI enabled detection of the G2576T mutation in staphylococci and enterococci. 
Furthermore, the restriction pattern produced allowed the distinction between hetero- and 
homozygosity (Woodford et a l, 2002). This method was adapted to allow a degree of gene 
quantitation by densometrically measuring the amounts of digested and undigested amplicons 
(Mazur et a l, 2002). The same principle has been applied to detect other mutations thought to 
confer linezolid resistance. Digestion of an amplified fragment of the 23 S rRNA genes with 
EcoRV will detect a G2505A mutation and with HinW will detect a T2504C mutation (Lobritz et 
al, 2003, North et a l, 2005b). Hetero- and homozygosity can be determined in both cases. This 
technique is accurate and can be applied to detect a variety of mutations, so long as these result in 
the acquisition or loss of a restriction site. Real-time PCR, with a lightcycler or Taqman system, 
was found to be a fast and accurate technique for the identification of a G2576T mutation in 
enterococci, although the need for expensive equipment is a disadvantage (Werner et a l, 2004, 
Woodford et a l, 2002).
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Pyrosequencing® A was successfully used for the detection of a G2576T mutation and estimation 
of the number of mutated 23S rRNA gene copies in enterococci (Sinclair et a l, 2003). During the 
pyrosequencing reaction, a sequencing primer hybridizes to single-stranded template DNA. The 
successful incorporation of a complementary nucleotide results in the emission of light that can be 
detected. The amount of light generated is directly proportional to the amount of nucleotide 
incorporated, thereby allowing quantification. However, this method works on the assumption that 
samples of the same species have a set amount of gene copies (Sinclair et al., 2003). In order to 
determine the number of 23S rRNA gene copies in linezolid-resistant isolates, Pillai et al., (2002) 
digested genomic DNA with the restriction endonuclease EcoRl. There is an identical EcoRl 
restriction site in each of the 23S rRNA genes and an additional variable restriction site 
downstream of each gene, meaning each gene can be distinguished by size. The products of 
digestion were separated by gel electrophoresis and southern blotted. Hybridization with a 420 bp 
DIG (digoxigenin)-labelled probe corresponding to domain V of the 23 S rRNA genes then enabled 
detection of each of the gene copies. Furthermore, by digesting genomic DNA with both NheI and 
EcoRl 23 S rRNA gene copies with a G2576T mutation were detectable. This technique allows 
successful quantification of 23 S rRNA gene copies, additionally, it allows comparison of restriction 
profiles produced by different strains. However, this method assumes that the downstream EcoRl 
sites are in different locations in all gene copies. Identical restriction sites in two or more copies 
would not be detectable. A similar technique was employed by Marshall et al., (2002) who used 
the restriction endonucleases EcoRl and Mae I to determine, firstly the number of 23 S rRNA gene 
copies and secondly, which of those had G2576T mutations.
1.3.3.8 Nosocomial spread of linezolid resistance
Resistance to linezolid, although still rare, is increasing, possibly due to growing use (Hogan et 
al., 2005). Resistance is confined to individual patient isolates in most cases, although in 2002 and 
2003, nosocomial spread of linezolid-resistant E. faecium strains were reported in the USA 
(Engemann et al., 2003, Herrero et al., 2002). More recently, reports of nosocomial spread of
(A Pyrosequencing and Pyrogram are registered trademarks of Biotage).
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linezolid-resistant CNS in the USA have been published (Fraimow et a l, 2005, Potoski et al.,
2006). Since the horizontal transfer of resistance is unlikely to occur, early detection would 
prevent the spread of such linezolid-resistant strains between patients.
1.4 Hypermutability
One concern for the emergence of linezolid resistance is the presence of strains with an elevated 
mutation rate which might be predisposed to developing resistance to linezolid. Hypermutability is 
a term used to describe the situation of organisms with elevated mutation rates. The mechanisms 
underlying hypermutability are most often associated with mutations in the genes encoding the 
DNA mismatch repair (MMR) machinery, resulting in the failure to correct mismatched bases 
incorporated during replication. In turn, this results in a hypermutable phenotype. Strains in the 
clinic with a hypermutable phenotype could be pre-disposed to developing resistance to antibiotics, 
especially where resistance is conferred by a single chromosomal mutation, followed by 
recombination, as is the case with linezolid. This section discusses the processes involved in DNA 
repair and the evidence for hypermutability in bacterial populations.
1.4.1 DNA repair mechanisms
1.4.1.1 Mismatch repair
Mutations in DNA arise during replication, homologous recombination, and as a result of DNA 
damage. Bacteria have DNA repair mechanisms in place to correct these mutations and ensure the 
fidelity of the genome; one of these is the MMR pathway (Schofield and Hsieh, 2003).
The MMR machinery is thought to be able to distinguish between the hemimethylated parent and 
daughter DNA strands and can direct its component parts, MutS, MutL and MutH, towards the 
daughter strand (Yang, 2000). MutS proteins follow behind the DNA polymerase and scan the 
newly synthesised strand, recognising and binding to seven of eight possible mismatches as well as 
to short insertions or deletions that have arisen via misincorporation of nucleotides or template 
slippage (Figure 6) (Schofield et al., 2001). MutS, present as a homodimer, recognises and binds
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Figure 6. The interaction of MutS and MutL at a mismatch. (From Schofield et al., (2001). 
MutS in solution (A) binds to a mismatch in an induced fit model involving extensive 
conformational changes in both MutS and the mismatch DNA (B). Binding of ATP induces an 
additional conformation change (C) resulting in diffusion o f MutS away from the mismatch (D). 
The signal to initiate downstream events is provided when MutL associates with MutS that has 
bound both a mismatch and ATP and prevents MutS from leaving the immediate vicinity o f the 
mismatch (E). This MutS-MutL complex is postulated to be a critical intermediate in the activation 
of MutH for incision of the daughter strand (F).
GATC
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to a mismatch, capturing the DNA between the two MutS molecules (Lamers et al., 2000). The 
binding of a DNA mismatch and ATP produces a conformational change in the MutS homodimer 
(Lamers et al., 2000, Lamers et al., 2004, Schofield et al., 2001). There are several theories as to 
how the binding of MutS to a mismatch signals subsequent proteins to assemble at the site of the 
mismatch. Allen et al., (1997) and Blackwell et al., (1998) proposed the translocation of MutS 
away from the mismatch was the trigger. Gradia et al., (1997, 1999) suggested the transformation 
of MutS into a sliding clamp which diffuses away from the mismatch triggered downstream events. 
Alternatively Junop et al., (2001) and Schofield et al., (2001) proposed the association of MutL 
with MutS that has bound ATP in situ was the trigger for ensuing actions. Regardless of the exact 
mechanism, MutL and MutH assemble at the site of the mismatch. MutL associates with MutS and 
the mismatch, and is thought to activate MutH and mediate interactions between MutS and MutH 
(Grilley et al., 1989). Additionally Schofield et al., (2001) proposed that MutL prevents MutS 
from leaving the immediate vicinity of the mismatch. In E. coli MutH is an endonuclease that 
nicks the daughter strand at methylation sites (GATC), enabling strand discrimination. However, 
no MutH protein has been found in gram-positive bacteria nor in some species of gram-negative 
bacteria, including Neisseria and Pseudomonas aeruginosa (P. aeruginosa)', rather it has been 
suggested an endonuclease homologue breaks the newly synthesised strand enabling strand 
discrimination (Jacquelin et al., 2005, Kline et al., 2003, Merino et al., 2002). Next, DNA helicase 
separates the two DNA strands, the defective daughter strand is degraded by an exonuclease and 
DNA polymerase fills in the gap before DNA ligase seals the strands (Yang, 2000).
The mismatch repair system is also thought to police homologous recombination events to ensure 
the fidelity of the genome. It has been shown to act as a barrier to interspecies recombination 
between E. coli and Salmonella. Inactivation of this system enables the transduction (i.e., phage 
mediated transfer) of chromosomal genes between similar species (Matic et al., 1994, Zahrt et al., 
1994).
1.4.1.2 SOS response
Another DNA repair mechanism implicated in hypermutability is the SOS response. In 1974
Radman determined that when bacteria are subjected to stress, proteins are produced that repair
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DNA damage and reactivate DNA synthesis. He proposed that this process, termed the SOS 
response, was also linked to mutability (Radman, 1974). The SOS response is controlled by two 
genes: lexA encodes for a suppressor protein and recA encodes for an anti-repressor protein, 
required to remove LexA (Gudas and Pardee, 1975). The SOS genes are scattered around the 
chromosome and their expression is controlled by the proteins LexA and RecA. LexA binds to the 
operons of the SOS genes and represses their transcription. When DNA is damaged, RecA 
facilitates the cleavage of LexA, decreasing the levels of LexA and enabling expression of the SOS 
genes (Little and Mount, 1982). In E. coli, three error-prone DNA polymerases are induced (Pol II, 
Pol IV and Pol V) as part of the SOS response (Yeiser et al., 2002). Their induction and 
involvement in DNA repair results in an increase in the number of mutations within the genome 
and, hence, a competitive advantage (Yeiser et al., 2002).
1.4.2 Hypermutability in clinical isolates
Hypermutators have been found in naturally occurring bacterial populations. LeClerc et al., 
(1996) determined that hypermutable isolates comprised more than 1% of E. coli and salmonella 
pathogens. Matic et al., (1997) surveyed mutation frequencies of E. coli isolates from different 
environments and discovered a high incidence of mutators, both pathogenic and commensal. 
Hypermutators have also been associated with clinical bacterial populations, especially in the 
lungs of patients with cystic fibrosis. Cystic fibrosis sufferers have altered electrolyte secretion by 
cells in the lungs, resulting in the production of a viscous mucus. Consequently the lung’s major 
anti-infective defence systems are impaired, resulting in chronic lung infection (Prunier et al., 
2003). The most commonly isolated species from the sputum of cystic fibrosis patients are P. 
aeruginosa (80%) and S. aureus (33-60%) (Govan and Nelson, 1992). Repeated treatment with 
antibiotics to combat persistent infections selects for multiply-resistant strains (Macia et al., 2005). 
Oliver et al., (2000) determined mutation frequencies to rifampicin for P. aeruginosa strains from 
30 cystic fibrosis patients. Results revealed 37% of patients harboured strains with a mutator 
phenotype whereas no hypermutable strains were isolated from non-cystic fibrosis patients. The 
epidemiology of these mutator strains suggested one or two successful strains that persisted in the
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lungs of patients over a number of years. Deletions in the mutS gene were detected in some strains 
and complementation of mutS lowered their mutation frequencies. A similar finding was made by 
Macia et al., (2005), who concluded that hypermutable strains of P. aeruginosa were extremely 
frequent in cystic fibrosis patients. However, a conflicting report from Gutierrez et al., (2004) 
concluded that the prevalence of hypermutable strains of P. aeruginosa in cystic fibrosis patients 
was low. In other species, Roman et al., (2004) reported hypermutable strains of Haemophilus 
influenzae (H. influenzae) in 33% of cystic fibrosis patients and Watson et al., (2004) found 
hypermutable H. influenzae isolates to have polymorphisms in the mutS gene.
Less research has been conducted concerning the prevalence of hypermutable S. aureus strains in 
cystic fibrosis patients. Prunier et al, (2003) found 13 of 89 isolates from cystic fibrosis patients 
were hypermutable and alterations in the mutS gene were found in five of eleven (45%) of these 
hypermutable strains tested. Conversely, O’Neill et al., (2002) studied 49 S. aureus isolates from 
cystic fibrosis patients and found little evidence for the existence of hypermutability.
It should be cautioned that comparisons between studies are difficult due to the lack of a 
standardized definition of hypermutability. Studies refer to hypermutable isolates as displaying 
mutation frequencies greater than 10'7 (Prunier et al., 2003) or > 10-fold greater than a laboratory 
strain (O'Neill and Chopra, 2002); alternatively divisions between mutators and non-mutators are 
made on a relative basis according to the results obtained in the study (Oliver et a l, 2000). 
Differences in methodologies could also be a source of varying mutation frequencies.
1.4.3 Transient hypermutability
Hypermutable organisms are not always detectable within multi-resistant bacterial populations. 
This is possibly because the organisms pass through temporary periods of high mutation, enabling 
rapid generation of genetic diversity to occur, followed by restoration of lower mutation rates. 
Perhaps such a period of transient hypermutability would reduce the risk of deleterious mutations 
that could have a fitness cost or lethal consequences (Chopra et al., 2003, Denamur et al., 2002). 
Alternatively it is possible that, within a bacterial population, a proportion of organisms are always 
undergoing a period of hypermutability, ensuring the population can benefit as a whole, if and
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when necessary, without suffering disadvantageous mutations (Blazquez et a l, 2002). However, 
proving that transient periods of hypermutability occur is difficult, as previous episodes do not 
leave detectable markers. Denamur et al., (2002) suggested that E. coli strains repeatedly pass 
through periods of high mutations rates during their evolutionary history, regardless of whether 
they are commensal or pathogenic.
These periods of hypermutability could be stress induced. Bjedov et al., (2003) found more than 
50% of worldwide strains of E. coli showed a high rate of stress induced (carbon-source starvation 
and oxidative shock) mutagenesis as a result of down-regulation of the MMR system and up- 
regulation of the SOS response. Furthermore, Denamur et al., (2000) proposed that MMR genes 
passed through periods of high mutation and recombination, allowing rapid generation of genetic 
diversity and adaptation, followed by a means of restoring lower mutation rates.
The induction of the SOS response is probably the best known example of transient 
hypermutability. DNA damage results in the induction of the SOS system, an error-prone DNA 
repair pathway, which results in many mutations. A selected beneficial mutation will enable 
survival and result in the down-regulation of the SOS response.
1.4.4 Hypermutability and the emergence of antibiotic resistance
Organisms containing a beneficial antibiotic resistance mechanism will be selected in the presence 
of that antibiotic. Furthermore, it has been suggested that antibiotics can inadvertently increase the 
chances of resistance occurring to new antimicrobials by selecting for mutator strains (Blazquez et 
al., 2002, Blazquez, 2003, Livermore, 2003). This theory assumes, to a certain extent, that 
hypermutability may be co-selected with resistance, since resistance is more likely to evolve in 
hypermutable strains but direct evidence for this theory is conflicting.
Mao et al., (1997) proposed that a single selection step can increase the percentage of mutators 
from 0.001% to 0.5% in a strain of E. coli and subsequent selection steps can result in the majority 
of the population being over-run by mutators. Komp et al., (2003), after studying E. coli isolates 
from urinary tract infections, determined that there was a strong relationship between antibiotic 
resistance and high mutation rate; selection for mutations conferring fluoroquinolone resistance co­
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selected for strains with an elevated mutation rate. Similarly, Miller et al., (2004b) proposed that 
the presence of mutators offered an enhanced risk for the emergence of antibiotic resistance during 
treatment of urinary tract infections (UTI) infections. However, Denamur et al., (2002) did not 
find mutator strains to be more often resistant than non-mutators and concluded that antibiotic 
selection pressure was probably not the major factor in the emergence of mutator strains. Baquero 
et al., (2004) likewise were unable to find any significant association between mutator phenotypes 
and antibiotic resistance in E. coli isolates from the clinic and from healthy volunteers from Spain, 
Denmark and Sweden.
Several of the studies involving isolates from cystic fibrosis patients make the association 
between hypermutability and the emergence of mutational antibiotic resistance. Oliver et al., 
(2000) hypothesized that rapid adaptation was required for survival in the lungs of patients with 
cystic fibrosis. Mutator P. aeruginosa strains were found to have multiple resistances, and due to 
their status as hypermutators, were likely to become resistant to new compounds. Prunier et al., 
(2003) investigated the mechanisms of resistance to macrolides in hypermutable S. aureus strains 
from cystic fibrosis patients and concluded that ribosomal mutation was the prevalent mechanism 
of resistance, possibly due to the higher proportion of hypermutable strains present. Furthermore, 
Giraud et al., (2002) concluded that by selecting for a resistance allele, a mutator allele was also 
selected as the mechanism that generated the resistance, therefore one failed therapy is a potential 
risk factor for the next. Oliver et al., (2004) and Negri et al., (2002) have also suggested the use of 
low, sub-inhibitory concentrations of antibiotics could provide conditions for the selection of 
hypermutable strains.
It has been suggested that certain DNA damaging antibiotics, such as fluoroquinolones, cause an 
increase in the mutation rate by inducing the SOS response (Phillips et al., 1987). Somewhat 
ironically, this induction of the SOS response could initiate a high mutation rate and therefore a 
greater chance of the emergence of favourable mutations that could result in resistance to the 
inducing antibiotic. Resistance to quinolones is associated with several mutations and the accrual 
of multiple mutations is associated with a corresponding increase in MIC (Ferrero et al., 1995, 
Fournier and Hooper, 1998, Ito et al., 1994). It was thought that the requirement of multiple 
mutations may delay the emergence of resistance to quinolones, however, hypermutators may
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rapidly provide organisms with the necessary mutations (Wang et al., 1998). This induction of the 
SOS response is not solely limited to DNA damaging antibiotics; more recently Miller et a l, 
(2004a) and Maiques et al., (2006) discovered that (3-lactam antibiotics are an extracellular 
stimulator of the SOS response in E. coli and S. aureus. By using SOS-inducible prophages, 
Maiques et al., (2006) showed exposure to p-lactam antibiotics resulted in phage reproduction and 
therefore induction of the SOS response in S. aureus. They also confirmed the finding of Ubeda et 
al., (2005) who noted exposure to P-lactam antibiotics promoted the transfer of virulence factors 
via pathogenicity islands in an SOS-dependent manner in S. aureus (Maiques et al., 2006).
Persistent exposure to antibiotics selects for antibiotic-resistant strains. The question is whether, 
in selecting for antibiotic-resistant strains, hypermutable strains are being co-selected, resulting in a 
population with a high number of mutators and therefore a more favourable chance of surviving the 
next antibiotic exposure? These hypermutators could present an increased risk of resistance 
occurring to antibiotics where resistance is conferred by chromosomal mutation, such as linezolid. 
Therefore treatment with multiple antibiotics is advisable (Chopra et al., 2003, Giraud et al., 2002, 
Oliver et al., 2004). Although the evidence is not entirely conclusive, this could explain the 
presence of hypermutable multi-resistant strains in cystic fibrosis patients and those with persistent 
UTI infections. Conflicting evidence does leave the door open for other unknown mechanisms for 
mutator selection.
1.5 Summary
In summary, S. aureus is a major nosocomial pathogen, worldwide, which is now emerging in the 
community setting. Many S. aureus strains are resistant to many antibiotics, meaning few 
treatment options are available. Linezolid, along with teicoplanin and vancomycin, is one of the 
antibiotics of last resort available to treat multi-resistant S. aureus strains. Resistance to linezolid 
in clinical isolates of S. aureus is rare but, nevertheless, does occur. Similarly, chromosomal 
mutational resistance to teicoplanin and vancomycin has been detected in S. aureus isolates from 
the clinical setting. It has been proposed that the emergence of chromosomal mutations conferring 
resistance to these antibiotics might be facilitated by a hypermutable phenotype. Due to a faulty
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mismatch repair system, a higher proportion of chromosomal mutations go uncorrected. This in 
turn might accelerate the development of resistance in the population and might lead to the co­
selection of hypermutability with these difficult to select resistances.
1.6 Aims and hypothesis
At the beginning of this project (March 2003) resistance to linezolid was infrequent, however, it 
had been reported in clinical isolates of E. faecium and E.faecalis (Zurenko et al., 1999) and in one 
clinical isolate of S. aureus (Tsiodras et al., 2001). Preliminary studies indicated that resistance 
was due to single nucleotide polymorphisms in the 23S rRNA genes. At this time the involvement 
of hypermutability in the emergence of linezolid resistance was unknown, although the importance 
of hypermutability in general was increasingly discussed, mostly in connection with gram-negative 
bacteria. Reports on the presence of hypermutable S. aureus strains in the clinic were limited. 
Therefore the aims of this project were:
(i) to study the mechanism and development of resistance to linezolid in staphylococci, 
including assessing the number of 23 S rRNA copies mutated in resistant isolates and 
mutants
(ii) to investigate the role of hypermutability in the emergence o f linezolid and teicoplanin 
resistance
(iii) to establish whether teicoplanin-resistant isolates express a hypermutator phenotype 
and as a consequence have an increased capacity to develop resistance to other anti- 
gram-positive antibiotics, such as linezolid.
The hypothesis to be tested was that resistance to linezolid could emerge more readily in 
hypermutable strains of S. aureus, and that hypermutability might be co-selected with resistance to 
linezolid or glycopeptide antibiotics.
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2 Materials and methods
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2.1 Bacterial identification
2.1.1 Clinical isolates
S. aureus isolates, obtained from hospital patients in the UK or Brazil (Table 5) and suspected to 
have reduced susceptibility to linezolid, were referred to the Antibiotic Resistance Monitoring and 
Reference Laboratory (ARMRL) at the Centre for Infections, Health Protection Agency (HPA) 
(London) for testing. A representative MSS A isolate, from the clinic, was used when establishing 
PFGE profiles and mutation frequencies. A pair of genetically-related teicoplanin-susceptible and - 
resistant isolates (ST/03/2121 and ST/03/2122), where resistance to teicoplanin emerged during 
therapy, were used for the generation of linezolid-resistant mutants and estimation of mutation 
frequencies. Genetically-related erythromycin-susceptible and -resistant pairs of S. aureus isolates, 
referred to ARMRL in 2002, were used to select linezolid-resistant mutants in-vitro. Details of 
these strains are listed in Table 6. A clinical S. aureus isolate, ST 251, was used as an internal 
control strain when determining MICs (Table 7). Teicoplanin-resistant S. aureus isolates, 
submitted to ARMRL for antibiotic testing from 2003-2005, were used to determine mutation 
frequencies to rifampicin and fusidic acid (Table 8).
2.1.2 Reference strains
Reference strains of S. aureus ATCC 29213, NCTC 12493 and NCTC 6571, were used as 
controls when determining MICs (Table 7). MICs of a range of antibiotics for these strains are 
shown in Table 7. Strains NCTC 13142 and NCTC 13143 were used as representatives of 
EMRSA-15 and EMRSA-16, respectively (Table 6). The laboratory strain RN4220 was used as a 
wild-type control strain and its wwAS-negative mutant, RN4220A/ww/£', as a hypermutable control 
strain (O'Neill and Chopra, 2002) (Table 6).
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Table 5. Suspected linezolid-resistant clinical isolates of S. aureus used in this study.
Patient No. Isolate Place of isolation Site of isolation
la H045360367 Kent (UK) Sputum (CFa patient)
lb H053540293 Kent (UK) Sputum (CF patient)
2a H045360368 Kent (UK) Sputum (CF patient)
2b H053540294 Kent (UK) Sputum (CF patient)
3a H042800236 Nottingham (UK) Swab from penis
3b H042800257 Nottingham (UK) Swab from drain site
3c H042800258 Nottingham (UK) Swab from perineum
4a H053760467 Dublin (UK) Sputum (CF patient)
4b H053760478 Dublin (UK) Sputum (CF patient)
5a Brazilian 1 (Bl) Porto Alegre (Brazil) Sputum (CF patient)
5b Brazilian 2 (B2) Porto Alegre (Brazil) Sputum (CF patient)
A Cystic fibrosis (CF)
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2.1.3 Identification of S. aureus
Isolates submitted to the Staphylococcus Reference Unit (HPA, London) for testing, presumed to 
be S. aureus, were identified by plating on CHROMagar (agar 15.0 g/L, peptone 40.0 g/L, sodium 
chloride 25.0 g/L, chromogenic mix 2.5 g/L, pH 6.9). S. aureus colonies appeared mauve, while 
other bacteria appeared blue, white or growth was inhibited (e.g. S. haemolyticus appeared blue).
2.2 Media, chemicals and apparatus
2.2.1 Media
Brain Heart Infusion (BHI) agar and broth, IsoSensitest (ISO) agar and broth, Nutrient Agar (NA) 
and Nutrient Broth (NB), Mueller-Hinton Agar (MHA), Columbia Agar (CA), Columbia Blood 
Agar (CBA) and Phosphate-Buffered Saline (PBS) (0.01 M, pH 7.4), (all from Oxoid Ltd. 
[Basingstoke, UK]) and CHROMagar (CHROMagar Microbiology, Paris) were used during the 
course of this work. See Appendix A Table 40 for more details.
2.2.2 Chemicals and apparatus
Chemicals and apparatus used in this study, together with a list of suppliers, are shown in 
Appendix A Table 41 and Table 42.
2.3 Antibiotic susceptibility testing
2.3.1 Antibiotics
The following antibiotics were used: chloramphenicol, ciprofloxacin, clindamycin, erythromycin, 
fosfomycin, fusidic acid, linezolid, oxacillin, quinupristin/dalfopristin, rifampicin, teicoplanin and 
vancomycin (see Appendix A Table 43 for suppliers). Antibiotics were dissolved according to 
BSAC guidelines (Andrews, 2001, Andrews, 2005). A stock solution was prepared and diluted,
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with an appropriate diluent, to give the required antibiotic range after being incorporated into agar 
(MacGowan and Wise, 2001). See Table 7 for antibiotic ranges tested and breakpoints used.
2.3.2 Determination of MICs by agar dilution
MICs were determined according to BSAC guidelines (Andrews, 2001, Andrews, 2005). Freshly- 
grown bacteria were suspended to a density of a 1.0 McFarland standard (approximately 1.0 x 108 
colony forming units (cfu/ml) in NB to ensure the correct inoculation density. Control strains with 
known MICs were included (Table 6 and Table 7). Antibiotics were incorporated into a series of 
ISO agar plates to yield a two-fold dilution series. ISO agar control plates, with no antibiotic 
incorporated, were also poured. Oxacillin was incorporated into CA with the addition of 2% NaCl. 
Where fosfomycin was incorporated into agar, 1 mg/L G-6-P was added to molten agar before 
pouring; G-6-P induces the glycerophosphate transport system, which aids the transport of 
fosfomycin into the cell (Kahan et al., 1974). Plates were dried before being inoculated with 104 
cfu/spot, using a multipoint inoculator, and were incubated at 37°C for 18-20 hours, except for 
oxacillin, which was incubated at 30°C for 24 hours. After incubation, control plates were checked 
for growth and MICs were read as the lowest concentration of antibiotic at which there was no 
visible growth of the organism. MICs for control organisms were checked to ensure they were 
within one two-fold dilution of the expected MIC (Table 7).
2.3.3 Determination of MICs by E Test
E Test strips were used to determine MICs of chloramphenicol, erythromycin, fosfomycin, fusidic 
acid, linezolid, rifampicin, teicoplanin and vancomycin. Freshly-grown bacteria were suspended to 
a density of a 1.0 McFarland standard in NB and used to inoculate an ISO agar plate with a swab so 
as to yield confluent growth. An E Test strip was placed on the agar in the direction of inoculation. 
The plate was incubated for 18-20 hours. The MIC was read at the point where the area of growth 
inhibition (including haze and isolated colonies) intersected the scale. The end point was read at 
complete inhibition of all growth, except for linezolid, which was read at 80% inhibition.
2.3.4 Population analysis
Population analysis was used to identify heterogeneous resistance to vancomycin and teicoplanin 
by detecting the existence of a sub-population of organisms for which the MIC was above the 
breakpoint. A streaked plate of freshly-grown bacteria was used to inoculate 10 mis of ISO broth 
which was incubated at 37°C for 24 hours. BHI agar plates containing appropriate dilutions of 
antibiotic (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0 mg/L) were poured and dried. Serial 
dilutions of 10'1 to 10'8 were prepared in PBS, from the overnight growth, and 2 x 20 pi drops of 
each dilution where plated at each antibiotic concentration and, additionally, on antibiotic-free 
media (CBA). Plates were incubated at 37°C for 24 hours. The viable count on antibiotic-free agar 
and at each antibiotic concentration was calculated and plotted.
2.3.5 Erythromycin/clindamycin synergy test
In order to detect inducible or constitutive macrolide resistance encoded by erm genes, a 0.5 
McFarland standard suspension was prepared from freshly-grown bacteria and spread on MHA, so 
as to yield confluent growth. Erythromycin discs (15 pg) and clindamycin discs (2 pg) were 
placed 15-20 mm apart. Following incubation at 37°C for 16-18 hours, growth up to the edge of 
the clindamycin disc was considered to indicate constitutive resistance while any flattening or 
blunting of the clindamycin zone was considered to indicate inducible resistance (Figure 7) 
(Fiebelkorn et al., 2003). It is acknowledged that growth up to the edge of the clindamycin disc 
could also indicate the presence of a lincosamide resistance mechanism, such as lin{A) along with 
an independent mechanism of macrolide resistance, e.g., by efflux (Lina et al., 1999b), but these 
combinations are rare.
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Figure 7. Disc diffusion testing for inducible clindamycin resistance in S. aureus (From 
Fiebelkorn et al., 2003). (A) Positive disc induction test showing blunting of the zones around the 
clindamycin disc, indicating inducible lincosamide resistance. (B) Negative disc induction test 
indicating the absence of inducible lincosamide resistance.
A)
lindamycin
erythromycin
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2.4 Growth of S. aureus
2.4.1 Growth conditions
RN4220A/WW/S was grown at 42°C or in the presence of a 30 pg erythromycin disc to maintain 
integration of the thermosensitive plasmid used to disrupt the mutS gene. All other strains were 
grown at 37°C.
2.4.2 Replica plating
Freshly grown bacteria were suspended to a density of a 1.0 McFarland standard in NB which was 
then serially diluted from 10'1 to 10'8 in PBS. Aliquots (200 pi) of 10'4 to 10'8 dilutions were 
spread on BHI agar plates and incubated at 37°C for 24 hours. Plates with between 50 and 100 
colonies were selected and colonies were transferred to BHI agar plates, one containing a suitable 
antibiotic, and the other drug-free, by replica plating, using a circular wooden block covered with 
sterile velvet. The two replica plates were then incubated for a further 24 hours at 37°C. The 
number of colonies on the original and both replica plates were recorded and compared.
2.4.3 Growth curves
Approximately four colonies of freshly-grown bacteria were used to inoculate 5 mis of ISO broth 
which then was incubated overnight at 37°C. ISO broth, 50 ml, was inoculated to a starting density 
of 0.05-0.1 (as measured at 600 nm) using approximately 100-200 pi of this overnight broth. This 
culture was incubated at 37°C, with gentle shaking, for approximately 9-10 hours. Samples were 
taken and the density read at 600 nm on a spectrophotometer every 10 minutes for the first 5 hours 
and every 45 minutes thereafter. To test whether the growth of erythromycin-resistant strains were 
affected by the presence of erythromycin, 100 mg/L of this drug was added to the broths.
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2.5 Selection of antibiotic-resistant S. aureus mutants in vitro
2.5.1 Selection of linezolid-resistant mutants
2.5.1.1 Method A
Strains were grown in 10 ml ISO broth for 24 hours. One millilitre of this culture was transferred 
to 10 ml fresh ISO broth and incubated at 37°C for approximately seven hours before linearly- 
increasing concentrations of linezolid were added (up to 10 mg/L in 0.5 mg/L increments). 
Cultures were incubated for a further 17 hours before being subcultured to fresh broth and left to 
grow before linezolid was added. After multiple passages, mutants able to grow in the presence of 
10 mg/L linezolid were transferred to BHI agar containing 10 mg/L linezolid and were passaged 
five times at this concentration, in an attempt to stabilize resistance. Mutants were characterized by 
MIC determinations, and PFGE was performed to confirm parentage.
2.5.1.2 Method B
Strains were grown on BHI agar plates containing increasing concentrations of linezolid (in 2 
mg/L increments, from 2 to 10 mg/L). Agar plates were incubated at 37°C for up to five days 
before colonies were picked off and passaged on agar containing the same or an increased 
concentration of linezolid. Once mutants were able to grow on BHI agar containing 10 mg/L 
linezolid, they were passaged five times at this concentration, in an attempt to stabilize resistance. 
Mutants were characterized by MIC determinations and PFGE to confirm parentage.
2.5.2 Generation of linezolid-resistant isolates in the presence of erythromycin
Erythromycin-resistant and -susceptible pairs of genetically-related isolates were grown on BHI 
agar containing increasing concentrations of linezolid (in 2 mg/L increments, up to 10 mg/L) in the 
presence or absence of erythromycin (100 mg/L) (see Figure 8 for details). Mutants were 
characterized by MIC determination, PFGE to confirm parentage, and PCR with primers erm{B)
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and erm{AJC) to confirm the presence or absence of erm determinants (see section 2.7.2, Table 9 
and Table 10 for details of PCR cycling conditions and primers, respectively).
2.5.2.1 Degradation of linezolid
To ensure that the slow emergence of colonies on agar containing linezolid was due to resistance 
and not the result of linezolid degradation, a set of linezolid MIC determination plates were poured 
(range 0.064 to 256 mg/L) and kept at 37°C for 5 days. On the fifth day, a second set of linezolid 
MIC determination plates were poured, both sets were dried and inoculated with strains with 
known linezolid MICs. Plates were incubated at 37°C for 24 hours. The two sets of MICs were 
read and compared.
2.5.3 Selection of chloramphenicol-resistant mutants
A similar methodology was employed to that used for raising linezolid-resistant mutants (see 
section 2.5.1.2). Strains were grown on BHI agar containing increasing concentrations of 
chloramphenicol (in 2 mg/L increments, from 2 to 16 mg/L). Once mutants could grow 
successfully at 16 mg/L chloramphenicol they were passaged five times at this concentration. 
Mutants were characterized by MIC determinations and PFGE.
2.6 Characterization of mutants of S. aureus
2.6.1 Extraction and purification of bacterial chromosomal DNA
BHI broth (5 ml) was inoculated with a 10 pi loop of freshly-grown bacteria and incubated 
overnight at 37°C with gentle shaking. Bacteria were harvested from 700 pi of this overnight 
growth and re-suspended in 100 pi salt/EDTA buffer (2.5 M NaCl, 50 mM EDTA, pH 7.5) to 
which was added 50 pi lysostaphin (stock solution of 1 mg/ml) and 100 pi lysozyme (stock 
solution of 100 mg/ml) and incubated at 37°C for a minimum of 1 hour. After lysing with 500 pi 
of GES (5.0 M guanidium thiocyanate, 0.1 M EDTA, 0.5% [w/v] sarkosyl), 250 pi of ammonium
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acetate (7.5 M) was added, mixed and left on ice for 10 minutes. Phenol:chloroform:isoamyl 
alcohol (25:24:1, saturated with 10 mM Tris, pH 8.0, 1 mM EDTA), 500 jxl, was then added and 
mixed well by hand for 10 minutes. The two phases were separated by centrifugation at 18300 x g 
for 10 minutes. The upper phase, 350 pi, was added to 875 pi of ice-cold ethanol and kept at - 
20°C for a minimum of one hour. DNA was spooled on to a 1 pi loop, washed with 1 ml 
ammonium acetate mix (1.5 M ammonium acetate in 70% ethanol) followed by 1 ml 100% 
ethanol, dried, and dissolved overnight at 4°C in 100 pi TE buffer (10 mM Tris, 1 mM EDTA, pH
8.0). Bacterial chromosomal DNA preparations were stored at -20°C.
2.6.2 Long and accurate PCR
Long PCR was used to confirm the presence or absence of the pGhost9+ plasmid inserted to 
disrupt the mutS gene in RN4220Amwf«S' and its descendants. A mastermix containing 1 pi (stock 1 
pg/pl) forward primer, 1 pi (stock 1 pg/pl) reverse primer, 1.75 pi of each of dATP, dCTP, dGTP, 
dTTP, 5 pi of 10 x PCR buffer (containing 17.5 mM MgC^), 0.75 pi of Expand Long Template 
PCR mix (Roche) and 34.25 pi of PCR-quality water (Sigma) was prepared, vortexed and 
centrifuged briefly. A final reaction volume was achieved by adding 1 pi of chromosomal DNA 
preparation (see section 2.6.1) to 49 pi of mastermix. Tubes were vortexed and centrifuged briefly 
before being transferred to a thermocycler (P x 2 Thermocycler [Thermo]). Details of PCR cycling 
conditions can be seen in Table 9 and PCR primers in Table 10; see section 2.7.3 for analysis of 
PCR products.
2.6.3 Pulsed-field gel electrophoresis (PFGE)
S. aureus strains were grown overnight on NA at 37°C, then suspended in 1 ml of SE buffer (75
mM NaCl, 25 mM EDTA, pH 7.5) to a density equivalent to a McFarland suspension of 2.4 - 2.6
using a spectrophotometer (Densimat). Bacterial suspension, 400 pi, was mixed with 400 pi of 2%
low-gelling agarose (dissolved in SE buffer) at 56°C and dispensed into moulds (five replicates per
isolate). Moulds were kept at 4°C until set. Agarose plugs, from the moulds, were incubated in 3
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ml gram-positive lysis buffer (6 mM Tris, 100 mM EDTA, 1M NaCl, 0.5% w/v Brij 58, 0.25 w/v 
sodium deoxycholate, 0.5% N-lauroyl sarcosine, 1 mM MgCb) containing 30 units/ml lysostaphin 
and 500 pg/ml lysozyme at 37°C, overnight, with gentle shaking. The lysis buffer was replaced 
with 3 ml gram-negative buffer (1% (w/v) N-lauroyl sarcosine, 0.5 M EDTA pH 9.5) containing
3.6 pi proteinase K (stock solution of 50 mg/ml) and incubated overnight at 56°C with gentle 
shaking. Agarose plugs were washed three times in 3 ml amounts of TE buffer. A portion of each 
plug was cut (approx 2 mm), covered with 100 pi reaction buffer (33 mM Tris acetate, 10 mM 
magnesium acetate, 66 mM potassium acetate, 0.5 mM dithiothreitol) and incubated at 4°C for a 
minimum of 30 minutes. The buffer was then replaced with fresh reaction buffer to which was 
added 2 pi of Smal restriction endonuclease (10 units/pl). Incubation was at 30°C for a minimum 
of 4 hours. A 1.2% agarose gel (molecular grade) was prepared in 0.5 x TBE buffer. Digested 
plugs were loaded into the wells along with molecular weight markers (lambda concatamer ladder) 
and the wells were sealed with molten agarose. The gel was placed into an electrophoresis tank 
(CHEF DR II apparatus) and 2 litres of electrophoresis buffer (0.5 TBE buffer), cooled to 4°C, 
were added. Standard running conditions were 6 V/cm, 12°C for 30 hours, switch times ramping 
from 1 to 80 seconds. Running conditions were altered to 6 V/cm, 12°C for 23 hours, with switch 
times ramping from 1 to 15 seconds in order to resolve fragments of 10-150 Kb. The PFGE gel 
was stained for 90 minutes with ethidium bromide (1 pg/ml), destained for 1 hour with distilled 
water, visualised under UV light, photographed and the image was stored electronically as .tif and 
.jpeg files.
2.7 Detecting and characterizing chromosomal mutations conferring 
antibiotic resistance
2.7.1 Primer design
Primers were designed manually using GenBank sequences (www.ncbi.nlm.nih.gov), accession
numbers BA 00018 (S. aureus N315 complete genome) and X68425 (S. aureus gene for 23 S
rRNA). The genome sequence of NCTC 8325 (http://micro-gen.ouhsc.edu/s_aureus/s_aureus_
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home.htm) was also used. Two primers were designed for each gene, spanning an area of interest. 
Forward and reverse primers were designed with two to three A or T bases at the 5’ end and with 
two to three G or C bases at the 3’ end. Primers were designed to be approximately 20 bp in length 
and to have a melting temperature of between 55°C and 65 °C. Primers were checked for secondary 
structure, self-annealing and melting temperature using an on-line oligo calculator 
(www.basic.northwestern.edu/biotools/oligocalc.html). Primers were also checked for specificity 
using the on-line BLAST tool (Basic Local Alignment Search Tool) (www.ncbi.nlm. 
nih.gov/BLAST).
2.7.2 PCR amplification of 23S rRNA genes and detection of antibiotic resistance 
genes
S. aureus strains were grown overnight on NA at 37°C. Two colonies were suspended in 100 fxl 
of PCR-quality water. Tubes were vortexed and centrifuged briefly. A PCR mastermix was 
prepared (78 jxl PCR quality water, 10 |_il 10 x Taq polymerase buffer, 5 |xl Buffer W l, 4 |xl MgCL 
[50 mM], 2pl dNTP mix [2.5 |xl of each of dATP, dGTP, dTTP, dCTP], 4 jxl primer mix [5 |xl of 
each primer; stock concentration of 1 jxg/|xl and 90 jxl PCR quality water] and 0.5 |xl Taq 
polymerase) for four reactions (or multiples of), vortexed and centrifuged briefly. A final reaction 
volume was achieved by adding 23 jxl of the PCR mastermix to 2 jxl of the template DNA. Tubes 
were vortexed and centrifuged briefly before being transferred to a thermocycler. PCR was also 
carried out in a 96-well PCR plate. Mastermix volumes were scaled-up appropriately and aliquoted 
into a plate using a multichannel pipette. Details of PCR cycling conditions and primers are given 
in Table 9 and Table 10 respectively.
2.7.3 Analysis of PCR products
Agarose gels, of suitable percentage (0.7-2.5%) were prepared by addition of 0.5 x TBE buffer to 
molecular grade agarose. Gel loading dye, 4 |xl, (50 mM EDTA pH 8, 25% ficoll, 0.25% 
bromophenol blue) was added to 4 |xl of the PCR product and loaded on to the gel. An appropriate
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linear size marker was also loaded (123 bp or 1 Kb ladder). Electrophoresis was carried out at 120- 
140V for approximately 80-110 minutes. Agarose gels were stained with ethidium bromide (1 
jig/ml), visualised under UV light, photographed and the images stored electronically as .tif and 
.jpeg files.
2.7.4 Detection o f linezolid resistance mutations by PCR-RFLP analysis
RFLP analysis of PCR amplicons was used to identify known mutations that confer resistance to 
linezolid. A 694 bp 23 S rDNA PCR amplicon was generated (see section 2.7.2) using primers 
LRE 5 and LRE 6 (Table 9 and Table 10), and visualised as described previously (see section 
2.7.3). PCR product, 8 pi, an appropriate restriction endonuclease (Roche or Fermentas), 1 pi, and 
an appropriate enzyme buffer, 1 pi, were vortexed and centrifuged briefly before being incubated at 
37°C for a minimum of 4 hours. Restriction enzymes NheI (Woodford et al., 2002), EcoRN 
(Lobritz et al., 2003) and H inll (this work), were used to detect G2576T, G2505A and T2504C 
mutations, respectively, in the genes encoding 23 S rRNA. Digested product, 8 pi, was analysed by 
gel electrophoresis (2.5% agarose gel), stained with ethidium bromide (1 pg/ml), visualised under 
UV light, photographed and stored electronically as .tif and .jpeg files.
Substitution of thymine for guanine at position 2576 (E. coli numbering) creates a new cutting site 
for Nhe I at 526 bp (on the 694 bp fragment). If no mutation is present, all copies of the S. aureus 
23S rRNA genes are wild-type G and Nhel will cut once producing fragments of 526 bp and 168 
bp. If all copies are mutated T, Nhe I will cut twice producing fragments of 430 bp, 168 bp and 96 
bp. If the mutant is heterozygous, with some copies wild-type and some mutated, digest with Nhe I 
provides a mixture of all of the fragments, 526 bp, 430 bp, 168 bp and 96 bp (see section 3.2.2, 
Figure 22).
The presence of a T2504C mutation results in the introduction of a new cutting site for HinW at 
516 bp (on the 694 bp fragment) (See section 3.2.2, Figure 24). If no mutation is present, all copies 
of the 23S rRNA genes are wild-type T and HinW will not cut the 694 bp fragment. If all copies 
are mutated C, HinW will cut once producing fragments of 516 bp and 178 bp. If the mutant is
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heterozygous, with some copies wild-type and some mutated, digest with HinW provides a mixture 
of all of the fragments, 694 bp, 516 bp, 178 bp.
Substitution of adenine for guanine at position 2505 (E. coli numbering) creates a new cutting site 
for EcoRl at 526 bp (on the 694 bp fragment). If no mutation is present, all copies of the 23 S 
rRNA genes are wild-type G and £coRI will not cut. If  all copies are mutated A, EcoRl will cut 
once, producing fragments of 528 bp and 166 bp. If the mutant is heterozygous, with some copies 
wild-type and some mutated, digest with EcoRl provides a mixture of all of the fragments, 528 bp 
and 166 bp (see section 3.4.1, Figure 40).
2.7.5 Designing PCR-RFLP assays
A T to C change at position 2504 in the 23S rDNA genes was detected by DNA sequencing (see 
section 2.7.6). Both the wild-type sequence (T2504) and the mutant sequence (C2504) were loaded 
into a restriction analysis website (http://rna.lundberg.gu.se/cutter2/) and theoretically ‘cut’ with all 
enzymes represented in the database. The restriction sites of the two sequences were compared. 
One enzyme, HinW, would only cut the mutant sequence and could, therefore, be used to detect the 
presence of a T2504C mutation in the 23 S rDNA genes. This method of detecting polymorphisms 
could only be used if a mutation introduced a new cutting site or caused loss of a site.
2.7.6 Partial DNA sequencing o f 23S rRNA genes
DNA to be sequenced was first amplified with primers LRE 5 and LRE 6 (Table 9 and Table 10)
to generate a 694 bp fragment of the genes encoding 23S rRNA (see section 2.7.2). PCR
amplicons were used for gel electrophoresis, as previously described (see section 2.7.3). PCR
products were purified using a Q-BIOgene Geneclean Turbo Kit (Q-BIOgene). Purified DNA (1-2
pi) and PCR quality water (to a final volume of 10 pi) were vortexed in a 96-well sequencing plate,
centrifuged and denatured in a thermal cycler at 96°C for 3 minutes. A relevant primer, forward or
reverse (0.64 pi [stock concentration of 1 pg/pl]) was added, along with Dye Terminator Cycle
Sequencing (DTCS) quick start mix (8 pi), giving a total reaction volume of 20 pi. This mix was
vortexed and centrifuged briefly before being returned to the thermal cycler. After amplification, 5
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pi of stop mix (0.4 pi 0.5M EDTA, 1.6 pi PCR water, 2.0 pi 3M sodium acetate, 1.0 pi glycogen) 
was added to each well, along with 60 pi of 95% ice-cold ethanol. The plate was vortexed and 
centrifuged at 1110 x g for 30 minutes at 4°C, then inverted to remove the ethanol. Ice-cold 
ethanol, 200 pi (70%) was added to each well and centrifuged at 1110 x g for 10 minutes at 4°C. 
The plate was inverted to remove the ethanol and the step repeated. The plate was again inverted 
to remove the ethanol and spun inverted at 10 x g for 15 seconds. The plate was removed, turned 
upright and was left for a minimum of 45 mins to dry at room temperature. Sample loading 
solution, 40 pi, was added to each well, vortexed well and centrifuged. One drop of mineral oil, 
from a pasteur pipette, was added to each well and the plate was loaded into the sequencing 
machine (Beckman CEQ8000 automated sequencer).
2.7.6.1 Analysis of chromatograms
Sequencing results were imported into Bioedit and Bionumerics software programs 
(www.applied-maths.com). These programs were used to align multiple sequence reads to produce 
a consensus sequence. The on-line BLAST tool was used for comparing sequence results with 
GenBank sequences.
2.7.7 Pyrosequencing
Pyrosequencing is a technique whereby a PCR product is generated, spanning the region of 
interest, using a forward primer, a reverse primer with a 21 bp handle attached, and a universal 
biotinylated primer, with a sequence matching that of the handle. The biotinylated primer is 
incorporated into one strand of the PCR product. A clean-up mechanism uses streptavidin beads to 
capture the biotinylated strand. A sequencing primer binds to the captured template strand. 
Nucleotides are dispensed in an order specified by the user, according to known sequence and 
mutations to be detected. Successful incorporation of a nucleotide, complementary to the template 
strand, initiates a cascade of events resulting in the emission and detection of light (see Figure 9). 
A peak is produced on the pyrogram® that is proportional to the amount of nucleotide 
incorporated.
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Figure 9. Pyrosequencing cascade. A sequence primer hybridizes to a single-stranded PCR 
product. The first dNTP is added. DNA polymerase catalyses the incorporation of the dNTP if it is 
complementary to the template. Each successful incorporation o f a nucleotide is accompanied by 
the release of pyrophosphate (PPi). A cascade reaction occurs which results in the emission of 
light, which is subsequently detected. The amount of light emitted is proportional to the number of 
nucleotides incorporated. Unincorporated nucleotides are degraded before the next nucleotide is 
added (From http://www.pyrosequencing.com/graphics/3019.pdf).
Polymerase
P Pi
Sulfurylase
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LuciferaseApyrase
light
time
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2.7.7.1 Pyrosequencing assay design
A pyrosequencing assay was designed to detect the presence of seven known mutations conferring 
resistance to linezolid. A 364 bp pair region of the 23S rDNA genes (2411 to 2775) was amplified 
with three primers (see Figure 10);
• a normal forward primer 5’AAGGGCCATCGCTCAACGGAT
• a reverse primer, with a universal handle sequence (Mostafa Ronaghi [Stanford University], 
personal communication) added to the 5’ end
5’(CCGAATAGGAACGTTGAGCCT)GTGAGGGGGGCTTCATGCTT
• a universal biotinylated primer, with a sequence matching that of the handle 
5’-biotin-CCGAATAGGAACGTTGAGCCT
Initially, pyrosequencing software was used to identify possible primer regions, but subsequently 
primers were designed manually (see section 2.7.1). A reverse primer was designed, and the 5’ 
handle added. The handle was an exact match of the universal biotinylated primer. This resulted 
in the integration of biotin into the reverse strand of the PCR product, which was then captured 
during the post-PCR clean-up. A forward sequencing primer was designed to anneal to the 
captured reverse template strand. The resulting pyrogram could then be read in the forward 
direction. Three sequencing primers were designed, spanning the seven mutations of interest (see 
Table 11). Sequencing primers were designed to anneal within five base pairs of the first mutation 
to be detected. All sequencing primers were between 17 and 20 base pairs in length and had a 
melting temperature of 57-58°C.
2.1.1.2 Pyrosequencing assay
A PCR reaction master mix was set up, as before (see section 2.7.2), but with forward, reverse and 
biotinylated primers (5 pi of forward and reverse primers [stock concentration 1 pg/ftl], 10 pi 
universal biotinylated primer [stock concentration 1 pg/pl] and 80 pi PCR quality water). The 
mastermix (23 pi) was multi-channelled into a PCR plate. A final reaction volume was achieved 
by adding 2 pi of the template DNA. PCR products were visualised as before (see section 2.7.3).
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Figure 10. 364 bp amplified region of 23S rRNA. PCR primers are underlined, sequencing 
primers are highlighted in blue, positions of mutations are highlighted in red.
AAGGGCCATCGCTCAACGGATAAAAGCTACCCCGGGGATAACAGGC
TTATCTCCCCCAAGAGTTCACATCGACGGGGAGGTTTGGCACCTCGA
TGTCGGCTCATCGCATCCTGGGGCTGTAGTCGGTCCCAAGGGTTGGG
CTGTTCGCCCATTAAAGCGGTACGCGAGCTGGGTTCAGAACGTCGTG
AGACAGTTCGGTCCCTATCCGTCGTGGGCGTAGGAAATTTGAGAGGA
GCTGTCCTTAGTACGAGAGGACCGGGATGGACATACCTCTGGTGTAC
CAGTTGTCGTGCCAACGGCATAGCTGGGTAGCTATGTGTGGACGGGA
TAAGTGCTGAAAGCATCTAAGCATGAAGCCCCCCTCAC
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Three repeat assays were performed for each isolate, with each of the sequencing primers. Binding 
buffer (40 pi per sample) (10 mM tris-HCl, 2M NaCl, ImM EDTA, 0.1% tween 20), streptavidin 
sepharose bead mix (2 pi per sample) and PCR quality water (20 pi per sample) were added to 20 
pi of PCR product and agitated for 10 minutes at room temperature (1400 rpm/3 mm mixing 
stroke). A 96-well pyrosequencing plate containing annealing buffer, 44.2 pi per sample, (20 mM 
Tris, 2 mM magnesium acetate, pH 7.6) and sequencing primer (0.8 pi per sample [0.14 nmols 
added]) was prepared. Strand separation was achieved using a vacuum preparation tool. Probes of 
the vacuum tool were washed with high purity water (20 seconds), before being moved to the PCR 
plate. Beads containing immobilized template were captured on the probes. The vacuum 
preparation tool was moved to a trough containing 70% ethanol and flushed through for 5 seconds. 
Next, denaturation solution (0.2M NaOH) was flushed through the probes for 5 seconds; finally, 
washing buffer (10 mM tris-acetate, pH 7.6) was flushed through the probes for 5 seconds. The 
vacuum was closed and the beads were released into the plate containing annealing buffer and 
sequencing primer master mix. The vacuum tool was washed through for 30 seconds with high 
purity water. The plate, now containing the beads, annealing buffer and sequencing primer, was 
heated at 80°C for 2 minutes before cooling slowly to room temperature, then the plate was loaded 
into the pyrosequencing machine. Freeze-dried enzyme (DNA polymerase, ATP sulfurylase, 
luciferase and apyrase) and substrate (adenosine 5’ phosphate and luciferin) mixtures were 
reconstituted using 620 pi of PCR quality water and left at room temperature for 5-10 minutes to 
dissolve. The amounts of enzyme or substrate required were calculated (50 pi + [5.5 x no. of 
wells]) and loaded into the reagent cartridge. The amount of nucleotides required (dCTP, dGTP, 
dTTP and dATPaS) was calculated (50 pi + [0.11 x 7 x no. of wells]), diluted with an equal 
amount of TE buffer and loaded into the reagent cartridge. The cartridge was loaded into the 
pyrosequencing machine and the run started. Controls were run alongside samples to be tested. 
Sequencing primer (no DNA added) was used to detect background signal. Negative PCR product 
was used to check a background signal was not being generated from the biotin-labelled PCR 
product. In one well a PCR fragment (no sequencing primer was added) was run to detect the 
presence of any hairpin loops within the PCR product. Additionally water was substituted in place
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of a PCR product to check for contamination. The results of the pyrosequencing run were analysed 
using pyrosequencing software to detect and quantify the presence of mutations.
2.8 DNA hybridization
2.8.1 Digestion o f chromosomal DNA for hybridization
DNA was extracted and purified as described in section 2.6.1. Chromosomal DNA preparation, 
6-8 (il EcoRl, 1 pi enzyme buffer (50 mM Tris-HCL, 10 mM magnesium chloride, 100 mM 
sodium chloride, 1 mM dithiothreitol, pH 7.5), 1 pi, and RNase, 1 pi (1 mg/ml), were vortexed, 
centrifuged briefly and incubated at 37°C overnight. Digestion products were analysed by gel 
electrophoresis (0.8% [w/v] agarose gel), stained with ethidium bromide (1 pg/ml), visualised 
under UV light, photographed and stored electronically as .tif and .jpeg files.
2.8.2 Vacuum blotting
A VacuGene blotting unit was assembled. The porous support was pre-wetted with distilled 
water. Hybond-N nylon membrane was pre-cut to the appropriate size, pre-wetted by immersing in 
distilled water and placed on the porous support under a plastic mask. The gel (see section 2.8.1) 
was placed on to the membrane and the vacuum applied at 45-50 mBar. Enough fragmenting 
solution (0.25 M HC1) to cover the gel was applied for eight minutes. The excess was removed 
before denaturing solution (0.5 M NaOH, 1.5 M NaCl) was added for six minutes, followed by 
neutralizing solution (1.5M NaCl, 0.5 M Tris, 1 mM EDTA, pH 7.2) for six minutes. Next, 20 x 
salt sodium citrate (SSC) transfer solution (175.3g NaCl, 88.2g sodium citrate, water to 1 litre, pH
7.0) was added for 60-90 minutes. A UV cross-linker was used to covalently bond DNA to the 
membrane, which was then left to dry at room temperature. The membrane and gel were viewed 
under UV light to ensure the DNA had transferred. The membrane was stored at room 
temperature.
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2.8.3 Preparation o f digoxigenin-labelled probes by PCR
A primary PCR reaction (25 pi volume) (see section 2.7.2) amplified a 420 bp region of 23S 
rDNA genes (primers 23S rRNA V F and R) (see Table 9 for PCR conditions and Table 10 for 
PCR primers). The resulting PCR products were analysed by gel electrophoresis, stained with 
ethidium bromide (1 pg/ml) and visualised under UV light. The primary PCR product was used in 
a secondary PCR reaction. The secondary PCR reaction was scaled up to a 100 pi volume, the 
volume of dTTP was reduced and digoxigenin-ll-dUTP incorporated. The ratio of unsubstituted 
dTTP to labelled dUTP was 2:1. A PCR mastermix was prepared, vortexed and centrifuged (62.5 
pi PCR quality water, 10 pi 10 x Taq polymerase buffer, 5 pi Buffer W l, 4 pi MgCl2 [50 mM], 
dNTP mix [2.5 pi dATP, 2.5 pi dGTP, 2.5 pi dCTP and 1. 7 pi dTTP], 8.3 pi dig-ll-dUTP), 
primer mix 1 pi [stock 1 pg/pl] of each of the two primers], 1 pi of the primary PCR product and 1 
pi Taq polymerase). PCR products were analysed by gel electrophoresis alongside the product 
from the primary PCR reaction, then stained with ethidium bromide (1 pg/ml), visualised under 
UV light, photographed and stored electronically as .tif and .jpeg files. Successful incorporation of 
digoxigenin slowed migration through the agarose gel, and the secondary PCR product appeared 
‘larger’ than the primary product.
2.8.4 Hybridization studies
The membrane (see section 2.8.2) was placed in a hybridization bottle, immersed in 25 ml of pre­
hybridization solution (16.25 ml water, 6.25 ml SSC [x 20], 50 pi SDS [10%], 83 pi sarkosyl 
[30%], 2.5 ml buffer set 3 [x 10] [Roche Applied Science, Lewes, UK]) and placed in a 
hybridization oven, pre-heated to 70°C, for a minimum of 1 hour. The pre-hybridization solution 
was replaced with 5 ml of fresh pre-hybridization solution to which had been added 30 pi of 
labelled probe DNA (see section 2.8.3) which had been denatured at 95°C for 2-3 minutes. The 
membrane was hybridized overnight at 70°C. After use, the probe mixture was stored at -20°C for 
future use and was re-used up to five times before being discarded. The hybridized membrane 
underwent two low stringency washes in the hybridization bottle with 50 ml 2 x SSC/0.1% SDS
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(100 ml 20 x SSC, 10 ml 10% SDS [lOg SDS, 100 ml water], 890 ml water) at room temperature 
for 5 minutes. The membrane was then washed twice with a high stringency solution, comprising 
50 ml 0.1% SSC/ 0.1% SDS (5 ml 20 x SSC, 10 ml 10% SDS, 9985 ml water) at 70°C for 15 
minutes. The remaining washes were all carried at room temperature. The membrane was rinsed 
with 100 ml washing buffer (100 ml buffer set I (xlO), 900 ml distilled water). Next, the 
membrane was blocked for 30 minutes with 100 ml of blocking buffer (10 ml buffer set 2 [xlO], 10 
ml buffer set 3 [xlO], 80 ml distilled water), before being rinsed for 1 minute in 100 ml washing 
buffer. Following this, the membrane was soaked for 30 minutes in anti-digoxigenin antibody 
conjugate, diluted 1:5000 in washing buffer, before being washed twice in washing buffer for 15 
minutes. Next, the membrane was rinsed for 2-3 minutes in developing buffer (3.33 ml buffer set 4 
[xlO], 30 ml distilled water). Colour development reagent was prepared (400 pi NBT [nitro blue 
tetrazolium chloride] /BCIP [5-bromo-4-chloro-3-indolyl phosphate] in 10 ml developing buffer). 
The membrane was transferred to a hybridization bag and the colour development reagent was 
added, the bag sealed and stored in the dark. When bands had appeared to a suitable intensity, the 
membrane was washed in 200 ml of TE buffer (50 mM, pH 8.2) and dried at 70°C for 1 hour. 
Membranes were photographed and images stored electronically as .tif and .jpeg files.
2.9 Detection of hypermutators among clinical S. aureus isolates
2.9.1 M utation frequencies
ISO broth, 10 mis, was inoculated using freshly-grown bacteria, and incubated overnight at 37°C. 
One ml of this overnight culture was used to inoculate 10 mis of fresh ISO broth, which was 
incubated with gentle shaking at 37°C for 5 hours. Viable counts (cfu/ml) were then determined. 
Serial dilutions from 10'1 to 10'8 were prepared in PBS, and 2 x 20 pi drops of lO^to 10’8 dilutions 
were plated on CBA and incubated at 37°C for 24 hours. The colony count was calculated as the 
arithmetic mean number of colonies present in 2 x 20 pi drops of the highest serial dilution with 
growth. This figure was multiplied by 50 to provide the number of cfu in 1 ml.
I l l
Mutants were selected by spreading 200 pi of the undiluted growth on to BHI agar, containing an 
appropriate concentration of antibiotic, and incubated at 37°C for 24 hours. The mutation 
frequency was calculated by obtaining an arithmetic mean number of colonies from four replicate 
antibiotic plates, multiplying by five (to obtain the number of mutants present in 1 ml) and dividing 
by the colony count. Experiments were carried out in triplicate. RN4220 was used as a wild-type 
control strain and RN4220AmutS as a hypermutable control strain.
2.9.2 Fosfomycin disc tests
Freshly-grown bacteria were suspended to a density of a 1.0 McFarland standard and swabbed 
over an ISO agar plate, containing 1 mg/ml G-6-P, to give confluent growth. A fosfomycin disc 
(50 jig) was placed on to the agar and incubated at 37°C for 24 hours. Three replicates were 
performed for each isolate. The numbers of colonies in the zone of inhibition around the 
fosfomycin disc were counted and the zone diameters measured (Galan et al., 2003). RN4220 and 
KN4220AmutS were used as wild-type and hypermutable control strains, respectively.
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3 Results
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3.1 Characterization of reference strains
3.1.1 Hypermutable and wild-type reference strains
RN4220, a derivative of the laboratory strain NCTC 8325, was used as a parent strain during the 
creation of a hypermutable mutS deletion mutant (Giachino et al., 2001). This hypermutable 
mutant, RN4220Atw«£S, was generated through the integration, via homologous recombination, of 
the plasmid, pGhost9+, (containing some mutS sequence), creating a strain with an inactivated mutS 
gene and consequently a hypermutable phenotype (O'Neill and Chopra, 2002). The PFGE profiles 
of RN4220 and RN4220AmwAS', after digestion with the restriction endonuclease Smal, differed by 
one band (see section 2.6.3) (Figure 11). This difference between the two strains was characterized 
further.
To do this, contigs of the genome of NCTC 8325 were downloaded from http://micro- 
gen.ouhsc.edu/s_aureus/s_aureus_home_b.htm and, using BioEdit, were searched for the mutS and 
mutL genes. Once the genes were located, the appropriate contig was searched for Smal sites. It 
was deduced that both genes were present on the largest fragment in the Smal PFGE profile of 
RN4220, fragment A, approximately 674 Kb in size (Figure 12). The pGhost9+ plasmid in 
RN4220AtwwAS', inserted to disrupt the mutS gene, itself has a Smal cutting site present. Digest of 
the plasmid with Smal linearises the plasmid, producing a fragment of 4.6 Kb (Figure 13) (Maguin 
et a l, 1996). This Smal site within the plasmid resulted in the 674 Kb fragment A being split into 
two fragments of approximately -520 Kb and -155 Kb in RN4220Amw/5' (Figure 14). By 
changing the PFGE running conditions it was possible to resolve the smaller fragments and a -150 
Kb fragment could be identified in the hypermutable strain that is not present in the wild-type strain 
(Figure 15). This difference in PFGE profiles between the two strains proved a valuable tool for 
differentiating between the two strains and confirming parentage of mutants.
MICs for the two strains revealed that KN4220AmutS was resistant to erythromycin, due to the 
erythromycin-resistance marker present on the pGhost9+ plasmid (see section 2.3.2) (Horinouchi 
and Weisblum, 1982). PCR confirmed the presence of an erm{B) determinant (Table 12) (see 
section 2.7.2). RN4220 was erythromycin-susceptible.
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Figure 11. PFGE gel showing Sm al digested DNA from RN4220 and RN4220Am«£S' 
illustrating the differences in their banding patterns. Lane 1 48.5 Kb lambda ladder, lane 2 
RN4220, lane 3 RN4220Aw«?S'.
Figure 12. Restriction digest map of S. aureus NCTC 8325. The mutS and mutL genes are 
situated on fragment A (highlighted in blue). (Adapted from http://microgen.ouhsc.edu/s_aureus/ 
s_aureus _home_b.htm).
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Figure 13. Smal digest of pGhost9+. Lane 1 1 Kb ladder, lane 2 undigested pGhost9 , lane 3 
pGhost9~ digested with Smal, lane 4 water control.
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Table 12. MICs (mg/L) for wild-type, hypermutable and clinical strains of S. aureus.
Strain ChlorA Clin® Eryc F usd LinE OxaF Rif° TeicH Vane1
RN4220 8 <0.25 1 0.125 4 1 0.0016 1 2
RN4220Am«/'/S 8 <0.25 >256 0.064 4 0.5 0.0016 2 2
ST/03/2121 4 <0.25 >256 0.125 4 >16 0.016 1 1
ST/03/2122 4 <0.25 >256 0.064 1 >16 >256 8 4
A Chloramphenicol, ®Clindamycin, cErythromycin, DFusidic acid, ELinezolid, FOxacillin, 
GRifampicin, HTeicoplanin, Vancomycin.
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3.1.2 Clinical reference strains
Two genetically-related clinical strains, isolated during therapy with teicoplanin - one teicoplanin- 
susceptible (ST/03/2121), MIC 1 mg/L, and the other teicoplanin-resistant (ST/03/2122), MIC 8 
mg/L, - were identified as EMRSA-15 by phage typing and PFGE. MICs were determined by agar 
dilution (Table 12).
3.1.3 M utation frequencies
Initially, the frequencies at which RN4220, RN4220AmutS, ST/03/2121 and ST/03/2122 selected 
mutants resistant to rifampicin (50 mg/L), fusidic acid (0.5 mg/L), teicoplanin (6 mg/L), 
vancomycin (6 mg/L) and linezolid (6 mg/L) were calculated (see section 2.9.1). Further mutation 
frequency experiments were carried out with the addition of sub-inhibitory concentrations of 
ciprofloxacin, teicoplanin, vancomycin and linezolid to the broths, both singularly and in 
combination. Mean mutation frequencies were calculated from a minimum of three replicated 
experiments.
Mutation frequencies revealed the hypermutable strain, RN4220Aww/*S', to mutate on average at 
the greatest frequency to all of the antibiotics and all but one of the antibiotic combinations tested 
(rifampicin and ciprofloxacin) at rates of 10'7 or 10'6 (Table 13). The two wild-type strains, 
RN4220 and ST/03/2121 mutated on average, at frequencies of 10‘9 to 10'7. The only measurable 
mutation frequency for the clinical isolate, ST/03/2122, was to fusidic acid. Intermediate or full 
resistance to the other antibiotics tested prevented the determination of mutation frequencies.
The hypermutable strain, KN4220AmutS, mutated to rifampicin at an average frequency of 5.4 x 
10'7, 11-fold greater than its wild-type parent, RN4220 (5.1 x 10"8), and nine-fold greater than the 
clinical isolate, ST/03/2121 (5.9 x 10'8) (Table 13 and in Appendix B, Table 44). The addition of a 
sub-inhibitory concentration of ciprofloxacin caused a two-fold increase in the mutation frequency 
of RN4220AmwAS' and a negligible difference in the mutation frequency of ST/03/2121, when 
compared with mutation frequencies to rifampicin (Appendix B Table 45). However, with the 
addition of ciprofloxacin, the mutation frequency of RN4220 jumped to 1.25 x 1 O'6, a 25-fold
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increase on the mutation frequency to rifampicin. Closer analysis revealed one individual 
experiment with an undetectable mutation frequency (<2.17 x 10‘7), another with a frequency of 
2.50 x 10'9 and a third anomalous mutation frequency of 2.50 x 10'6 (Appendix B, Table 45). The 
mutation frequencies for ST/03/2121 with the addition of sub-inhibitory concentrations of 
antibiotics were estimated only once.
The addition of sub-inhibitory concentrations of ciprofloxacin and teicoplanin, in combination, 
caused negligible differences in the mutation frequencies of RN4220Aww/5' (7.5 x 10'7) and 
RN4220 (6.2 x 10'8) to rifampicin. An eight-fold drop in the mutation frequency for ST/03/2121 
was seen when compared with that seen for rifampicin singularly. The addition o f sub-inhibitory 
concentrations of ciprofloxacin and vancomycin caused a three-fold increase in the mutation 
frequency of RN4220Am«£S' (1.5 x 1 O'6), a ten-fold increase in that of RN4220 (5.2 x 10‘7) and a 
four-fold decrease in that of ST/03/2121 (1.5 x 10'8) to rifampicin when compared with those seen 
for rifampicin alone. The addition of sub-inhibitory concentrations of ciprofloxacin and linezolid 
caused a two-fold increase in the mutation frequencies of RN4220 (8.4 x 10'8) and ST/03/2121 (1.4 
x 10'7) and an insignificant shift in those of RN4220A/WW/S' (4.7 x 10"7), when compared with those 
seen for rifampicin. Overall, no consistent increases or decreases in the mutation frequency to 
rifampicin were seen with the addition of sub-inhibitory concentrations of ciprofloxacin and 
teicoplanin, vancomycin or linezolid.
The highest, average mutation frequencies to fusidic acid were seen for RN4220Aww/iS' (3.5 x 
Kf6) being ten- and seven-fold higher, respectively, than those seen for RN4220 (3.5 x 10'7) and 
ST/03/2121 (5.0 x 10'7) (Appendix B, Table 46). The average mutation frequency seen for 
RN4220Aww/5' to fusidic acid was 61-fold higher than that for ST/03/2122 (5.7 x 10'8). Mutation 
frequencies to fusidic acid were higher than those to rifampicin with RN4220Aww/5', RN4220 and 
ST/03/2121 seeing seven-fold and eight-fold increases in mutation frequencies.
The highest mutation frequency to teicoplanin was for the hypermutable isolate, KN4220AmutS
(1.5 x 10'6) (Appendix B, Table 47). This was 20-fold and 22-fold higher than those for RN4220
and ST/03/2121, respectively. However, looking at the mutation frequencies for RN4220AmutS
among experiments, there was a 68-fold difference between the highest and lowest mutation
frequencies produced. A similar finding occurred with mutation frequencies to vancomycin, with
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the hypermutable isolate showing mutation frequencies 222-fold higher than for RN4220 and 559- 
fold higher than for ST/03/2121 (Appendix B, Table 48). The mutation frequencies to vancomycin 
for RN4220A/WW/S ranged immensely, from 6.48 x 1 O'6 to 4.17 x 10'9. Mutation frequencies to 
teicoplanin and vancomycin proved difficult to estimate due to the clustering of colonies on the 
antibiotic plates. No detectable mutation frequencies were calculable for RN4220, RN4220AwwAS', 
ST/03/2121 or ST/03/2122 to linezolid with or without the addition of a sub-inhibitory 
concentration of linezolid in broth prior to plating on linezolid (Appendix B, Table 49).
RN4220Amw£S' showed high rates of mutation to resistance to all antibiotics, with ratios above its 
parent, RN4220, of 11-, 10-, 20- and 222-fold and ST/03/2121 of 9-, 7-, 22- and 560-fold, 
respectively to rifampicin, fusidic acid, teicoplanin and vancomycin. All mutants selected 
underwent PFGE to confirm parentage (Figure 16).
3.1.4 Population analysis o f mutants
Mutants selected from the mutation frequency experiments, that had been exposed to sub- 
inhibitory concentrations of vancomycin in broth or plated on agar containing 6 mg/L of 
vancomycin, underwent population analysis to identify heterogeneous antibiotic resistance, a 
common occurrence with vancomycin resistant strains, which is only detectable by population 
analysis (Table 14) (see section 2.3.4). Hetero-resistance was defined by sub-populations with 
vancomycin MICs between 5 and 8 mg/L. Population analysis revealed six of 13 mutants, 
generated from mutation frequency experiments, with intermediate-resistance to vancomycin, 
however, hetero-resistant mutants of ST/03/2122 inherited the trait from their parent strain, i.e., it 
did not emerge as a result of selection by vancomycin (2 x RN4220AmwAS' mutants, 4 x ST/03/2122 
mutants and the parent strain ST/03/2122, MICs 5-7 mg/L) (Figure 17, Figure 18 and Figure 19). 
Vancomycin-selected mutants of RN4220A#m/iS' were convincingly more resistant than its parent, 
RN4220, vancomycin-selected variants, with MICs for the latter only reaching a maximum of 3 
mg/L (Figure 17 and Figure 18).
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Figure 16. PFGE of rifampicin-selected mutants of RN4220Aww/‘iS' to confirm parentage.
Lane 12 48.5 Kb lambda ladder, lane 1 RN4220AmutS control strain, lanes 2-11 RN4220AtnutS 
rifampicin-selected mutants.
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3.1.5 Teicoplanin-resistant mutants
Strain NCTC 8325 and its descendants, RN4220 and RN4220Aww/5', are colourless (Bischoff and 
Berger-Bachi, 2001). However, when looking at the mutants of RN4220 and RN4220Aw«/S' 
selected by exposure to teicoplanin, it was noted that some appeared orange. Mutants selected with 
other antibiotics did not show this colour change. These mutants consistently appeared after 
incubation in the presence of teicoplanin (6 mg/L) for a minimum of 48 hours. One orange and one 
colourless mutant of each of the two strains were investigated further. Teicoplanin MICs for the 
four mutants, by E Test on Iso agar, ranged from 2-4 mg/L, no different to their parent strains 
(Table 15) (see section 2.3.3). Additionally, no difference in MIC was observed between the two 
colony types. Colonies reverted to colourless after serial passage on antibiotic-free agar. The two 
colony types underwent ten passages, on BHI agar containing 6 mg/L teicoplanin. Serial passage 
of the orange colony type resulted in a predominance of orange colonies, whereas passage of the 
colourless colony type resulted in the majority appearing colourless, but also gave rise to a few 
orange colonies. Teicoplanin MICs, by E Test, after serial passage ranged from 4-8 mg/L, with no 
obvious differences in MIC between the two colony types. Population analysis revealed parent 
strains RN4220 and RN4220A/WW/5' with teicoplanin MICs of 3 mg/L and 5 mg/L, respectively, and 
all mutants with MICs of >8 mg/L (Figure 20). PFGE confirmed parentage of both colony types 
before and after passaging. No differences in the PFGE profiles of mutants were observed.
3.1.6 Summary
The wild-type and hypermutable reference strains, RN4220A/WW/.S' and RN4220, differed in their 
PFGE profiles due to the integration of the pGhost9+ plasmid, with an extra Smal cutting site, in the 
mutS gene of the hypermutable strain. The insertion of the plasmid also resulted in the introduction 
of an erm{B) determinant into the hypermutable strain. These differences enabled differentiation of 
RN4220 and RN4220A/ww/S' and their mutants. Mutation frequencies of these two strains along 
with two clinical isolates confirmed that the hypermutable strain had elevated mutation frequencies 
to a range of antibiotics when compared with its wild-type parent strain or with clinical isolates.
131
Ta
bl
e 
15
. 
M
ut
an
ts 
of 
RN
42
20
 
an
d 
H
N4
22
0A
m
ut
S 
ob
ta
in
ed
 
un
de
r 
te
ico
pl
an
in
 
se
le
ct
io
n.
Te
ic
op
la
ni
n 
MI
C 
(m
g/
L
) Af
ter
 
po
pu
la
tio
n 
an
al
ys
is
>
8
>
8 <D >
8 00
A
Af
ter
 
se
ria
l 
pa
ss
ag
e
N
/A
N
/A 00
Be
fo
re
 
se
ria
l 
pa
ss
ag
e
(N Tf •*fr
C
lo
ne
R
N
42
20
R
N
42
20
-o
ra
ng
e
R
N
42
20
-c
ol
ou
rl
es
s
■*2
1<
o
<N
rr
0>OD
cc3s-t01
£
a
o<N
<N
§
COCO
—
3JD
O01
3a
S<oCN<N
Fi
gu
re
 
20
. 
Po
pu
la
tio
n 
an
al
ys
is 
of 
te
ic
op
la
ni
n-
re
si
st
an
t 
m
ut
an
ts 
of 
RN
42
20
 
an
d 
RN
42
20
A
w
«/
-S
'.
(|ui/np) junoo eiqeiA
Te
ic
op
la
ni
n 
co
nc
en
tr
at
io
n 
(m
g/
L)
Mutation frequencies to teicoplanin and vancomycin proved difficult to calculate due to the 
clustering of colonies on antibiotic-containing plates, making counting difficult and resulting in a 
wide range of mutation frequencies being found. Population analysis of the mutants exposed to 
vancomycin during mutation frequency experiments revealed that six of 13 mutants selected had 
hetero-resistance to vancomycin, but that only two emerged as heteroresistant during the 
experiment. Two colony types were generated from mutation frequency experiments to teicoplanin 
and serial passage in the presence of teicoplanin stabilized these mutant strains. Population 
analysis revealed the mutant strains with teicoplanin MICs in excess of 8 mg/L. No mutation 
frequencies to linezolid were determined as no mutants were obtained.
3.2 Laboratory-selected linezolid-resistant mutants
No mutants were selected in the single-step linezolid mutation frequency experiments; therefore 
to obtain linezolid-resistant mutants a change in methodology was adopted. Linezolid-resistant 
variants were selected by exposure to increasing concentrations of linezolid in broth or on 
antibiotic plates (see section 2.5.1).
3.2.1 Raising linezolid-resistant mutants in vitro
Once mutants were able to grow in broth containing 10 mg/L linezolid they were transferred to 
BHI agar containing 6 mg/L linezolid (see section 2.5.1). Linezolid E Tests revealed these mutants 
with MICs of 4 or 8 mg/L (see section 2.3.3). The mutants were then passaged five times on BHI 
agar containing 10 mg/L of linezolid to try to stabilize resistance. After serial passage however, 
linezolid MICs of some mutants fell to 4-8 mg/L, implying selected resistance was unstable. 
However the variations in MIC might also be attributed to the medium used; mutants were selected 
on BHI agar but MICs were determined on ISO agar.
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3.2.2 Characterization o f laboratory-selected linezolid-resistant mutants
Seventeen linezolid-resistant mutants of RN4220, RN4220Am«AS' and ST/03/2121 were selected 
in vitro; no mutants of ST/03/2122 were raised (Table 16). Firstly, in order to characterize the 
mutants, linezolid MICs were determined (Table 16) (see section 2.3). Secondly, all mutants were 
screened for a G2576T mutation by PCR-RFLP with the restriction endonuclease Nhel (see section 
2.7.4) (Woodford et al., 2002). A 694 bp fragment of the 23S rRNA genes was amplified and then 
digested with Nhel (Figure 21 and Figure 22). Next, the same 694 bp amplicon of the 23 S rRNA 
genes was amplified and DNA sequenced for all mutants (see section 2.7.6). Sequences of the 
linezolid-resistant isolates were aligned with those of their parents to identify any differences. 
DNA sequencing confirmed the presence of G2576T, T2504C and G2447T mutations in various 
mutants (Figure 23 [A], [B] and [C]). Finally, after a T2504C mutation had been identified by 
sequencing, a H inlI PCR-RFLP was developed to detect the presence of a T to C change at 
position 2504 and used to screen all mutants (Figure 24) (see section 2.7.4 and 2.7.5).
Linezolid MICs for mutants ranged from 8-64 mg/L. Ten of 17 mutants had a G2447T mutation, 
four had a G2576T mutation, and one mutant had a T2504C mutation. The G2576T mutation was 
seen only in mutants of RN4220A/«w£S'. All mutants were heterozygous for their respective 
mutations. All mutants had a single mutation type. Two mutants with MICs 8 and 32 mg/L had 
unidentifiable mechanisms of resistance. Parentage of mutants was confirmed by PFGE (see 
section 2.6.3).
Pyrosequencing, with three primers, was used to detect the presence of seven mutations already 
known to confer resistance to linezolid; T2500A, A2503G, T2504C, G2505A, G2445T, G2447T 
and G2576T (see sections 2.7.1 and 2.7.7). Three replicate pyrosequencing experiments were 
performed for each isolate for each sequencing primer and an average of the percentage mutated 
and wild-type 23S rRNA gene copies for each mutation was calculated (Table 17). 
Pyrosequencing detected mutations in all but two of the mutants and allowed quantification of 
mutated 23S rRNA gene copies in six mutants. Pyrosequencing results for identification of 
mutation type and heterozygosity were in agreement with PCR-RFLP and sequencing results, with
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Table 16. MICs for laboratory-selected linezolid-resistant mutants.
Clone Mutation LinA MIC (mg/L) Chlor® MIC (mg/L)
RN4220 Control 2 4
RN4220-M1 G2447T 32 4
RN4220-M2 G2447T 8 4
RN4220-M3 G2447T 32 4
RN4220AmutS Control 2 4
KN4220AmutS-M4 G2447T 32 4
KN4220AmutS-M5 G2447T 16 4
KN4220AmutS-M6 G2447T 32 4
KN4220AmutS-M7 G2576T 32 8
RN4220Aw«t5'-M8 G2576T 32 32
RN4220Athw/<S-M9 G2576T 32 32
RN4220AWW/S-M10 G2576T 16 32
ST/03/2121 Control 4 8
ST/03/2121-M11 T2504C 64 32
ST/03/2121-M12 G2447T 16 8
ST/03/2121-M13 G2447T 16 8
ST/03/2121-M14 G2447T 16 8
ST/03/2121-M15 G2447T 32 8
ST/03/2121-M16 Unknown mutation 8 4
ST/03/2121-M17 Unknown mutation 32 8
ST/03/2122 Control 1 2
ALinezolid, BChloramphenicol.
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Figure 21. PCR to amplify a 694 bp fragment of the 23S rRNA genes. Lanes 1 and 9 123 bp
ladder, lanes 2-7 694 bp PCR product, lane 8 water control.
694 bp product
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Figure 22. Digestion of a 694 bp amplicon of the 23S rRNA genes with the restriction enzyme 
N hel to determine the presence of a G2576T mutation conferring linezolid resistance. Lane 1 
homozygous T (all 23S rRNA copies mutated) lane 2 homozygous G (wild type, no copies 
mutated), lane 3 heterozygous T/G (some mutated copies and some wild-type copies), lane 4 123 
bp ladder.
2 3 4
430 bp fragment ;>
526 bp fragment >
168 bp fragment ^
96 bp fragment ^
<■
492 bp
123 bp
138
Fi
gu
re
 
23
. 
DN
A 
se
qu
en
ci
ng
 
ch
ro
m
at
og
ra
m
s 
of 
lin
ez
ol
id
-r
es
is
ta
nt
 m
ut
an
ts
. 
(A
) 
RN
42
20
A/
ww
/*
S-
M
7 
wi
th 
a 
G2
57
6T
 
m
ut
at
io
n.
 
Th
e 
red
 
‘T
’ p
ea
k 
un
de
r 
the
 
bla
ck
 
‘G
’
3o
■-5
c1 <u a.
"3
CD
3O
30
NO
<D
T3C3
34
3
CD
C l.
U
CDDC
c_o
■4—>3
£
U
3-oin
<Nf—
3
33
<N
CN
mo
h-c/o
o
£3s_
30o
3
£o
J5u
03
3o
30
Nos-.
CD
I d
3
O
'-a_c
3
CDQ.
CD
33
3CD
T3
.£
3
CDa.
a
Mo
3
CD-3
CD
T3C
3
M
3
CD
C l.
-a
CD
fc.
CD3=H
co
03
■4—>
3
Hi>
3"
3"(N
o
3
33
o<N<N
3-
Z
<+Ho
33u
3O
30>4
NO
CD33
© © © © o © © © © ©
o a o o o o o o o  o
1- t- 1- 1- 1- (- H 1- 1-
< < < < < < < < <  <
o o o o o o o o o  o
1- 1- 1- 1- 1- 1- 1- (- H 1-
o o o o o o o o o  o
© © © © © © © © © ©
© © © © © © © © © ©
o o o o o o o o o  o
1- 1- 1- 1- (- N 1- 1-
© © © © © © © o © ©
1— 1— 1— t— 1— 1— I— 1— K ©
< < <  < < < < < < <
© © © © © © © © © ©
o o o  o o o o o o o
1- h- h- h - h- f- »- 1- H (-
o o o  o o o o o o o
o o o  o o o o o o o
< < <  < < < < < < <
o o o  o o o o o o o
© © © © o © © © © ©
© © © © © © © © © ©
1- 1- 1- h- (— f- h- 1- 1- 1-
h- 1- 1- 1- I— t— 1- 1— 1— K-
1- 1- 1- t- I— t- 1- 1— 1- t—
ONm
03
o o o o o
h- h- 1—1-h-
h- 1—1— 1—
o ©©©©
o ©©©©
o ©©©©
1—1— h- 1—
o o o o o
o ©©©©
< < < < <
:o ©©©<*> -o o o o o
o ©©©©
o o o o o
< < < < <
1—1- 1—1—h-
©©©©©
©©©©©
o o o o o
©©©©©
< < < < <
1 - 1 - 1 - 1 - 1 - H H
o o o o o o o
o © © © © © ©
o © © © © © ©
< < < < < < <
o o o o o o o
< < < < < < <
< < < < < < <
1 - 1 - 1- I - 1- (— 1 -
< < < < < < ; <
© f N  ("N © <'|N -3
© © © © © © ©
o © © © © © ©
© © © © © © ©
o o o o o o o
o o o o o o o
o o o o o o o
o o o o o o o
< < < < < < <
1 - I - 1 - 1 - H - h - 1 -
o o o o o o o
© © © © © © ©
d f d T d T d f d f
Figure 24. Digestion of a 694 bp amplicon of the 23S rRNA genes with the restriction enzyme 
HinW, to determine the presence of a G2576T mutation conferring linezolid resistance. Lane 
1 123 bp ladder, lane 2 homozygous T (no 23S rRNA copies mutated), lane 3 heterozygous T/C 
(some wild-type copies and some mutated copies).
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all three techniques detecting the same mutations. Five mutants, all with linezolid MICs of 16 
mg/L and the G2576T mutation, had between 32% and 49% of copies mutated. All five mutants 
had the same number of genes encoding 23S rRNA copies as their parent strains. One mutant, with 
a T2504C mutation, had three of eight (38%) gene copies mutated. Identification of the resistance 
mechanism of two mutants (ST/03/2121-M l6, ST/03/2121 -M l7) could not be elucidated using 
these methods.
More generally, no mutants with a G2445T mutation were detected, meaning that the assay could 
not be verified as detecting this mutation. Mutations G2445T and G2447T are present within a 
homopolymer of G nucleotides and, whilst detection of these mutations was possible (or 
theoretically possible in the case of G2445T), the pyrosequencing software did not allow 
quantification (see section 3.6 for more details on the use of pyrosequencing and hybridization to 
determine the number of mutated 23S rRNA gene copies).
Hybridization was used to determine 23S rRNA gene copy number (see section 2.8). The results 
of the hybridization and pyrosequencing were combined to calculate the actual number of mutated 
23S rRNA gene copies (Table 17). Linezolid MICs for the mutants were repeated shortly before 
hybridization and pyrosequencing were performed, and slight decreases in linezolid MIC were 
noted when compared with previous values. RN4220 and RN4220Am«/<S' had six gene copies and 
ST/03/2121 had five gene copies encoding 23S rRNA (Figure 25), whereas the 23S rRNA gene 
copy number in their mutants varied from four to eight. Six mutants had changes in gene copy 
number when compared with their parent strains; specifically one RN4220 mutant (M4) and five 
ST/03/2121 mutants (M il, M12, M14, M15, M16, M17). In four of the six mutants the 23S rRNA 
gene copy number increased or decreased by one whereas mutants M l 1 and M l7 had increases in 
23 S rRNA gene copy number by two and three copies, respectively. Four of the six mutants with 
changes in 23S rRNA gene copy number had G2447T mutations (M4, M12, M14, M l5), one had a 
T2504C mutation (M il); one had no detectable mechanism of resistance (Ml 7). Linezolid MICs 
for those mutants with changes in 23S rRNA gene copy number were all 16 mg/L. The four 
mutants with a G2576T mutation did not have any changes in gene copy number.
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Figure 25. Hybridization of DNA from linezolid-resistant mutants of RN4220 and 
RN4220Am«/,5' with a 420 bp 23S rRNA gene probe. Lanes 1 and 10 DIG-labelled ladder, lane 2 
RN4220, lanes 3-5 RN4220-M1-M3, lane 6 RN4220Amw^, lanes 7-9 RN4220Aiwwtf-M7-M9.
One mutant with a T2504C mutation (Ml 1) showed a four-fold increase in chloramphenicol MIC 
from 8 to 32 mg/L (Table 16), whilst eight-fold increases in chloramphenicol MIC were observed 
in three out of the four mutants with G2576T mutations (MICs rose from 4 to 32 mg/L in mutants 
M8, M9, M10). However, one mutant with a G2576T mutation only had a small increase in 
chloramphenicol MIC from 4 to 8 mg/L (M7).
3.2.3 Reversion to wild type o f linezolid-resistant RN4220A/w«/S' mutants
Further characterization of the m-vz'/ro-selected linezolid-resistant mutants revealed some 
RN4220A/ww/iS' mutants to be erythromycin-susceptible (Table 18), whereas their parent strain, 
RN4220AmutS, had an erythromycin marker, erm(B), on the plasmid inserted to disrupt the mutS 
gene and, consequently, had an erythromycin MIC >256 mg/L. PFGE confirmed reversion to a 
‘wild-type’ RN4220 profile in five of seven KN422QAmutS linezolid-resistant mutants, with loss of 
the pGhost9+ plasmid (Figure 26). Long PCR of the mutS gene was used to confirm the presence 
or absence of the pGhost9+ plasmid and to determine whether complete excision had taken place 
(Figure 27) (see sections 2.6.1 and 2.6.2). PCR of the mutS gene in RN4220 produces a 1.5 Kb 
product, whereas PCR of mutS in RN4220Amwf<S' produces a PCR product of 6.1 Kb, due to the 
presence of the plasmid. RN4220Amwf«S' variants from which the plasmid has been excised should 
produce a 1.5 Kb PCR product, as with RN4220. Five of seven RN4220Aw«7S' linezolid-resistant 
mutants did this, with seemingly complete excision of the plasmid leaving an intact, restored mutS 
gene. Long PCR also revealed that, in RN4220A7wwf<S', and its erythromycin-resistant mutants, 
some excision of the plasmid was occurring, indicated by both 1.5 Kb and 6.1 Kb PCR products 
being produced. Subsequent to this discovery, KN4220AmutS and its mutants were grown at 42°C 
to force integration of the thermosensitive plasmid or in the presence of an erythromycin disc (30 
jug) to prevent reversion to wild type (O'Neill and Chopra, 2002) (see section 2.4.1).
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Table 18. Characteristics of laboratory-selected linezolid-resistant mutants.
Clone Mutation Characteristics Lin MIC (mg/L) Ery MIC (mg/L)
RN4220 Control N/A 2 1
RN4220-M1 G2447T N/A 32 1
RN4220-M2 G2447T N/A 8 1
RN4220-M3 G2447T N/A 32 1
RN4220A/ww*S' Control AmutS 2 >256
RN4220Amwtf-M4 G2447T mutS (revertant) 32 1
RN4220Amwtf-M5 G2447T mutS (revertant) 16 1
RN4220Amw^-M6 G2447T mutS (revertant) 32 1
KN4220AmutS-Ml G2576T mutS (revertant) 32 1
RN4220Amwtf-M8 G2576T mutS (revertant) 32 1
RN4220AmwfS-M9 G2576T AmutS 32 >256
RN4220Am w/S-M 10 G2576T AmutS 16 >256
ST/03/2121 Control N/A 4 >256 A
ST/03/2121-M il T2504C N/A 64 >256 A
ST/03/2121-M12 G2447T N/A 16 >256 A
ST/03/2121-Ml 3 G2447T N/A 16 >256 A
ST/03/2121-M14 G2447T N/A 16 >256 A
ST/03/2121-Ml 5 G2447T N/A 32 >256 A
ST/03/2121-M16 Unknown mutation N/A 8 >256 A
ST/03/2121-M17 Unknown mutation N/A 32 >256 A
ST/03/2122 Control N/A 1 >256 A
A Parent strains ST/03/2121 and ST/03/2122 and their mutants all have an erm(C) gene, conferring 
resistance to erythromycin.
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Figure 26. PFGE of 5>wtfl-digested DNA from laboratory-selected linezolid-resistant 
mutants. Lanes 1 and 22 48.5 Kb lambda ladder, lane 2 RN4220 control, lanes 3-5 RN4220 
mutants M l-M3, lane 6 RN4220Awm^  control, lanes 7-13 RN4220A/77W/S mutants M4-M10, lane 
14 ST/03/2121 control, lanes 15-21 ST/03/2121 mutants M11-M17. Note that mutants M4-M8 
(lanes 7-11) have regained the profile of wild-type RN4220 (lane 2).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
48.5 KB
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Figure 27. Long PCR of laboratory-selected linezolid-resistant mutants of RN4220Awm//S'.
Lane 1 1 Kb ladder, lane 2 RN4220 control, lane 3 RN4220A/??wAS' control, lanes 4-10 
KN4220AmutS mutants M4-M7 (revertants), lane 11 RN4220Aw«/S' mutant-M9, lane 12 
RN4220A/«wrS' mutant-M8 (revertant), lane 13 RN4220A/wwrS' mutant-MIO, lane 14 water control.
1 2  3 4 5 6 7 8 9 10 11 12 13 14
6.1 Kb PCR product
1.5 Kb PCR product
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3.2.4 Raising a linezolid-resistant mutant homozygous for T2576
This experiment was designed to determine whether mutated 23S rRNA gene copy number would 
increase in direct correlation with linezolid MIC. The resulting mutant was predicted to have a 
relatively high linezolid MIC and all 23 S rRNA gene copies would be mutated to a T at position 
2576.
RN4220mw/*S-M9 was heterozygous for the G2576T mutation in its 23 S rRNA genes and, in an 
attempt to generate a mutant homozygous for the G2576T mutation, was passaged on increasing 
concentrations of linezolid. As well as linezolid, the mutant (now designated RN4220/ww£S'-M9a) 
was grown in the presence of a 30 pg erythromycin disc or with 50 mg/L erythromycin 
incorporated into agar to prevent reversion to wild-type. The mutant was passaged over the course 
of four months on BHI agar containing increasing concentrations of linezolid (in 2 mg/L 
increments from 16-300 mg/L). The mutant was passaged at the same concentration of linezolid 
until it had grown adequately before being passaged at a higher concentration. The mutant was 
tested at fortnightly intervals to see whether all 23 S rRNA gene copies had mutated, by digesting a 
694 bp PCR product with the restriction endonuclease Nhel (Woodford et al., 2002). All Nhel 
digests nevertheless remained heterozygous for G2576T. The mutant linezolid MIC was >256 
mg/L by E Test but resistance was unstable and some reversion towards linezolid susceptibility 
occurred if the mutant was passaged on antibiotic-free agar. DNA sequencing of a 694 bp region 
of the 23S rRNA genes confirmed the presence of a G2576T mutation (Figure 28 [A]). More 23S 
rRNA gene copies were mutated (T) than wild-type (G), as indicated by peak heights on the 
chromatogram. Additionally, an adenine to guanine change at position 2503 was detected (Figure 
28 [B]). Pyrosequencing detected and determined the percentage of mutated 23S rRNA gene 
copies for the two mutations (Table 19). For the A2503G mutation 32% of copies were mutated 
and for the G2576T mutation 64% of copies were mutated, compared to 45% in the parent strain. 
Hybridization estimated the number of 23S rRNA copies present, and using both pyrosequencing 
and hybridization, the number of mutated copies was determined. Hybridization confirmed the 
presence of six 23S rRNA gene copies in both the parent and mutant strains. For the
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Figure 28. Chromatogram of G2576T and A2503G mutations in laboratory-selected 
linezolid-resistant mutant RN4220A/wwt)S'-M9a. (A) G2576T mutation. The presence o f a black 
‘G’ peak under the red ‘T ’ peak indicates heterozygous resistance. The sequencing software is 
calling a T% indicating an increase and predominance in the number o f mutated copies after 
passage on increasing concentrations of linezolid. (B) A2503G mutation. The presence o f a black 
‘G’ peak under a green ‘A ’ peak indicates heterozygosity.
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A2503G mutation, two gene copies were mutated and for the G2576T mutation, four gene copies 
were mutated. Using this technique it is not possible to determine which of the gene copies were 
mutated. All six gene copies might have one mutation present, or four gene copies could be 
mutated with two of these carrying both G2576T and A2503G mutations. PFGE confirmed 
parentage of the mutant.
3.2.5 M utation frequencies o f laboratory-selected linezolid-resistant mutants
In order to determine whether selecting for linezolid resistance altered the mutability of the 
strains, and co-selected for hypermutability, mutation frequencies of the linezolid-resistant mutants 
were determined. The frequency at which in vzYro-selected linezolid-resistant mutants of RN4220, 
RN4220AmwYS' and ST/03/2121 and their parent strains generated mutants to rifampicin (50 mg/L) 
and fusidic acid (0.5 mg/L) was determined (see Table 20 for MICs) (see section 2.9.1). The 
arithmetic mean of three mutation frequency experiments was graphed and the mean mutation 
frequencies represented.
RN4220, RN4220AmwYS' and ST/03/2121 controls all had mutation frequencies to rifampicin and 
fusidic acid comparable with those found in previous experiments (Table 21, Figure 29, Figure 30, 
Appendix B Table 50 and Table 51). Out of 34 average mutation frequencies to rifampicin and 
fusidic acid, half increased and half decreased compared with their parent strains. Twelve mutants 
had increases in mutation frequency to rifampicin, five had decreases in mutation frequencies, 
when compared with their parent strains. Four mutants had increases in mutation frequency to 
fusidic acid and 13 had decreases, when compared with their parent strains. Four mutants had 
increases in average mutation frequencies to both rifampicin and fusidic acid, when compared with 
their parent strains; two mutants of RN4220 (M l, M2,), one revertant mutant (wild-type, 
erythromycin-susceptible) of RN4220Am«YS' (M6) and one mutant of RN4220AwwYS' (M10). Of 
these four mutants, three had G2447T mutations and one had a G2576T mutation conferring 
resistance to linezolid. Five mutants had decreases in both rifampicin and fusidic acid mutation 
frequencies when compared with their parent strains, four of the five were mutants of ST/03/2121
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(M13, M14, M15, M17). Eight mutants had inconsistencies between rifampicin and fusidic acid, 
with both increases and decreases in mutation frequencies when compared with the parent strains. 
RN4220Amw£S' revertants produced mutation frequencies more comparable to RN4220 than to 
RN4220AmutS, consistent with accurate loss of the pGhost9+ plasmid and restoration of mutS 
function.
Mutant RN4220-M3 had a nine-fold increase in the average mutation frequency to rifampicin. 
Looking at the individual mutation frequencies, one experiment produced a mutation frequency 
substantially higher than the other two experiments, resulting in an elevated average mutation 
frequency and a large increase when compared with the parent strain, possibly due to a jackpot 
culture. A mutation can occur at any time during the period of growth of a culture and therefore, 
the number of mutants at the end of the experiment represents the number of independent mutation 
events as well as the accumulation of clones of the mutants themselves. Therefore, a mutation 
occurring relatively early during the period of growth, known as a “jackpot culture”, will result in a 
greater final mutation frequency (Saunders et al., 2003). This increase in mutation frequency to 
rifampicin was not reflected in the mutation frequency to fusidic acid. Mutant RN4220Aw«/<S'-M8 
had a nine-fold increase in rifampicin mutation frequency when compared with the parent strain, 
again without any parallel increase in the mutation frequency to fusidic acid.
These results show that there is little evidence that selection for linezolid resistance could co­
select for hypermutability. Increases in the mutation frequencies to rifampicin occurred in a 
number of mutants, but this was not necessarily echoed in the mutation frequencies to fusidic acid; 
only three mutants had increases in mutation frequencies to both rifampicin and fusidic acid. These 
increases ranged between two- and five-fold. The type of mutation conferring resistance to 
linezolid did not seem to affect the mutation frequency of the mutant.
3.2.6 Fosfomycin disc tests to detect hypermutability
This method was used as a screen for hypermutators (see section 2.9.2). Briefly, bacteria were 
suspended to a density of a 1.0 McFarland standard and swabbed over an ISO agar plate before a 
50 pg disc was applied. After 24 hours incubation, the numbers of colonies in the zone of clearing
159
were counted and the zone diameter measured. The mean of three replicates was calculated and the 
results plotted. RN4220AmM/<S' produced a mean of 292 colonies in the zone of clearing, five times 
that of RN4220, which produced a mean of 60 (Table 22 and Figure 31). ST/03/2121 produced a 
mean of 251, four times that of RN4220. ST/03/2122 produced nearly three times as many 
colonies in the zone of clearing as RN4220. The number of colonies produced in the zone of 
clearing decreased for 14 of 17 linezolid-resistant mutants. Mutants gave between 14 and 174 
colonies fewer in the zone of clearing than parent strains, with mutants of ST/03/2121 producing 
the largest drops in colony numbers. Only two mutants produced more colonies in the zone of 
clearing than their parent strains (M5, M7) and these only produced, on average, 12 to 19 more 
mutants than their parent, RN4220. Mutant M4 produced the same number of colonies in the zone 
as its parent strain. The mutants which had increased mutation frequencies to rifampicin and 
fusidic acid (Ml, M2, M6, M10) (see section 3.2.5) did not produce more colonies in the zone of 
clearing than their parent strains.
All mutants had increased zone diameters compared with their parent strains (Table 22 and Figure 
32). Zone diameters increased considerably for linezolid-resistant mutants of RN4220 and 
KN4220mutS, however increases in zone sizes of mutants of ST/03/2121 were less marked. Zone 
diameters increased by 0.2 mm to 12.5 mm. Fourteen mutants had decreases in the number of 
colonies produced in the zone of clearing and increases in zone diameter compared with their 
parent strains. One of these, mutant M l 7, produced, on average, 146 colonies fewer and a diameter
12.5 mm larger than its parent strain, ST/03/2121. The remaining three had increases in the 
number of mutants produced in the zone of clearing and in the zone diameter compared with their 
parent strains. The zone diameters correlated well with fosfomycin MICs (by agar dilution), with 
increased zone sizes relating to decreased MICs. There was a difference in both MICs and zone 
sizes between parents and mutants, possibly indicating some loss of mutability. Approximately a 5 
mm change in zone size was required to see a change in MIC. Overall, there was no indication that 
there is co-selection of hypermutability with linezolid resistance using fosfomycin as an indicator, 
in fact there seems to be some evidence pointing towards a reduction in mutability.
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3.2.7 Summary
Many laboratory-selected linezolid-resistant mutants proved unstable. However, 17 linezolid- 
resistant mutants were selected. These mutants had a variety of mutations (G2576T, G2447T, 
T2504C), as detected by PCR-RFLP, DNA sequencing and pyrosequencing. Pyrosequencing and 
hybridization revealed that 23 S rRNA gene copy number varied between parents and their 
linezolid-resistant mutants. Chloramphenicol MICs increased for some of the mutants. Some 
RN4220Amw?-S,-derived mutants reverted to wild-type, with the excision of the pGhost9+ plasmid, 
carrying an erm determinant, inserted to disrupt the mutS gene. The evidence to support the co­
selection of hypermutability and linezolid resistance is lacking, with no linezolid-resistant mutants 
producing increased numbers of mutants to all three antibiotics tested.
3.3 Loss of erythromycin resistance with the emergence of linezolid 
resistance
Whilst raising linezolid-resistant mutants in vitro, it was noted that some mutants of 
RN4220AwM/iS lost the pGhost9+ plasmid, inserted to disrupt the mutS gene. This plasmid 
contained an erm(B) resistance marker. The next section investigates this further.
3.3.1 Characterization o f mutants
A group of erythromycin-resistant, with erm(B) and erm(C) genes, and erythromycin-susceptible 
clinical isolates were grown in the presence and absence of erythromycin along with increasing 
concentrations of linezolid to try to establish, firstly, whether erythromycin would delay the 
emergence of linezolid resistance in erythromycin-resistant isolates, and secondly, whether 
reversion to erythromycin susceptibility consistently occurred with the emergence of linezolid 
resistance (Table 23) (see section 2.5.2). The erythromycin-resistant strains were tested for erm 
determinants by PCR and their inducibility was addressed by double disc tests (Table 23) (see 
section 2.3.5)
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Strains were passaged on agar containing a constant concentration of linezolid until sufficient 
growth had occurred, before then being passaged at the next concentration. Upon being able to 
grow on agar containing 10 mg/L of linezolid, mutants were passaged five times at this 
concentration to try to stabilize resistance. The number of days each strain spent plated on agar 
containing each concentration of linezolid was recorded. The experiment was repeated four times 
using 100 mg/L of erythromycin (Appendix B Table 55, Figure 64, Figure 65, Figure 66, Figure 
67). The fifth experiment was conducted in the presence of 8 mg/L of erythromycin, a 
concentration around the serum peak (the maximum concentration in the body after dosing ranges 
from <1-14 mg/L) (Figure 36) (Bryskier and Butzler, 1997).
Mutants selected from the five experiments underwent linezolid and erythromycin MIC 
determinations (see section 2.3.2). Mutants were screened for G2576T, T2504C and G2505A 
mutations by RFLP of a 694 bp PCR product of the 23 S rRNA genes with the restriction 
endonucleases NheI, H inll and EcoRW, respectively (see section 2.7.4). Sequencing and 
pyrosequencing confirmed the presence or absence of the above mutations as well as T2500A, 
A2503G, G2445T and G2447T mutations (see section 2.7). Initially, erythromycin MIC 
determinations confirmed the presence or absence of erm determinants in the mutants and was later 
confirmed by PCR (Figure 33 [A] and [B]) (see section 2.7.2). Mutants underwent PFGE to 
confirm parentage (Figure 34) (see section 2.6.3).
Forty-two mutants were selected from five repeated experiments (Table 24). Mutants were 
numbered M l to M42. Linezolid MICs ranged from 4 to 64 mg/L. Twenty-six mutants were 
resistant to linezolid, the remaining 16 were susceptible. Of the 16 mutants that were linezolid- 
susceptible, ten were grown in the presence of erythromycin and linezolid. Linezolid MICs ranged 
from 4 to 64 mg/L for mutants grown in the absence of erythromycin and from 4 to 8 mg/L for 
mutants grown in the presence of erythromycin. Linezolid resistance was unstable, with some 
mutants able to grow on agar containing 10 mg/L linezolid yet, after one passage on antibiotic-free 
agar, with a MIC of 4 mg/L.
Eleven mutants had G2576T mutations, three had G2447T mutations, six had T2504C mutations 
and six isolates had unidentifiable mechanisms of resistance (all six with linezolid MICs of 8 
mg/L). Four out of 14 mutants, selected in the presence of erythromycin, were resistant to linezolid
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(MICs 8 mg/L); two with T2504C mutations and one with a G2576T mutation were identified, one 
mutant had no identifiable mechanism of resistance. Mutations G2576T, G2447T and T2504C 
were all identified in linezolid-resistant isolates selected in the absence of erythromycin.
Six of 14 erythromycin-resistant mutants, grown in the absence of erythromycin, reverted to 
erythromycin susceptibility with the loss of an erm determinant; one of four erm{B) mutants and 
five of ten erm(C) mutants. Of these six, only one had a detectable mutation (G2447T). Four of 
the six had linezolid MICs of 4 mg/L. No erythromycin-resistant mutants grown in the presence of 
erythromycin lost an erm determinant.
The average time taken (experiments one to four, with 100 mg/L erythromycin) for linezolid 
resistance to emerge (i.e., for mutants to develop the ability to grow with 6 mg/L of linezolid) 
ranged from 11 to 44 days, with resistance developing quickest in the hypermutable isolate 
RN4220Aw«aS' (Table 25 and Figure 35 and Appendix B Figure 64, Figure 65, Figure 66 and 
Figure 67). Erythromycin-susceptible strains took between 23 and 37 days to grow in the presence 
of 6 mg/L linezolid. Erythromycin-resistant strains took between 11 and 44 days to grow in the 
presence of 6 mg/L linezolid. Growing erythromycin-resistant isolates in the presence of 
erythromycin and increasing concentrations of linezolid delayed the emergence of linezolid 
resistance, on average, by 17 days in mutants of strain 7500 and 19 days in mutants of strain 7501. 
Growing the hypermutable strain in the presence of erythromycin did not delay the time taken for 
linezolid resistance to emerge. Mutants took 13 to 54 days to grow in the presence of 6 mg/L 
linezolid with the erythromycin concentration at 8 mg/L (Table 25 and Figure 36 and Appendix B 
Table 52). Erythromycin-susceptible strains took between 29 and 54 days to grow in the presence 
of 6 mg/L linezolid. Erythromycin-resistant strains took between 13 and 46 days to grow in the 
absence of erythromycin and in the presence of 6 mg/L linezolid. Linezolid resistance was delayed 
by eight and 23 days in erythromycin-resistant strains 7500 and 7501, respectively, by growing 
them in the presence of 8 mg/L erythromycin. Again, linezolid resistance emerged quickest in the 
hypermutable strain, and here, the addition of erythromycin made no difference in the time taken 
for linezolid resistance to emerge. It resulted in an increase of four days in strain 7501 and a 
decrease of nine days in strain 7500. However, this experiment (with the addition of 8 mg/L
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erythromycin) was only carried out once and the four experiments using 100 mg/L of erythromycin 
show variation between them.
To establish whether the growth of erythromycin-resistant strains was hindered in the presence of 
erythromycin, growth curves of erythromycin-resistant strains were carried out in the presence and 
absence of 100 mg/L of erythromycin (Figure 37) (see section 2.4.3). The results showed no 
difference in growth in the presence or absence of erythromycin. Additionally, the stability of 
linezolid in agar over a period of five days was investigated and results showed no evidence for the 
degradation of linezolid (see section 2.5.2.1).
Hybridization and pyrosequencing were used in conjunction to determine the number of mutated 
23S rRNA gene copies in linezolid-resistant mutants and parents (see section 2.7.7 and 2.8). 
Hybridization revealed 24 of 42 mutants had altered 23 S rRNA gene copy number compared with 
their parent strains, the remaining 18 had the same copy number as their parent strains (Table 26 
and Figure 38). Of the 24 mutants with changed copy number, 21 had increased, three had 
decreased. All three with a decreased copy number, when compared with their parent strains, had 
decreased by one. Of the 21 mutants with an increased copy number when compared with their 
parent strains, 14 had increased by one copy, four mutants had increased by two copies, one had 
increased by three copies and two had increased by four copies. Pyrosequencing and hybridization 
combined, revealed mutants with a G2576T mutation had 15-65% of copies mutated, which 
equated to between one and four mutated 23 S rRNA gene copies (Table 26). Mutants with a 
T2504C mutation had 33-48% of copies mutated, which equated to two or three mutated 23S rRNA 
gene copies. One mutant with a A2503G mutation had 14% of copies mutated, which equated to 
one mutated 23 S rRNA gene copy.
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Figure 38. Hybridization to detect 23S rRNA gene copy number in linezolid-resistant 
mutants. Lanes 1 and 10 DIG-labelled ladder, lanes 2-5 M16-M19, lane 6 7500, lane 7 7501, lane 
8 7499, lane 9 7717. 23S rRNA gene copy numbers for M l7 (lane 3) are shown in white. Weak 
bands, an example of which are boxed, were not counted.
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3.3.2 Replica plating
Mutants M26, M28 and M29 (all derived from isolate 7501) seemed to be in a transition period 
between erythromycin resistance and susceptibility, with some colonies still resistant to 
erythromycin whilst others were susceptible, resulting in a mixed population. Replica plating on to 
erythromycin (100 mg/L) enabled determination of the proportion of colonies still resistant to 
erythromycin and the proportion that were susceptible (see section 2.4.2). Replica plating was 
repeated three times for each isolate. The numbers of colonies on BHI, with no antibiotic added, 
were counted and compared with the numbers of colonies on BHI agar with 100 mg/L of 
erythromycin added. The percentage of erythromycin-resistant colonies was calculated and the 
average taken from the three replicated experiments. The average percentage of erythromycin- 
resistant colonies was 48.3%, 8.5% and 46.6% for M26, M28 and M29, respectively.
3.3.3 Sum m aiy
Linezolid resistance emerged quickest in mutants of the hypermutable strain, RN4220Amw£S'.
Linezolid resistance was unstable in the majority of mutants, with mutants initially able to grow in
the presence of 10 mg/L linezolid reverting back to linezolid susceptibility after a single passage on
antibiotic-free medium. Growing erythromycin-resistant isolates in the presence of erythromycin
and increasing concentrations of linezolid delayed the emergence of linezolid resistance in two of
three strains, the exception being mutants of the hypermutable strain where the presence of
erythromycin had no effect on the emergence of linezolid resistance. Growing erythromycin-
resistant strains in the presence of lower concentrations of erythromycin, i.e., 8 mg/L as opposed to
100 mg/L and increasing concentrations of linezolid caused both increases and decreases in the
time taken for resistance to emerge with little or no overall trend. There were no differences in the
growth curves of erythromycin-resistant strains grown in the presence or absence of 100 mg/L
erythromycin. Nearly half of the erythromycin-resistant isolates, grown in the absence of
erythromycin, lost an erm determinant during selection of linezolid resistance, the majority losing
an erm(C) determinant. No loss of erm determinants was seen with erythromycin-resistant strains
grown in the presence of erythromycin and linezolid. A range of mutations were found in mutants,
183
with G2576T being the predominant one. Hybridization revealed that copy number in mutants 
ranged from one fewer to four more copies than the parent strain. Pyrosequencing and 
hybridization revealed mutants had between one and four mutated copies.
3.4 Selection of chloramphenicol-resistant mutants with cross­
resistance to linezolid
Whilst growing linezolid-resistant mutants in vitro, some mutants were noticed with an elevated 
chloramphenicol MIC. The next section discusses these findings in greater detail and explores the 
possibility of cross-resistance between linezolid and chloramphenicol.
3.4.1 Characterization o f chloramphenicol-resistant mutants
Whilst raising linezolid-resistant mutants in vitro, mutant ST/03/2121-M11 developed a T to C 
change at position 2504 in the genes encoding 23S rRNA, detected by sequencing and confirmed 
by a HinW PCR-RFLP. MIC determinations for this mutant revealed a four-fold increase in the 
chloramphenicol MIC, thought to be conferred by the T2504C mutation (see section 3.2, Table 16). 
Additionally, three of four mutants with G2576T mutations had 8-fold increases in 
chloramphenicol MICs. It was hypothesised that generating mutational resistance to 
chloramphenicol might select for cross-resistance to linezolid, and specifically for T2504C and 
G2576T mutations.
Mutants of RN4220, RN4220Amw/5', ST/03/2121 and ST/03/2122 were selected in the presence of 
chloramphenicol, by passaging on agar containing increasing concentrations (in 2 mg/L intervals 
up to 16 mg/L) (see section 2.5.3). Mutants were passaged five times at 16 mg/L chloramphenicol 
to try to stabilise resistance. Mutants were designated by lettering A-E, prefixed by the number of 
the parent strain. Thirteen chloramphenicol-resistant mutants were selected, eight of which were 
cross-resistant to linezolid (Table 27). MICs of linezolid, chloramphenicol and erythromycin were 
determined for mutants (see section 2.3). No loss of erythromycin resistance was seen in any of the
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mutants. In cross-resistant mutants chloramphenicol MICs ranged from 16 to >256 mg/L (parent 
strains 4 to 16 mg/L) and linezolid MICs from 8 to 64 mg/L (parent strains 1 to 4 mg/L). 
Resistance was unstable, especially in mutants of ST/03/2122, with three of five with 
chloramphenicol and linezolid MICs the same as their parent strain after a single passage on 
antibiotic-free agar. A positive correlation co-existed between chloramphenicol and linezolid 
MICs (Table 27).
Two mutants of RN4220, RN4220-A and RN4220-E, showed the highest chloramphenicol MICs. 
A 694 bp region of the 23 S rRNA genes of these two mutants was DNA sequenced (see section
2.7.6), revealing T2500A and G2505A changes in RN4220-A and RN4220-E, respectively (Figure 
39 [A] and [B]). The G2505A mutation was confirmed by PCR-RFLP with TscoRI-digested DNA 
(Figure 40) (see section 2.7.4) (Lobritz et al., 2003). PCR-RFLP with Nhel and Hin\I did not 
detect the G2576T and T2504C mutations in any of these mutants (see sections 2.7.4 and 2.7.5). 
All mutants underwent pyrosequencing to screen for seven mutations in the 23S rRNA genes: 
T2500A, A2503G, T2504C, G2505A, G2445T, G2447T, G2576T (see section 2.7.7). 
Pyrosequencing detected and quantified T2500A mutations in RN4220-A and RN4220Awiw/*S'-C 
and a G2505A mutation in RN4220-E (Table 28). No mutations were detected in any of the other 
mutants by PCR-RFLP, DNA sequencing or pyrosequencing.
Hybridization was used to determine the 23 S rRNA gene copy number in parents and mutants 
(Figure 41 [A] and [B]) (see section 2.8). 23S rRNA gene copy number varied between five and six 
copies. One mutant lost one gene copy, eight gained one gene copy and the remaining 11 had the 
same copy number as their parent strains. The pyrosequencing and hybridization data were 
combined to determine how many gene copies were mutated. RN4220-A, RN4220-E and 
RN4220A/wwaS,-C all had one gene copy mutated. However, mutants RN4220-A and RN4220-E 
had chloramphenicol MICs of 256 mg/L and 32 mg/L, respectively. Resistance was highly 
unstable and some reversion to chloramphenicol and linezolid susceptibility occurred between MIC 
determinations and subsequent investigation of the number of mutated 23 S rRNA gene copies by 
pyrosequencing and hybridization. Repeats of linezolid and chloramphenicol MICs confirmed
186
Figure 39. Chromatogram of the 23S rRNA genes of chloramphenicol-resistant mutants (A)
Mutant RN4220-E with a G2505A mutation. (B) Mutant RN4220-A with a T2500A mutation.
(A) G G O A C C T C G A T
G G C A C C T C G A T
V
T C G G C T C A T C
T C G G C T C A T C
(B) T T T G G C A C C
T T T G G C A C C
T T T G G C A C C
T T T G G C A C C
C G A T G T C G t
C G A T G T C G t
C G A T G T C G t
C G A T G T C G f
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Figure 40. EcoRl digest to detect a G2505A mutation. Lane 1 homozygous G2505, lane 2 
heterozygous G2505A, lane 3 water control, lane 4 123 bp ladder.
1 2  3 4
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Figure 41. Hybridization of DNA from chloramphenicol-resistant mutants of RN4220, 
RN4220A/MM/S', ST/03/2121 and ST/03/2122 to detect 23S rRNA copy number. (A) Lanes 1, 4, 
15 DIG-labelled ladder, lane 2 RN4220, lane 3 RN4220AWW/S, lanes 5-9 RN4220 mutants A-E, 
lanes 10-14 KN4220AmutS mutants A-E. (B) Lanes 1, 4 and 12 DIG-labelled ladder, lane 2 
ST/03/2121, lane 3 ST/03/2122, lanes 5-9 ST/03/2121 mutants A-E, lanes 10-11 KN4220A>nutS 
mutants A-B. Weak bands, an example of which are boxed, were not counted.
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reversion towards susceptibility and were in agreement with pyrosequencing results (Table 28 and 
Appendix B Table 55). This reversion to susceptibility was further confirmed by mutants RN4220- 
A and RN4220-E having nearly equal numbers of mutated and wild-type copies present in their 
sequencing chromatograms (carried out before reversion towards susceptibility), however, only 17 
and 14% of copies, respectively, are mutated according to the pyrosequencing result (carried out 
after reversion towards susceptibility had occurred).
Parentage of mutants was verified by PFGE (Figure 42 [A] and [B]). Mutants RN4220-A, 
ST/03/2122-D and ST/03/2122-E displayed a change in their PFGE banding profiles. On the 
PFGE profile of mutant RN4220-A there is an increase in the size of fragment D, possibly as a 
result of the loss of a Smal site at one end of fragment D and its subsequent fusion with another 
fragment (Figure 42 [A] and see section 3.1.1 Figure 12). Fragment D was approximately 262 Kb 
in size and its adjacent fragment on the restriction digest map is fragment L, approximately 44 Kb 
in size (http://micro-gen.ouhsc.edu/s_aureus/s_aureus _home.htm). The two fragments have rrnA  
and rrnE operons at their junction. It is possible that changes in these regions due to exposure to 
chloramphenicol resulted in the loss of a Smal site and fusion of the two fragments. However, this 
did not occur in all chloramphenicol-resistant mutants.
3.4.2 Summary
It was possible to raise chloramphenicol-resistant mutants that were cross-resistant to linezolid 
and there was a positive correlation between chloramphenicol and linezolid MICs for these 
mutants. Mutants of RN4220 produced high-level resistance to chloramphenicol. 23 S rRNA 
mutations were only detectable in three of eight mutants cross-resistant to chloramphenicol and 
linezolid, the remainder had unstable resistance. These three mutants, with chloramphenicol MICs 
of >32 mg/L and linezolid MICs of >8 mg/L, harboured T2500A or G2505A mutations. No cross- 
resistant mutants were detected with T2504C and G2576T mutations. Changes in the number of 
genes encoding 23 S rRNA were seen in nine of the 20 mutants, with loss or gain of one gene copy. 
Resistance was unstable with reversion to linezolid and chloramphenicol susceptibility in the
192
Figure 42. PFGE of 5'mal-digested DNA from RN4220, RN4220Am«/S' and their 
chloramphenicol-resistant mutants. (A) Lanes 1 and 14, lambda ladder, lane 2 RN4220, lanes 
3-7, RN4220 mutants A-E, lane 8 RN4220AWW/51 control, lanes 9-13, RN4220A/7?w/5' mutants A-E. 
Lane 3 shows changes in banding profile. (B) Lanes 1 and 14, lambda ladder, lane 2 ST/03/2121, 
lanes 3-7, ST/03/2121 mutants A-E, lane 8 ST/03/2122 control, lanes 9-13, ST/03/2122 mutants A- 
E. Lanes 12 and 13 show shifts in banding profiles.
(A) 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Changes in 
banding profile 
(Fragment D)
48.5 Kb
(B) 7 8 9 10 11 12 13 14
Changes in
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absence of selection pressure, irrespective of mutation type. No loss of erythromycin resistance 
was associated with any of the mutants.
3.5 Analysis of linezolid-resistant clinical isolates
Clinical isolates suspected of linezolid resistance sent to ARMRL for susceptibility testing 
between 2003 and 2005 were characterized further.
3.5.1 Characterization o f clinical linezolid-resistant isolates
Eleven suspected linezolid-resistant S. aureus isolates from five patients were submitted to 
ARMRL for susceptibility testing and confirmation of linezolid resistance (Table 29). Eight of the 
11 isolates were from patients with cystic fibrosis. Most isolates were from the UK; exceptions 
were for 4a and 4b (Ireland) and 5 a and 5b (Brazil) (Table 29).
An initial linezolid MIC, determined by agar dilution, established whether the MIC for each 
isolate was above the breakpoint (i.e., >4 mg/L). This was followed by an E Test to confirm the 
MIC (see section 2.3). The MICs for nine of 11 isolates were >16 mg/L. In the absence of 
treatment with linezolid the second isolate from patient 1 (lb) showed reversion to linezolid 
susceptibility, with an MIC of 0.5 mg/L. Its precursor isolate (la) was linezolid-resistant, with an 
MIC of 16 mg/L. Isolate 5a was isolated at the beginning of therapy with linezolid (linezolid MIC 
2 mg/L) and 5b was isolated later on during the course of therapy (linezolid MIC 32 mg/L).
Digestion of a 694 bp PCR amplicon of the 23S rRNA genes with the restriction endonuclease 
Nhel revealed that all clinical linezolid-resistant isolates had a G to T mutation at position 2576 in 
the genes encoding 23S rRNA (see section 2.7.4). Seven of the nine were heterozygous for this 
mutation and two (4a and 4b) were homozygous. By HinW PCR-RFLP, none of the isolates had a 
T2504C mutation. Sequencing a 694 bp region of the 23 S rRNA genes confirmed the presence of 
the G2576T mutation and the absence of other mutations. Pyrosequencing confirmed and 
quantified G2576T mutations in all linezolid-resistant isolates (Table 30) (see sections 2.7.6 and
2.7.7), revealing 35% to 100% of 23S rRNA gene copies were mutated. Isolates 4a and 4b had
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all copies mutated, however, their linezolid MICs were only 16 mg/L, which is low compared to 
several linezolid-resistant heterozygous isolates. Hybridization revealed 23S rRNA copy number 
to range from four to six among isolates. Isolates 4a and 4b produced an unusual fragment pattern 
with only four 23S rRNA gene copies (Figure 43). Combined, the pyrosequencing and 
hybridization data enabled the numbers of 23S rRNA copies mutated to be detected. Linezolid- 
resistant isolates had between two and four 23S rRNA copies mutated.
PFGE of the isolates, linezolid- susceptible and resistant, revealed three isolates to be EMRSA-15 
(3a, 3b, 3c,), four to be EMRSA-16 (la, lb, 2a and 2b), two to be MSSA isolates (4a and 4b) and 
two to be the Brazilian endemic MRSA clone (5a, 5b) (Figure 44) (see section 2.6.3).
3.5.2 M utation frequencies o f linezolid-resistant clinical isolates
In order to see whether the linezolid-resistant clinical isolates were hypermutable, the frequency at 
which they generated mutants to rifampicin and fusidic acid at 4 x MIC was determined, unless 
resistance to these agents prevented this (Table 31) (see section 2.9.1). A mean mutation frequency 
was calculated from three replicated experiments.
There was an 86-fold difference in mutation frequencies to rifampicin between RN4220 and 
RN4220Aww£S' (Table 31, Figure 45 and Appendix B Table 53). RN4220, ST/03/2121, the MSSA 
control strain (H051000333) and the EMRSA-16 control strain (NCTC 13143) all had similar 
mutation frequencies to rifampicin. The EMRSA-15 control strain (NCTC-13142), had a mutation 
frequency five-fold greater than that of RN4220. A mutation frequency to rifampicin was only 
determinable for five of 11 isolates, as the remainder had high-level resistance to rifampicin. 
Clinical isolate ST/03/2122 also had high-level resistance to rifampicin. All the linezolid-resistant 
clinical isolates tested had mutation frequencies to rifampicin two- to seven-fold higher than that of 
RN4220, but 10 to 40-fold lower than RN4220Am«/5'.
KN4220AmutS had a mutation frequency to fusidic acid 18-fold higher than that of RN4220 
(Table 31, Figure 46 and Appendix B Table 54). RN4220 and ST/03/2121 had similar mutation 
frequencies to each other. ST/03/2122 had a mutation frequency two-fold lower than RN4220.
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Figure 44. PFGE of representative linezolid-resistant clinical isolates. Lanes 1 and 9 48.5 Kb 
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The MSSA (H051000333) and EMRSA-16 (NCTC 13143) control strains had mutation 
frequencies 25-fold and 21-fold lower than RN4220, respectively. The control strain, EMRSA-15 
(NCTC 13412), mutated at a level below the detectable limit. A mutation frequency was detectable 
for all clinical isolates. Four of the clinical isolates had mutation frequencies higher than RN4220, 
the remaining six had mutation frequencies lower than RN4220. The isolate lb, isolated from the 
same patient approximately six months after la, had a mutation frequency to fusidic acid 12-fold 
higher than its precursor. However, both had mutation frequencies lower than RN4220. Isolates 2a 
and 2b, isolated sequentially from the same patient, had similar mutation frequencies, both of 
which were lower than that of RN4220. Isolates 4a and 4b, isolated sequentially from the same 
patient, had mutation frequencies 31- and 35-fold lower than RN4220. The linezolid-resistant 
isolate 5b had a mutation frequency six-fold greater than its linezolid-susceptible precursor, 5a. 
Three sequential, clinical isolates from the same patient (3a, 3b, 3c) had mutation frequencies four- 
to six-fold higher than RN4220. These three isolates were the only ones that displayed increased 
mutation frequencies to rifampicin and fusidic acid.
3.5.3 Fosfomycin disc tests
This method was used as a screen for hypermutators (see section 2.9.2). The number of colonies 
in the zone of clearing were counted and the zone diameter measured. The average of three 
repeated experiments was calculated.
The number of colonies in the zone of clearing for control strains was as for section 3.2.6. 
Briefly, RN4220Amw/*S' produced an average five-times that of RN4220 (Table 32 and Figure 47). 
ST/03/2121 and ST/03/2122 produced averages four- and three-times that of RN4220, respectively. 
Isolates 5a and 5b were resistant to fosfomycin, all other clinical isolates were tested. Five isolates 
had between three and 158 more colonies in the zone of clearing than KN4220AmutS. O f these 
five, three were from the same patient (3 a, 3 b, 3 c) and had previously displayed mutation 
frequencies to rifampicin and fusidic acid higher than those for RN4220. Four isolates had 
between 57 and 163 fewer colonies in the zone of clearing than RN4220AmutS, but still more than
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produced by RN4220. Isolate la  had, on average, 171 more colonies in the zone of clearing than 
the subsequent isolate (lb). Isolate 2a had, on average, 118 more colonies less in the zone of 
clearing than the subsequent isolate (2b). Isolates 3a, 3b and 3c had, on average, 158, 93 and 117 
more colonies in the zone of clearing than RN4220Aww/<S'.
Three mutants had a zone diameter smaller than that produced by RN4220Amw/iS', one of which 
had more colonies in the zone of clearing (la) (Table 32 and Figure 48). The remaining six all had 
larger zone diameters, with four of these producing more colonies in the zone, than RN4220Aww/S'. 
Fosfomycin MICs related to zone diameters, with seven out of eight strains tested with an MIC of 
0.25 mg/L. Results showed a high fosfomycin MIC is not necessarily a prerequisite for a greater 
number of colonies appearing in the zone of clearing.
3.5.4 Summary
Nine out of 11 isolates were resistant to linezolid, with MICs >16 mg/L. All were positive for the 
G2576T mutation. Two were homozygous for the G2576T mutation, the remainder were 
heterozygous. No additional mutations were found in the 694 bp region of the 23 S rRNA genes 
sequenced. The 23S rRNA copy number varied from four to six and the number of mutated copies 
ranged from two to four. Two isolates of the same strain had all four 23 S rRNA gene copies 
mutated, yet only with a linezolid MIC of 16 mg/L. Mutation frequencies were difficult to 
ascertain with the majority of isolates being resistant to rifampicin. RN4220Am«/S' mutated at the 
greatest frequency to both rifampicin and fusidic acid. All the clinical isolates, that were able to be 
tested, had a mutation frequency to rifampicin greater than RN4220. However, only four isolates 
had mutation frequencies to fusidic acid greater than RN4220, and none so high as RN4220Am«/<S'. 
Only three isolates had elevated mutation frequencies to both rifampicin and fusidic acid when 
compared with RN4220. The same three isolates had more colonies in the zone of inhibition 
surrounding a fosfomycin disc than the hypermutable strain RN4220Awwf<S'.
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3.6 Determination of 23S rRNA copy number in linezolid-resistant 
isolates and mutants
The next section summarises the results from pyrosequencing and hybridization experiments to 
determine the number of mutated 23 S rRNA gene copies in linezolid-resistant isolates from the 
clinic and laboratory-selected mutants and the relationship between this and linezolid MIC.
3.6.1 Pyrosequencing
Pyrosequencing was used to detect and quantify the percentage of mutated 23 S rRNA gene copies 
in clinical linezolid-resistant isolates, laboratory-selected mutants, and their parent strains (see 
section 2.7.7).
A 364 bp region of the 23S rRNA genes was amplified (Figure 49). Three pyrosequencing 
primers were then used to detect the presence of seven known mutations; T2500A (Figure 50), 
A2503G (Figure 51), T2504C (Figure 52), G2505A (Figure 53), G2445T (not shown), G2447T 
(Figure 54) and G2576T (Figure 55). Quantification of the percentage of mutated copies was not 
possible for G2445T and G2447T mutations due to their presence within a homopolymer of four G 
nucleotides which the software found difficult to distinguish. A mutant with a G2445T mutation 
was not available to validate the assay. See relevant sections (3.2, 3.2.7, 3.4, 3.5) for detailed 
analysis of pyrosequencing results and Appendix B Table 55.
In total, 103 S. aureus isolates were pyrosequenced; 11 control strains, 46 linezolid-resistant 
mutants, 35 linezolid-susceptible isolates and 11 suspected linezolid-resistant clinical isolates. 
Mutations were successfully detected in 50 mutants. Mutations were detected in 41 of 46 in vitro- 
selected mutants; 16 had G2576T, 13 had G2447T, seven had T2504C, two had T2500A, one had a 
A2503G mutation and one had a G2505A mutation (Table 33 and Appendix B Table 55). One 
mutant had two mutations, G2576T and A2503G. All other mutations were present singularly. 
Mutations could not be detected in five laboratory-selected mutants (linezolid MICs 8-16 mg/L).
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Figure 49. PCR to amplify 364 bp of the 23S rRNA genes. Lane 1 123 bp ladder, lanes 2-9 364 
bp PCR product, lane 10 water control.
1 2 3 4  5 6  7 8 9  10
^364 bp PCR product
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G2576T mutations were detected in nine of 11 suspected linezolid-resistant clinical isolates. Two 
isolates were linezolid susceptible.
Linezolid-resistant clinical isolates had 35-100% of 23S rRNA gene copies mutated, the majority 
had 40-50% of copies mutated. Laboratory-selected mutants with a G2576T mutation had between 
15% and 65% of gene copies mutated, the majority of mutants had 40-50% of copies mutated. 
Laboratory-selected mutants with a T2504C mutation had between 13 and 48% of gene copies 
mutated, the majority had 30-40% of copies mutated and mutants with T2500A, A2503G and 
G2505A mutations all had 10-20% of copies mutated. Regardless of mutation, only laboratory- 
selected mutants had between 10 and 20% of 23 S rRNA copies mutated, all linezolid-resistant 
clinical isolates had over 35% of copies mutated (Table 33) (see sections 3.2, 3.2.7, 3.4, 3.5 for a 
more detailed analysis of pyrosequencing results).
Figure 56 illustrates the positive correlation between linezolid MIC and the percentage of 23S 
rRNA copies mutated; an increased percentage of mutated 23S rRNA copies leads to an increased 
linezolid MIC. There were exceptions to this trend. Two clinical isolates, 4a and 4b, had four 23S 
rRNA gene copies, all mutated, yet only a linezolid MIC of 16 mg/L. Another exception was 
clinical isolate, 2b, which had 75% of copies mutated but only a linezolid MIC of 16 mg/L.
3.6.2 Hybridization
Hybridization was used to determine the number of genes encoding 23 S rRNA in linezolid- 
resistant clinical isolates, laboratory-selected linezolid-resistant and -susceptible isolates and parent 
strains (see individual results chapters for more details) (see section 2.8). The same 103 isolates 
and mutants that were pyrosequenced underwent hybridization to detect 23 S rRNA gene copy 
number. The 23S rRNA gene copy number in control isolates was five or six, with the majority 
having five copies (Table 34 and Appendix B Table 55). The 23S rRNA gene copy number in 
laboratory-selected mutants, both linezolid-resistant and -susceptible (81), ranged from four to nine 
with 52 (64%) having six copies. In linezolid-resistant clinical isolates copy number ranged from 
four to six, with equal numbers of isolates having four, five and six copies. Of 46 laboratory- 
selected linezolid-resistant mutants, 25 mutants had no changes and 21 mutants had
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Figure 56. Percentage of mutated 23S rRNA gene copies versus linezolid MIC (mg/L). The
different 23 S rRNA mutations found are indicated.
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Table 34. Summary of 23S rRNA gene copy number in isolates and mutants tested. (See 
Table 17, Table 19, Table 26, Table 28, Table 30 and Appendix B Table 55 for individual results).
23S rRNA copy no. Controls Laboratory mutants Clinical isolates Total
Lins LinR Lins LinR
4 1 1 1 3 6
5 8 11 7 1 3 30
6 3 21 31 — 3 58
7 - - 4 — — 4
8 - 1 2 — — 3
9 - 1 1 — — 2
Total 11 35 46 2 9 103
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changes in 23S rRNA gene copy number when compared with parent strains, with the majority of 
these having one extra copy (Table 35). Clinical isolates lb  and 2b had one 23S rRNA gene copy 
fewer than their precursors. There were no differences in 23S rRNA gene copy number between 
other sets of clinical isolates from individual patients.
3.6.3 Determination of the number of mutated 23S rRNA gene copies
Hybridization and pyrosequencing were used in conjunction to determine the number of mutated 
23S rRNA gene copies in all linezolid-resistant mutants and isolates. The number of mutated 23 S 
rRNA copies ranged from one to four (Table 36). Of 17 laboratory-selected mutants with G2576T 
mutation, most (seven) had three gene copies mutated. Of nine linezolid-resistant clinical isolates, 
all with G2576T mutations, four had three gene copies mutated, with the number of mutant copies 
ranging from two to four. Of seven mutants with T2504C mutations, equal numbers of mutants 
had two and three copies mutated. Mutants with T2500A, A2503G and G2505A mutations had 
one copy mutated. There was a positive correlation between linezolid MIC and the number of 
mutated 23S rRNA gene copies (Figure 57). Overall, the data showed the majority of mutants to 
have a G2576T mutation, a linezolid MIC of 16 mg/L and three 23S rRNA gene copies mutated.
3.6.4 Summary
Pyrosequencing successfully identified six of seven known 23 S rRNA mutations conferring 
linezolid resistance and allowed five to be quantified. There was a positive correlation between the 
proportion of mutated copies and the linezolid MIC. The majority of isolates and mutants had 40- 
50% of 23S rRNA copies mutated. Gene copy number in control strains varied, with the majority 
having five copies. 23 S rRNA gene copy number in mutants exposed to linezolid and 
chloramphenicol varied, the majority having six. 23S rRNA gene copy number varied between 
parent and mutant strains. The majority of laboratory-selected linezolid-resistant mutants had 
G2576T mutations (17/27), three gene copies mutated (6/17) and a linezolid MIC of 16 mg/L
221
Table 35. Summary of changes in 23S rRNA gene copy number between parents and 
laboratory-selected mutants. (See Table 17, Table 19, Table 26, Table 28, Table 30 and 
Appendix B, Table 55 for individual results)
Changes in 23S rRNA copy no. Lin-susceptible Lin-resistant All laboratory mutants
-1 2 4 6
0 17 25 42
+ 1 14 10 24
+ 2 0 5 5
+ 3 1 1 2
+ 4 1 1 2
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Figure 57. Number of 23S rRNA mutated gene copies versus linezolid MIC (mg/L). Numbers 
indicate isolates with each combination. Mutant RN4220Aww/5'-M9a has not been included in this 
graph due to the presence of two mutations.
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(12/27). The majority of linezolid-resistant clinical isolates had G2576T mutations (9/9), 3 gene 
copies mutated (4/9) and a linezolid MIC of 16 mg/L (5/9).
3.7 Teicoplanin-resistant clinical isolates
Clinical S. aureus isolates, resistant to teicoplanin and sent to ARMRL for testing (2003 to 2005), 
were collected. As with linezolid it was hypothesised that isolates such as these might be 
hypermutable and, having already undergone chromosomal mutations to become teicoplanin- 
resistant, might be predisposed to generating linezolid resistance more readily. The frequency at 
which these isolates generated mutants to rifampicin and fusidic acid was therefore determined. 
Additionally, fosfomycin disc tests were used to screen for hypermutability in general.
3.7.1 M utation frequencies
Isolates suspected of being teicoplanin-resistant had MICs determined by agar dilution to 
determine whether they were above the then breakpoint (> 8 mg/L) (see section 2.3.2). The MIC 
was also determined by E Test (Table 37) (see section 2.3.3). These isolates were further 
characterized by PFGE (Table 37) (see section 2.6.3). The frequency at which these clinical 
isolates generated mutants to rifampicin and fusidic acid, individually, at 4 x MIC was determined 
in three replicated experiments (Table 38) (see section 2.9.1). The mean mutation frequency was 
calculated (Figure 58 and Figure 59).
Five of 13 teicoplanin-resistant clinical isolates had high-level resistance to rifampicin and 
therefore no mutation frequency could be established for this drug (Table 38, Figure 58 and 
Appendix B Table 56). Of the eight teicoplanin-resistant clinical isolates testable, three had 
mutation frequencies between two- and six-fold higher than RN4220, the remainder had equivalent 
or lower mutation frequencies. RN4220 mutated to rifampicin at an average mutation frequency of
1.4 x 10'8. RN4220AWW/51 mutated at a frequency 166-fold greater than that of RN4220. RN4220, 
MSSA (H051000333) and EMRSA-16 (NCTC 13143) isolates all mutated to fusidic acid at similar 
frequencies. ST/03/2121 and EMRSA-15 (NCTC 14132) had mutation frequencies two- and five­
fold higher than RN4220.
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Mutation frequencies to fusidic acid were determined for all but one of the 13 isolates (Table 38, 
Figure 59 and Appendix B, Table 57). RN4220 mutated at a frequency of 5.0 x 10'8.
~RN4220AmutS mutated to fusidic acid at a frequency 31-fold higher than RN4220. Isolates 
ST/03/2121, ST/03/2122 and the control strain EMRSA-16 mutated at seven-, four- and three-fold 
greater than RN4220, respectively. The MSS A control strain and isolates H035220342 and 
H041560346 mutated at the same frequency as RN4220. Isolate H034840069 was the only isolate 
to produce a mutation frequency to fusidic acid greater than RN4220 (12-fold increase). Eight 
isolates mutated at a frequency six to 100-fold lower than RN4220. The control strain EMRSA-15 
and H042240308 mutated at a frequency to fusidic acid below the detectable limit. The mutation 
frequency for isolate H041560345 was 100-fold lower than RN4220 and was only detected from 
one experiment. The other two experiments had mutation frequencies below the detectable limit.
One isolate, H034840069, had mutation frequencies elevated above those produced by RN4220 to 
both rifampicin and fusidic acid; a six-fold increase to rifampicin and a 12 fold-increase to fusidic 
acid. However, ST/03/2121 also produced mutation frequencies two-fold and seven-fold greater 
than RN4220 to rifampicin and fusidic acid, respectively.
Figure 58 and Figure 59 compare the mutation frequencies to rifampicin and fusidic acid of 
teicoplanin-resistant clinical isolates with linezolid-resistant clinical isolates. There are no obvious 
differences in the mutation frequencies of the control strains between the two data sets. Linezolid- 
resistant clinical isolates, on average, mutated at a greater frequency to rifampicin (two-fold) and 
fusidic acid (8-fold) than teicoplanin-resistant clinical isolates.
3.7.2 Fosfomycin disc tests
The number of colonies in the zones of inhibition around 50pg fosfomycin discs were counted in 
three replicated experiments and the diameter of zones was also measured (Table 39) (see section 
2.9.2). The arithmetic mean of these measurements was calculated and graphed (Figure 60 and 
Figure 61). Wild-type control strains MSSA, EMRSA-15 and EMRSA-16 produced, on average, 
between 42 and 76 more colonies in the zone of clearing around a fosfomycin disc than RN4220. 
RN4220Aww^ produced, on average, 191 more colonies than RN4220. Two isolates had four and
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24 less colonies in the zone of clearing than RN4220, the remaining ten had between two and 228 
more. Four isolates had 22 to 152 more colonies than EMRSA-15. None of these isolates had as 
many colonies in the zone of clearing as RN4220Aw«/«S'; the nearest isolate produced 64 colonies 
fewer.
Zone diameters in RN4220 and RN4220Am«£S' were similar, 42.5 mm and 43.5 mm, respectively. 
Only two isolates had bigger zone diameters around a fosfomycin disc than RN4220. Isolate 12 
had a zone diameter 13 mm larger than RN4220. Ten isolates had zone sizes between 0.5 mm and 
16.5 mm less than RN4220. Only four isolates had zone diameters smaller than EMRSA-15, 1.7 
mm to 6 mm smaller. Fosfomycin MICs reflected zone diameters. There is no correlation between 
zone diameter and the number of colonies in the zone of clearing, nor between fosfomycin MIC 
and the number of colonies in the zone of clearing.
3.7.3 Summary
Only one clinical teicoplanin-resistant isolate, H034840069, had mutation frequencies elevated 
above those for RN4220 to both rifampicin and fusidic acid, however, control isolate ST/03/2121 
also produced elevated mutation frequencies. When compared with clinical linezolid-resistant 
isolates, teicoplanin-resistant isolates had lower mean mutation frequencies to both rifampicin and 
fusidic acid. Fosfomycin disc tests revealed four isolates that produced more colonies in the zone 
of inhibition around a fosfomycin disc than the control EMRSA-15 strain. No isolates produced 
more colonies than RN4220Atw«/»S'. There was no correlation between zone diameter and the 
number of colonies in the zone of inhibition surrounding a fosfomycin disc.
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4 Discussion
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4.1 Linezolid resistance in S. aureus
The aims of this project were to study the mechanism and development of resistance to linezolid 
in staphylococci, including assessing the number of mutated 23S rRNA copies in clinical isolates 
and laboratory-selected mutants, to investigate the role of hypermutability in the emergence of 
linezolid and teicoplanin resistance and to establish whether teicoplanin resistant isolates express a 
mutator phenotype.
4.1.1 M utant generation and characterization
Due to the low number of linezolid-resistant S. aureus isolates available from the clinic, 
linezolid-resistant mutants were selected in the laboratory. This enabled a greater number of 
linezolid-resistant mutants to be investigated for their mechanisms of resistance and enabled 
analogies to be made with those from the clinic.
Fifty linezolid-resistant cultures were studied, nine of which were from the clinic, the remainder 
were laboratory-selected. Additionally, 35 variants in which, after repeated exposure to linezolid, 
resistance had not emerged or reversion to linezolid susceptibility had occurred were studied. 
Linezolid MICs ranged from 16-32 mg/L in clinical isolates and 8->256 mg/L in laboratory- 
selected mutants.
Resistance to linezolid was selected, in the main, by passage in the presence of increasing 
concentrations of linezolid. This method was successful and enabled the generation of linezolid- 
resistant mutants, although sometimes this was a lengthy process. Mutations in the 23S rRNA 
genes conferring resistance to linezolid were detected by PCR-RFLP, sequencing o f a 694 bp 
region of the 23S rRNA genes and pyrosequencing. Additionally, hybridization was used to 
quantify the number of 23 S rRNA gene copies in all mutants exposed to linezolid and their parent 
strains.
One of the aims of this work was to assess the number of 23 S rRNA gene copies that are mutated
in linezolid-resistant mutants, both laboratory-selected and from the clinic, as limited work has
been carried out on determining, firstly the total number of 23 S rRNA genes in linezolid-resistant
S. aureus isolates and, secondly, the number of these that are mutated (Meka et al., 2004b, Pillai et
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al., 2002). The number of mutated 23 S rRNA gene copies has previously been determined by 
sequencing five pre-defined published gene copies (Miller et al., 2005, Paterson et al., 2003). 
However both Meka et al., (2004b) and this work have proved that 23S rRNA gene copy number is 
variable in isolates of staphylococci exposed to linezolid. Hence just sequencing five published 
gene copies is not a reliable method for detecting the number of mutated 23 S rRNA genes.
This work has developed a new strategy for quantifying the number of mutated 23 S rRNA gene 
copies in linezolid-resistant mutants using a combination of pyrosequencing and hybridization. 
Pyrosequencing has previously been used to detect and quantify mutations in linezolid-resistant 
enterococci (Sinclair et al., 2003). Hybridisation has been used previously to determine 23S rRNA 
gene copy number in S. aureus (Meka et al., 2004a, Meka et ah, 2004b). Additionally, 
hybridization after digest with NheI has been used to detect the number of 23 S rRNA gene copies 
with a G2576T mutation in linezolid-resistant clinical isolates of S. aureus (Meka et al., 2004b, 
Pillai et al., 2002). Pyrosequencing and hybridization have not been used in combination before to 
enable the detection and quantification of the number of mutated 23S rRNA gene copies in 
linezolid-resistant isolates or mutants of S. aureus.
4.1.2 Linezolid-resistant S. aureus clinical isolates
To date there are relatively few published reports of linezolid-resistant S. aureus isolates from the 
clinic (Gales et al., 2006, Hill et al., 2005, Machado et al., 2003, Meka et al., 2004b, Paterson et 
al., 2003, Pillai et al., 2002, Roberts et al., 2006, Tsiodras et al., 2001, Wilson et al., 2003). In 
addition, resistant S. aureus isolates have been described in a survey (Brauers et al., 2005) and 
there have been other occurrences that remain unpublished (This work, M. Mulvey personal 
communication, N. Woodford personal communication). The commonest mutation detected in 
these isolates from the clinic is a G to T change at position 2576 of the 23 S rRNA genes (Gales et 
al., 2006, Hill et al., 2005, Machado et al., 2003, Paterson et al., 2003, Pillai et al., 2002, Roberts et 
al., 2006, Tsiodras et al., 2001, Wilson et al., 2003). Heterozygosity and homozygosity at this 
position has been reported (Gales et al., 2006, Hill et al., 2005, Machado et al., 2003, Pillai et al.,
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2002, Tsiodras et al., 2001), although reports of homozygous isolates may be incorrect if only five 
gene copies are sequenced (Paterson et al., 2003, Wilson et al., 2003).
Nine clinical linezolid-resistant S. aureus isolates, representing five strains, were studied in this 
work. They were fully characterized in order to investigate their mechanisms of resistance to 
linezolid. Consistent with published findings, all of the clinical linezolid-resistant S. aureus 
isolates tested in this study had a G2576T mutation. Two of the nine were confirmed homozygous 
by multiple methods, the remainder were heterozygous. Linezolid resistance did not seem to 
develop preferentially in certain strains from the clinic. Resistance emerged in two MSSA isolates 
and both of the main UK epidemic strains, EMRSA-15 (three isolates) and EMRSA-16 (four 
isolates). The G2576T mutation was present in 17 laboratory-selected mutants in this study, all of 
which were heterozygous.
Very few mutants homozygous for the G2576T mutation have been selected in vitro (Miller et al., 
2005), yet they do occur in the clinic (This work, Pillai et al., 2002, Tsiodras et al., 2001, Wilson et 
al., 2003). An attempt was made in this study by serially passaging a KNAllQkmutS mutant in the 
presence of increasing concentrations of linezolid. This did not result in a mutant homozygous for 
the G2576T mutation, but did produce a mutant with a linezolid MIC of >256 mg/L and two 
mutations, G2576T and A2503G. Hybridization revealed that this mutant had six 23S rRNA gene 
copies. From the results of the pyrosequencing it was deduced that the G2576T mutation was 
present in four gene copies and that the A2503G mutation was present in two gene copies, although 
it was not determined whether these two mutations were present on different 23S rRNA gene 
copies, meaning all six were mutated, or whether four copies were mutated with two of the four 
each harbouring two different mutations. This mutant proved unstable and some reversion towards 
susceptibility occurred even in the presence of low levels of linezolid, consequently, it had to be 
grown in the presence of a high concentration of linezolid to maintain a high MIC. Passaging in 
the presence of very high linezolid concentrations still did not generate a mutant homozygous for 
the G2576T mutation. Clinical isolates are not exposed to such high levels of linezolid yet 
homozygosity still occurs. Homozygosity at position 2576 seemed to be more difficult to generate 
in the laboratory than in the clinic and could be a phenomenon that is strain dependent.
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An isolate with two or more different mutations in the 23S rRNA genes, conferring linezolid 
resistance, has not been isolated from the clinic. However, in the laboratory Miller et al., (2005) 
have selected linezolid-resistant recA-negative mutants of S. aureus with up to three different 
mutations in five copies of the 23S rRNA genes (G2576T, G2447T and T2500A). It is not clear 
whether the mutations were in the same or different 23 S rRNA gene copies and there was no 
mention of the stability of these mutants.
It is not yet apparent why the G2576T mutation is so dominant amongst linezolid-resistant isolates 
of both enterococci and staphylococci from the clinic. The growth rates of clinical linezolid- 
resistant isolates of S. aureus have been compared to wild-type strains in order to determine 
whether there is a fitness cost associated with this mutation. Pillai et al., (2002) found a linezolid- 
resistant S. aureus isolate, with a G2476T mutation, had in vitro growth at a rate similar to 
linezolid-susceptible strains and Gales et al., (2006) found a S. aureus clinical isolate with a 
G2576T mutation did not show any significant decrease in growth in vitro. Similarly, Meka et al., 
(2004b) saw no appreciable difference in growth rates between susceptible and linezolid-resistant 
S. aureus strains with a G2576T mutation in the 23 S rRNA genes, although a difference in colony 
morphology was noted. Contrary to this, Lobritz et al., (2003) found an inverse relationship 
between the number of mutated 23S rRNA genes (G2576T) and growth rate in linezolid-resistant 
mutants of E. faecalis.
If the G2576T mutation carries no fitness cost, or less of a fitness cost than other mutations, it 
would be expected to be selected over other mutations conferring resistance and therefore be the 
most successful mutation. This does not explain why it is possible to generate other mutations in 
the laboratory, although in vitro conditions do not mimic those in vivo resulting in the selection of 
different mutations. Studies are needed to compare the fitness costs of the different mutations to 
see whether the G2576T mutation has a fitness cost associated with it, or less of a fitness cost than 
other mutations.
Only one other mutation, a T to A change at position 2500, has been identified from a linezolid- 
resistant S. aureus isolate from the clinic (Meka et al., 2004b). Similarly, in enterococci from the 
clinic no mutations other than G2576T have been detected. It has been possible to select the 
G2576T and T2500A mutations, associated with isolates from the clinic, in the laboratory (Barrett,
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2000, Bryskier, 1999, Howe et al., 2002, Miller et al., 2005, North et al, 2005a, North et al., 
2005b, Swaney et al., 1998a). The T2500A mutation was not identified in any of the linezolid- 
resistant clinical isolates tested in this study, but was identified in two laboratory-selected mutants 
(see sections 3.3, 3.4 and 4.1.7). Other mutations were also detected in laboratory-selected 
linezolid-resistant mutants including a G to T change at position 2447, which has previously been 
detected in enterococci and staphylococci (Miller et al., 2005, Swaney et a l, 1998a, Wichelhaus et 
al., 2003). Thirteen mutants with this mutation were selected in this study; all were heterozygous. 
Interestingly, another laboratory-selected mutation previously detected in staphylococci, a G to T 
change at position 2445, was not detected in this study (Barrett, 2000). Mutations G2505A, 
A2503G and T2504C were also identified in laboratory-selected linezolid-resistant mutants (see 
section 4.1.7).
4.1.3 Alternative mechanisms of linezolid resistance
Five laboratory-selected linezolid-resistant mutants had no detectable mutations in a 694 bp 
sequenced region of the 23 S rRNA genes (MICs 8-16 mg/L), furthermore, other mutants only had 
one 23 S rRNA gene copy mutated, which is conventionally thought to be insufficient to confer 
resistance. This implies that there is another mechanism or mechanisms of linezolid resistance or 
that there are mutations outside of domain V of the 23S rRNA genes that can confer resistance. 
This is a finding previously encountered by others. Clinical isolates of staphylococci, have been 
isolated with no detectable mutations in the 23 S rRNA genes (M.Mulvey personal communication, 
Fraimow et al., 2005). Likewise, Carsenti-Dellamonica et al., (2005) could not detect any 
mutations in the 23 S rRNA genes of linezolid-resistant mutants of streptococci selected in vitro. 
Rare linezolid-resistant isolates of enterococci from the clinic and laboratory-selected have had no 
detectable mutations (N. Woodford, personal communication, Prystowsky et al., (2001)).
These examples indicate that there are alternative mechanisms, besides mutations in the 23 S 
rRNA genes, which encode for resistance to linezolid. One possible mechanism is mutations in the 
ribosomal protein L4. Mutations in the L4 ribosomal protein, with and without the addition of 
mutations in the 23S rRNA genes, have been encountered in pneumococci and streptococci (Farrell
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et al., 2004, Wolter et a l, 2005). Furthermore, it was suggested linezolid may bind to proteins L27 
and Lep and mutations in these genes may confer a degree of resistance (Colca et al., 2003). There 
are, as yet, no reports of mutations in ribosomal proteins conferring resistance to linezolid in 
enterococci or staphylococci, either in vivo or in vitro.
4.1.4 Proliferation of linezolid resistance
It was originally thought that independent, spontaneous mutations would have to occur in multiple 
copies of the 23S rRNA genes to enable phenotypic linezolid resistance to occur; a feat that was 
proposed to be virtually impossible (Xiong et al., 2000). However, resistance to linezolid did occur 
in the clinical and laboratory, indicating resistance was occurring via another route. Lobritz et al., 
(2003) proposed that proliferation of mutations within an individual mutant occurred as a result of 
homologous recombination between resistant and susceptible 23S rRNA genes, i.e., a spontaneous 
mutation in one 23S rRNA gene copy is transferred to at least one other resulting in phenotypic 
resistance. Lobritz et al., (2003) provided evidence to support this theory by demonstrating recA- 
negative mutants of enterococci, upon exposure to linezolid, were only able to generate a 
(G2505A) mutation in one 23S rRNA gene copy. In comparison, recA-positive mutants exposed to 
linezolid had (G2576T) mutations in a minimum of two copies. Similarly, Miller et al., found 
rec^-negative mutants of S. aureus generated three different mutations in five 23 S rRNA gene 
copies when grown in the presence of linezolid. Conversely, recA-positive strains had identical 
mutations (G2576T) in five gene copies. This proved that in rec/f-negative strains, without 
homologous recombination, proliferation of a single mutation throughout the 23S rRNA gene 
copies does not occur. It seems that in an attempt to generate linezolid resistance, different types of 
mutations occur spontaneously in different gene copies. This indicates that linezolid resistance 
could occur without homologous recombination, however, this is statistically improbable. Lobritz 
et al., (2003) and Miller et al., (2005) both concluded that homologous recombination is the 
mechanism by which the proliferation of linezolid resistance occurs in clinical isolates. Lobritz et 
al., (2003) also stated that the emergence of the first mutation in the 23S rRNA genes is the rate 
limiting step for this process.
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If recombination is the mechanism by which a mutation is transferred to other 23 S rRNA gene 
copies, it is probably the route by which reversion to susceptibility occurs. However, in order to 
revert to linezolid susceptibility one wild-type 23 S rRNA copy needs to remain in order to act as a 
non-mutated template (Meka et al., 2004a). Isolates with all copies mutated would not be able to 
revert to susceptibility unless a wild type 23 S rRNA template was obtained from an exogenous 
source or via a mutational event. Consistent with this theory Pillai et al., (2002) found a linezolid- 
resistant S. aureus mutant, homozygous for the G2576T mutation, remained unchanged after 15 
passages in the absence of linezolid. Similarly, clinical linezolid-resistant isolates from this study, 
homozygous for the G2576T mutation, proved stable with no reversion towards susceptibility 
occurring in the absence of linezolid.
4.1.5 Stability of linezolid resistance
Whilst selecting linezolid-resistant mutants it was noted that heterozygous linezolid resistance 
was more stable in isolates from the clinic whereas those selected in the laboratory tended to revert 
to susceptibility if passaged repeatedly on antibiotic-free agar. Other published reports of unstable 
linezolid resistance have been published. Meka et al., (2004a) reported a clinical isolate in which 
some reversion had occurred after 30 passages and complete reversion had occurred after 60 
passages on antibiotic-free agar. Kaatz et al., (1996) found laboratory-selected mutants of 
staphylococci were only stable for three passages in the absence of linezolid.
It is possible that a specific, preferential 23S rRNA gene copy needs to be mutated in order for 
resistance to become stable; if this gene copy is not mutated, unstable resistance occurs. It has 
been shown that in the clinic, in patients where linezolid resistance has occurred, the removal of 
linezolid therapy led to the isolation of bacteria susceptible to linezolid, yet still with one 23 S 
rRNA gene copy mutated. Subsequent re-introduction of treatment with linezolid has led to the 
proliferation of resistance among the remaining 23 S rRNA gene copies and consequently resulted 
in phenotypic resistance (Geiss et al., 2005). It is possible that the one copy that remained mutated 
could be the stabilising copy, which, enabled rapid proliferation amongst the remaining wild-type 
23S rRNA gene copies upon re-exposure to linezolid.
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4.1.6 Gene dosage effect
It has been shown that there is a positive correlation between the number of mutated 23 S rRNA 
gene copies and linezolid MIC for enterococci (Marshall et al., 2002). It has been proposed that a 
similar relationship exists in staphylococci (Meka et al., 2004a, Swaney et al., 1998a, Wilson et al., 
2003, Wichelhaus et al., 2003). One of the aims of this work was to investigate whether the gene 
dosage effect also exists in S. aureus linezolid-resistant mutants from the clinic and those selected 
in vitro. After fully characterising all the linezolid-resistant mutants by pyrosequencing and 
hybridisation it was concluded that there is a positive correlation between the number of mutated 
23S rRNA gene copies and the linezolid MIC. The pyrosequencing data alone proved there was a 
positive correlation between the percentage of mutated 23S rRNA gene copies and the linezolid 
MIC. Additionally, the pyrosequencing and hybridization data combined proved there was a 
positive correlation between the actual number of mutated 23S rRNA genes and the linezolid MIC 
in clinical and laboratory-selected mutants of S. aureus. The pyrosequencing method had one 
drawback; detection of a G2447T mutation was possible, however, due to this mutation residing 
within a homopolymer of four G nucleotides, limitations of the proprietary software meant 
quantification of the number of wild-type and mutated 23S rRNA gene copies was not feasible. 
For mutations other than G2576T, a gene dosage effect was harder to determine due to the low 
numbers involved or the inability to determine the number of 23S rRNA gene copies in the case of 
G2447T mutations.
Analysis of the linezolid-resistant clinical S. aureus isolates using pyrosequencing and 
hybridization revealed 36% to 100 % of 23 S rRNA gene copies were mutated, while hybridization 
revealed that four to six gene copies were present. By combining these results it was determined 
that two to four 23 S rRNA gene copies were mutated (linezolid MICs 16-32 mg/L). In laboratory- 
selected mutants, with a G2576T mutation, the percentage of mutated 23S rRNA gene copies 
ranged from 15% to 65% and the number of mutated 23S rRNA gene copies ranged between one 
and four.
A comparison of the linezolid-resistant isolates from the clinic and those selected in the laboratory 
revealed linezolid-resistant isolates from the clinic had a minimum of two 23 S rRNA gene copies 
mutated, whereas phenotypic linezolid resistance was conferred by even one mutated copy in those
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mutants selected in vitro. From the literature a similar picture emerges with isolates from the clinic 
usually having a minimum of two and a maximum of five gene copies mutated (Paterson et al., 
2003, Pillai et al., 2002, Tsiodras et al., 2001, Wilson et al., 2003).
A linezolid-resistant S. aureus isolate from the clinic, reportedly homozygous for the G2576T 
mutation, with a linezolid MIC of 64 mg/L and all five sequenced gene copies mutated has 
previously been reported (Pillai et al., 2002). Interestingly, in this study, two clinical isolates 
(linezolid MICs 16 mg/L) from the same patient had G2576T mutations in all four gene copies. In 
functional terms, the homozygous isolates reported here and that reported by Pillai et al., (2002) 
should have similar linezolid MICs as four of four mutated 23S rRNA gene copies should be 
equivalent to five of five mutated gene copies as in both cases the target site has been altered and 
there are no wild-type copies available, but this does not seem to be the case.
Hybridization revealed that the control and parent strains used in this study had five or six 23S 
rRNA gene copies, indicating five 23 S rRNA gene copies is not always the norm. Furthermore, the 
linezolid-resistant clinical isolates tested had four, five or six 23 S rRNA gene copies. After 
exposure to linezolid, changes in 23S rRNA copy number occurred in 46% of mutants exposed to 
linezolid, with the majority increasing in gene copy number by one. Changes in 23S rRNA copy 
number have not previously been associated with the G2576T mutation in staphylococci, but loss 
of a gene copy was reported in a clinical linezolid-resistant S. aureus isolate with a T2500A 
mutation (Meka et al., 2004b). Meka et al., (2004b) proposed that loss of a 23S rRNA gene copy 
would increase the overall proportion of mutant copies relative to wild-type copies. The findings 
here are inconsistent with this theory. It is possible that increasing the number of functional, non­
mutated 23 S rRNA gene copies allows greater flexibility and incurs less of a fitness cost. Not all 
mutants had altered 23S rRNA gene copy number but some did have differences in the 
hybridisation RFLP banding profiles. For three laboratory-selected mutants, although 23 S rRNA 
gene copy remained the same as their parent strains, the banding profiles changed indicating 
selected detectable mutations occurred in the enzyme recognition sequence downstream of the 23 S 
rRNA genes themselves.
The evidence from this study indicates that 23 S rRNA gene copy number is variable in linezolid- 
resistant mutants and in those mutants which are exposed to linezolid but in which resistance does
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not emerge. Therefore the assumption that all clinical linezolid-resistant and laboratory-selected 
isolates have five 23S rRNA gene copies (Miller et al, 2005, Paterson et a l, 2003, Wilson et al., 
2003) may be misleading. For the full characterization of linezolid-resistant mutants the 23S rRNA 
gene copy number needs to be established before the number of mutated gene copies can be 
determined.
4.1.7 Cross-resistance between linezolid and other classes of antibiotics
Cross-resistance between linezolid and other protein synthesis inhibitors is generally thought not 
to occur. However, whilst generating linezolid-resistant mutants in the laboratory it was 
discovered that certain mutations conferring linezolid resistance also conferred resistance to 
chloramphenicol. Linezolid-resistant mutants with a T to C change at position 2504 or a G to T 
change at position 2576 had increased MICs for both linezolid and chloramphenicol. Those 
mutants with T2504C and G2576T mutations displayed 4-fold and 2- to 8-fold increases in 
chloramphenicol MICs, respectively.
The T2504C mutation has previously been described in laboratory-selected mutants of H. 
halobium, where it conferred resistance to linezolid (Kloss et a l, 1999). It has also been reported 
to confer resistance to chloramphenicol in human and mouse mitochondrial rRNA (Blanc et a l, 
1981a, Blanc et a l, 1981b). Moreover, T2504 is thought to be important for binding site of 
chloramphenicol in bacteria (Figure 62) (http://www.molgen.mpg.de/~agribo/agfranceschi/ 
franceschi-projects-50S-antibiotics-cam3D.html).
If passaging in the presence of increasing concentrations of linezolid could select chloramphenicol 
resistance it was hypothesised that passaging strains on increasing concentrations of 
chloramphenicol might produce mutants resistant to both chloramphenicol and linezolid and select 
for the T2504C or G2576T mutations. Indeed, the resulting mutants showed a positive correlation 
between linezolid and chloramphenicol MICs and three mutants had G2505A and T2500A 
mutations. The former has previously been described in laboratory-selected linezolid-resistant 
enterococci (Lobritz et al., 2003, Prystowsky et a l, 2001) and the latter has been found in clinical
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Figure 62. Interaction of chloramphenicol with the ribosome o f Deinococcus radiodurans.
Diagram shows the chloramphenicol binding site at the peptidyl transferase cavity. Green 
represents chloramphenicol and nucleotides that interact with the antibiotic are shown with their 
chemical structure. Nucleotide numbering is according to the E. coli sequence. Putative Mg ions 
(M g-Cl, Mg-C2) are indicated. From http://www.molgen.mpg.de/~ag_ribo/ag_franceschi 
/franceschi-projects-50S-antibiotics-cam3D.html.
U2504
U2500 G2061
A2451
C2452
U2506
G2505
248
and laboratory linezolid-resistant isolates of S. aureus and H. halobium (Kloss et a l, 1999, Meka et 
al., 2004b, Miller et al., 2005). Surprisingly, no mutants with a T2504C mutation were detected 
following chloramphenicol selection. Furthermore no mutants with the G2576T mutation, most 
commonly found in the clinic, were detected.
When these chloramphenicol- and linezolid-resistant mutants were analysed by pyrosequencing 
and hybridisation it was noted that they only had one 23S rRNA gene copy mutated. These results 
were at odds with the chloramphenicol and linezolid MICs of the mutants (chloramphenicol MICs 
8->256 mg/L). Upon determining the linezolid MICs for a second time it was discovered that the 
mutants were unstable and reversion towards susceptibility had occurred, even in high-level 
resistant mutants, before the mutants underwent pyrosequencing. These subsequent MICs 
(chloramphenicol and linezolid MICs 1-16 mg/L) were in agreement with the pyrosequencing 
results. No changes in 23S rRNA gene copy number could be detected in these three mutants.
No mutations could be detected in the remainder of the mutants where chloramphenicol resistance 
did not emerge or reversion to susceptibility occurred. However, if analysis by pyrosequencing had 
been performed before reversion to susceptibility had occurred other mutations might have been 
detected in the remainder of the mutants. In these mutants exposure to chloramphenicol resulted in 
changes in 23 S rRNA gene copy number in nine of 20 mutants, with eight of the nine increasing in 
gene copy number by one. This increase in gene copy number echoes the results found with 
clinical and laboratory-selected linezolid-resistant isolates. Slight differences were apparent 
between the PFGE profiles of parents and chloramphenicol-resistant mutants. In one 
chloramphenicol- and linezolid-resistant mutant one of the Smal cutting sites should have been 
located at the junction between rrnA and rrnE operons, however a change in the Smal recognition 
sequence resulted in the loss of this cutting site (Figure 63). It appears that fragment D was 
subsequently incorporated into one of the adjacent fragments on either side of it. Exposure to 
chloramphenicol possibly resulted in the selection of a detectable mutation in the enzyme 
recognition sequence.
Cross-resistance between chloramphenicol and linezolid due to mutations in the 23 S rRNA genes 
has not previously been reported in clinical isolates or laboratory-selected mutants of S. aureus. 
Nevertheless, laboratory studies have reported competition between the two antibiotics for
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Figure 63. Restriction digest map of S. aureus NCTC 8325. The rrnA and rrnE operons are 
located between fragments D and L (Adapted from http://microgen.ouhsc.edu/s_ aureus /s aureus 
_home.htm).
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ribosomal binding sites in E. coli and H. halobium resulting in partial cross-resistance (Bobkova et 
al., 2003, Kloss et al., 1999, Lin et al., 1997). Also, mutational resistance to chloramphenicol has 
previously been described in laboratory-selected isolates of H. halobium (Mankin and Garrett, 
1991). This discovery has few clinical implications as, firstly, chloramphenicol is not widely used 
and secondly, resistance to chloramphenicol is usually via plasmid mediated acetylation of the drug 
(via the cat gene), which confers no cross-resistance with linezolid (Fines and Leclercq, 2000). In 
clinical linezolid-resistant isolates high-level chloramphenicol resistance, conferred by the cat 
gene, would mask any mutational cross-resistance between the two antibiotics.
4.1.8 Loss of erythromycin resistance with the emergence of linezolid resistance
Whilst raising linezolid-resistant mutants in vitro, loss of erythromycin resistance occurred in five 
of seven mutants of RN4220A#mriS'. This phenomenon has previously been seen with linezolid- 
resistant S. aureus isolates from the clinic, but is not essential for the emergence of resistance to 
occur (Howe et al., 2002, Meka et al., 2004b, Wilson et al., 2003). Sakoulas et al., (2003) proved 
that linezolid resistance can occur in combination with erythromycin resistance by successfully re­
introducing an erm gene into a linezolid-resistant strain of S. aureus.
An experiment was designed to determine the frequency at which loss of erythromycin resistance 
would occur with the emergence of linezolid resistance, whether growing strains in the presence of 
linezolid and erythromycin would prevent the loss of erythromycin determinants, and whether 
preventing the loss of erythromycin would slow the emergence of linezolid resistance.
Results revealed that nearly half (six of 14) of all strains tested reverted to erythromycin 
susceptibility with the emergence of linezolid resistance. Curiously, only 25% (one of four) of 
mutants with an erm{B) determinant reverted to erythromycin susceptibility, whereas strains with 
an erm(C) determinant showed a greater propensity towards loss of an erm determinant in the 
presence of linezolid, with this occurring in 50% (five of ten) of mutants. One of the mutants that 
lost an erm{B) determinant had a G2447T mutation. However, mutations could not be detected in 
the 23 S rRNA genes of the remaining strains in which loss of erythromycin determinants occurred. 
In these strains stable linezolid- resistance was not achieved (linezolid MICs of 4 mg/L), despite
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repeated passage in the presence of 10 mg/L of linezolid. From these results it is apparent that on 
the occasions when loss of an erm determinant does occur, exposure to linezolid is enough to 
trigger the loss, full resistance to linezolid does not have to occur before loss of erythromycin 
occurs. Furthermore, after the loss of erythromycin resistance, linezolid resistance is not 
guaranteed to emerge any quicker or become any more stable. It has not yet been elucidated what 
advantage (if any) loss of erythromycin resistance confers on bacteria exposed to linezolid.
This work supports that of Howe et al., (2002) which showed loss of erythromycin determinants 
can occur with the emergence of mutations other than G2576T. From previous reports concerning 
the loss of erythromycin determinants with the emergence of linezolid resistance in the clinic in 
isolates of S. aureus it is not apparent whether there is a propensity for one type of determinant to 
be lost more readily than another (Howe et al., 2002, Wilson et al., 2003).
It was also noted that growing erythromycin-resistant strains in the presence of linezolid and 
erythromycin delayed the emergence of linezolid resistance in two out of three strains, though not 
in the hypermutable strain (RN4220Aww/iS). These results imply that treating patients with 
erythromycin and linezolid, even if the isolate is erythromycin-resistant, might delay the emergence 
of linezolid resistance.
4.2 Hypermutability
In S. aureus resistance to linezolid and the glycopeptide antibiotics, vancomycin and teicoplanin, 
occurs via chromosomal mutational events. In the clinic resistance to these antibiotics is rare, but 
nevertheless occurs. In the laboratory resistance to these antibiotics is difficult to generate. It is 
plausible that, in the clinic, a hypermutable phenotype might enable the rapid generation of the 
chromosomal mutations required for resistance to linezolid or the glycopeptide antibiotics. 
Subsequent exposure to these antibiotics would co-select for resistance and hypermutability in 
combination.
The mutation frequencies of linezolid-resistant staphylococci selected either in vitro or in the 
clinic have not previously been determined. Therefore this study aimed to investigate whether 
linezolid-resistant S. aureus isolates from the clinic were hypermutable. The selection of linezolid-
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resistant isolates in the laboratory allowed investigation into whether hypermutability was co­
selected with linezolid resistance. Teicoplanin-resistant isolates from the clinic were investigated 
for any evidence of hypermutability. It is possible that these isolates might have a hypermutable 
phenotype.
4.2.1 Mutation frequencies of laboratory-selected linezolid-resistant mutants
In order to determine, firstly, whether linezolid resistance would emerge preferentially in 
hypermutable S. aureus and, secondly, whether hypermutability would be co-selected with the 
emergence of linezolid resistance, linezolid-resistant mutants were selected in the laboratory. A 
hypermutable mw/S-negative control strain and its wild-type parent strain were used as controls to 
determine whether the strains tested here had mutation frequencies comparable to the hypermutable 
control strain and hence were themselves hypermutable.
Linezolid resistance was easier to generate in the hypermutable control strain, RN4220AmutS than 
the wild-type control strain, RN4220, or any of the clinical strains tested. Furthermore, the 
G2576T mutation was preferred in the hypermutable control strain, occurring in eight of 14 
mutants. Initial mutation frequencies of the control strains RN4220AmutS, RN4220, ST/03/2121 
and ST/03/2122 proved that inactivation of the mutS gene in S. aureus resulted in a hypermutable 
phenotype, echoing the results of O’Neill et al., (2002). The linezolid resistant mutants raised in 
the laboratory were tested for the co-selection of linezolid resistance and hypermutability by 
determining the frequency with which they mutated to rifampicin and fusidic acid. The results of 
these mutation frequencies provided some evidence of hypermutability. A few (four of 17) of the 
mutants of RN4220, RN4220A/w«/<S' and ST/03/2121 had mutation frequencies to fusidic acid and 
rifampicin elevated above those of their parent strains, although this was more apparent for fusidic 
acid than for rifampicin.
The laboratory-selected linezolid-resistant mutants were further tested for any evidence of 
hypermutability using the fosfomycin disc test developed by Galan et al., (2003, 2004). The results 
of the disc tests were not in agreement with the results of the mutation frequencies to rifampicin 
and fusidic acid, showing an overall decrease in mutability compared with parent strains. The
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linezolid-resistant mutants in this study showed a decrease in the number of colonies in the zone of 
inhibition along with increased zone diameters when compared to their parent strains. One 
possible explanation for this could be decreased growth rate as a result of exposure to fosfomycin 
(Nilsson et al., 2003). However, if this were the case then similar zone sizes and numbers of 
colonies in the zone of inhibition would be expected from the parent strains, instead, they were 
seemingly unaffected. Another explanation could be that in selecting for linezolid resistance a 
decreased growth rate has also been selected for.
If hypermutability had been co-selected with linezolid resistance an increase in mutation 
frequency to both rifampicin and fusidic acid as well as fosfomycin would be expected. The 
mutants tested here do not show consistent, elevated mutation frequencies to more than one 
antibiotic as would be expected with the co-selection of linezolid resistance and hypermutability.
4.2.2 Mutation frequencies of linezolid-resistant clinical isolates
The mutation frequencies of linezolid-resistant clinical isolates were determined to investigate 
whether there was any evidence for hypermutability, which could have been involved in the 
emergence of resistance. Evidence was lacking for the majority of strains. However, there were 
three isolates (3a, b and c), all of the same strain (EMRSA-15) and from the same patient, that 
displayed elevated mutation frequencies to rifampicin, fusidic acid and increased mutability to 
fosfomycin than wild-type strains and other linezolid-resistant clinical isolates (Table 31, Figure 
45, Figure 46, Table 32, Figure 47 and Figure 48). This indicates hypermutability could have 
played a role in the emergence of linezolid resistance in this strain. This strain was not isolated 
from a cystic fibrosis sufferer but from the penis, perineum and a drain site of a patient.
Interestingly, six of the nine linezolid-resistant isolates from the clinic were isolated from the 
sputum of cystic fibrosis patients (Gales et al., 2006, Hill et al., 2005, Machado et al., 2003). The 
lung of a cystic fibrosis patient is associated with the rapid development of multi-resistant strains of 
S. aureus, P. aeruginosa and H. influenzae, possibly due to hypermutability. The limited research 
on the role of hypermutability and the emergence of antibiotic resistance in S. aureus in patients 
with cystic fibrosis are conflicting. Prunier et al., (2003) discovered that ribosomal mutations
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conferring macrolide resistance in strains of S. aureus from cystic fibrosis patients were the most 
frequent mechanism of resistance, possibly due to the high proportion of hypermutable strains 
present (13 of 89 strains). However O’Neill et al., (2002) assessed 493 S. aureus isolates from the 
clinical and community setting, including 49 strains from cystic fibrosis patients. No evidence for 
hypermutability was detected and it was concluded that S. aureus hypermutators have an extremely 
low clinical prevalence.
If hypermutable strains do exist in the cystic fibrosis lung and play a role in the rapid emergence 
of antibiotic resistance it could explain the high proportion of linezolid-resistant isolates originating 
from cystic fibrosis patients. However this may not be the only reason. A simple explanation is 
that a higher proportion of patients with cystic fibrosis are treated with linezolid and therefore 
resistance is more likely to occur in these isolates. Alternatively, resistance could be attributed to 
the variability of linezolid levels in the CF lung, with sub-therapeutic levels facilitating selection of 
resistance (Bosso et a l, 2004, Hill et al., 2005, Saralaya et al., 2004). Additionally, most of the 
published cases where linezolid resistance has occurred involve intermittent dosing, dosing at sub- 
therapeutic levels and long-term therapy (Meka et al., 2004b, Tsiodras et al., 2001, Wilson et al., 
2003). Perhaps it is these dosing regimens which provide the ideal opportunity for resistance to 
emerge and not the presence of hypermutable strains. A point to note is that inter-patient spread of 
S. aureus strains is common between cystic fibrosis sufferers and the emergence of linezolid 
resistance in one patient may provide the ideal opportunity for the dissemination of a linezolid- 
resistant strain (Gales et al., 2006).
Due to the rarity of linezolid-resistant clinical isolates, this study was only able to investigate six 
linezolid-resistant isolates from cystic fibrosis patients. A larger group of isolates would give a 
more definite picture of the role, if any, of hypermutability in the emergence of linezolid resistance. 
In this study the linezolid-resistant isolates from cystic fibrosis patients investigated showed no 
evidence of hypermutability. However, the possibility of these isolates previously going through a 
period of transient hypermutability that cannot subsequently be detected should not be ruled out. 
Although stable hypermutability seems not to have played a role in the emergence of linezolid 
resistance the fact that such a high proportion of the resistant strains tested here are from cystic
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fibrosis patients indicates that there is a link between cystic fibrosis and the emergence of linezolid 
resistance.
4.2.3 Mutation frequencies of teicoplanin-resistant clinical isolates
Very little work has been carried out on determining the mutation frequencies of teicoplanin- 
resistant clinical isolates. More work has been carried out in relation to vancomycin-resistant 
isolates. There is conflicting evidence as to whether these glycopeptide-resistant isolates are 
hypermutable. Initially it was thought that the vancomycin-intermediate resistant strain, Mu50, had 
an inactive mutS gene which was thought to have aided in the development of vancomycin 
resistance (Avison et al., 2002) but this was later disproved (O'Neill and Chopra, 2003). Similarly, 
Muthaiyan et al., (2004) found no mutations in the mutS genes of nine vancomycin-intermediate S. 
aureus clinical and laboratory strains that would result in a non-functional gene. However, Schaaff 
et al., (2002) found that vancomycin resistance evolved quicker in a S. aureus mw/S-negative 
mutant when compared with its wild-type parent strain, indicating an elevated mutation frequency, 
due to a defective mutS gene, could be involved in the emergence of resistance. Similarly, in this 
study, linezolid resistance was found to emerge quicker in a mw/S'-negative strain, confirming the 
finding of Schaaff et al., (Schaaff et al., 2002).
Selecting spontaneous mutants resistant to vancomycin and teicoplanin proved difficult, 
furthermore mutants that were selected were difficult to differentiate from each other due to 
clumping of colonies. However, the results obtained here were in agreement with Schaaff et al., 
(2002) with the mw/S-negative strain producing the highest mutation frequencies to the 
glycopeptide antibiotics.
A group of teicoplanin-resistant isolates from the clinic were assessed to determine whether they 
had a hypermutable phenotype that could have been associated with the emergence of teicoplanin 
resistance. Only one clinical teicoplanin-resistant isolate generated mutation frequencies to 
rifampicin and fusidic acid greater than those of the wild-type control, RN4220. Furthermore, it 
was comparable to the hypermutable control strain, RN4220Aww/5', in mutability to fosfomycin. 
However, this group of isolates had, on average, mutation frequencies lower than linezolid-resistant
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isolates from the clinic. This group of teicoplanin-resistant isolates showed no evidence of pre­
existing hypermutability.
Teicoplanin-selection generated both orange and colourless mutants of the wild-type control 
strain, RN4220, and the hypermutable control strain, RN4220Am«/1S'. NCTC 8325 and its 
descendants, RN4220 and KN4220AmutS, are natural non-pigmented mutants due to an 11 bp 
deletion in the gene encoding the sigmaB regulator, RsbU (Kullik et al., 1998). This deletion 
generates a premature stop codon, consequently RN4220 and RN4220Aww/5’ are unable to activate 
the RsbU-initiated cascade that leads to sigmaB activity (Giachino et al., 2001). One of the 
properties influenced by sigmaB is pigment formation and hence RN4220 and RN4220Aww/5' are 
pigmentless (Bischoff and Berger-Bachi, 2001). Pigment formation has been found to be restored 
in pigmentless mutants by over-expression of sigmaB (Kullik et al., 1998). Bischoff et al., (2001) 
selected spontaneous teicoplanin-selected mutants of NCTC 8325. In the presence of teicoplanin 
these mutants produced an intense orange colour, usually after 48 hours. Similarly, in this study, 
orange pigmented mutants only emerged after 48 hours. The orange pigmented mutants were 
found to have point mutations in the rsbW  gene. The RsbW protein regulates sigmaB activity; 
without it, excessively high sigmaB activity occurs, resulting in over expression of pigmentation 
and the intense orange colour (Bischoff and Berger-Bachi, 2001). Bischoff et al., concluded that 
the sigmaB operon is one of the preferred mutation sites associated with first step teicoplanin 
resistance in pigmentless S. aureus strains. However, it is not known how a mutation in the sigmaB 
operon results in increased resistance to teicoplanin. In this study and that by Bischoff et al., 
(2001) the presence of both white and orange colonies suggests there is another pathway to 
teicoplanin resistance. Additionally, both studies found orange mutants occurred in the presence of 
vancomycin, although this phenomenon was more pronounced in the presence of teicoplanin.
4.2.4 Hypermutability, linezolid and other antibiotic classes
Whilst investigating the phenomenon of loss of erythromycin resistance with the emergence of 
linezolid resistance it became apparent that linezolid resistance, in the presence and absence of 
erythromycin, emerged quickest in RN4220AmutS, some ten days before its comparator wild-type
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strain. This indicates that pre-existing hypermutability could be a factor in the emergence of 
linezolid resistance. Growing this hypermutable strain in the presence of erythromycin and 
increasing concentrations of linezolid, unlike other erythromycin-resistant strains tested here, did 
not slow the emergence of resistance. It is possible that if hypermutability were a factor in the 
emergence of resistance, using erythromycin and linezolid against erythromycin-resistant strains 
would not delay the emergence of resistance.
Surprisingly when the hypermutable strain was grown in the presence of increasing concentrations 
of chloramphenicol, low-level chloramphenicol resistance only occurred in three of five mutants 
selected, whereas resistance occurred in all five mutants of its wild-type counterpart, one of which 
had high-level resistance. Chloramphenicol resistance was more difficult to select than linezolid 
resistance in the hypermutable control strain, RN4220Aww/1S'.
4.2.5 Summary of hypermutability and the emergence of linezolid resistance
It was hypothesised that hypermutable strains would be predisposed to the emergence of antibiotic 
resistance. Evidence to support this theory in this work was provided by linezolid resistance 
emerging quicker in the hypermutable control strain than in wild-type and clinical isolates and, 
furthermore, in one mutant two different mutations emerged. These results indicate that if 
hypermutable strains were present in the clinic they would be more predisposed to developing 
linezolid resistance.
From the results of this study evidence against the role of stable hypermutability seems to 
outweigh that supporting it. The involvement of hypermutability in the emergence of linezolid 
resistance in clinical isolates is not proven, especially in isolates from cystic fibrosis patients. It 
has been proposed that strains residing in the lungs of cystic fibrosis are hypermutable and 
therefore more prone to chromosomal mutations which confer antibiotic resistance. There is 
circumstantial evidence here, with six of nine linezolid-resistant isolates studied being isolated 
from the lungs of cystic fibrosis patients, that hypermutability could be a plausible explanation as 
to why resistance emerges so quickly, especially given the evidence supporting hypermutability in 
P. aeruginosa strains from cystic fibrosis patients. However, given the mutation frequencies of
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these linezolid-resistant strains, both from the clinic and those selected in the laboratory, there is no 
direct and convincing evidence that points towards hypermutability being involved in the 
emergence of resistance, nor for it being co-selected along with linezolid resistance. Furthermore, 
the only linezolid-resistant isolates with elevated mutation frequencies were not isolated from a 
patient with cystic fibrosis. There could be a simpler explanation for the emergence of resistance 
in strains of S. aureus from the cystic fibrosis lung other than hypermutability. It could be that the 
number of linezolid-resistant isolates from cystic fibrosis patients could reflect its greater use in 
these patients. Alternatively, it has been shown that penetration of antibiotics into the cystic 
fibrosis lung is difficult and results in variable antibiotic levels (Bosso et al, 2004, Hill et al., 2005, 
Saralaya et al., 2004). This could provide strains with the ideal conditions for the emergence and 
selection of antibiotic resistance, especially where only one chromosomal mutation is required in 
the case of linezolid.
Further evidence supporting the lack of hypermutability was provided by the mutation frequencies 
of teicoplanin-resistant isolates, which provided no evidence of pre-existing hypermutability. If 
hypermutability were involved in the emergence of linezolid resistance this group of isolates would 
be no more prone to undergoing chromosomal mutations, resulting in the emergence of linezolid 
resistance.
In conclusion the evidence provided in this study supports that of O’Neill et al., (2002) who 
proposed that there is some evidence of hypermutability in S. aureus strains. This was confirmed 
in this study by the isolation of one linezolid-resistant strain from the clinic with elevated mutation 
frequencies to two antibiotics, but their prevalence in the clinic is low and they may not be an 
important pathway to resistance as shown in other species. Hypermutability is not a prerequisite 
for the emergence of linezolid resistance, nor is hypermutability co-selected with linezolid 
resistance. However, it cannot be ruled out that the linezolid-resistant and teicoplanin-resistant 
isolates tested here were previously hypermutable or underwent a transient period of 
hypermutability when exposed to linezolid or teicoplanin that enabled them to rapidly generate 
mutations conferring resistance.
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5 Conclusions
260
5.1 Conclusions
• Mutations in the 23 S rRNA genes were associated with high-level resistance to linezolid in S. 
aureus isolates from the clinic and in laboratory-selected mutants. The G2576T mutation was 
the only mutation detected in clinical isolates and was prevalent amongst laboratory-selected 
mutants. Other mutations detected in mutants from the laboratory included G2447T, T2500A, 
A2503G, T2504C and G2505A. Mutations in the 23S rRNA genes could not be detected in 
five laboratory-selected mutants. Resistance selected in vitro was more unstable than that 
which had emerged in the clinic. This might be attributed to the need for a specific 23 S rRNA 
gene copy to be mutated in order for resistance to become stable.
• Pyrosequencing successfully identified and quantified six of seven mutation types conferring 
resistance to linezolid. There was a positive correlation between the percentage of mutated 
23S rRNA genes and the linezolid MIC. Hybridization was successfully used to quantify 23 S 
rRNA gene copy number. The 23 S rRNA gene copy number in linezolid-resistant clinical 
isolates of S. aureus ranged from four to six and from four to nine in laboratory-selected 
mutants. Furthermore, 23 S rRNA gene copy number was affected by exposure to linezolid in 
half of all laboratory-selected mutants exposed to linezolid, both susceptible and resistant; the 
majority increased by one gene copy. Additionally, linezolid-resistant mutants were selected 
with no changes in 23 S rRNA copy number when compared with their parent strains, but with 
changes in hybridization banding profile indicating changes in the restriction enzyme 
recognition sequence downstream of the 23S rRNA genes. Combined, the pyrosequencing 
and hybridization data revealed a positive correlation between the number of mutated 23 S 
rRNA genes and the linezolid MIC.
• Cross-resistance between linezolid and chloramphenicol occurred in mutants selected either in 
the presence of linezolid or chloramphenicol. Mutations G2576T, T2500A, T2504C and 
G2505A all conferred resistance to both linezolid and chloramphenicol. Chloramphenicol- 
selected mutants were very unstable and reversion to susceptibility was frequent.
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• Loss of erm-mediated erythromycin resistance occurred in nearly half of all linezolid-selected 
mutants. A mutation conferring resistance to linezolid was only detected in one of the mutants 
where reversion to susceptibility occurred. Loss of erythromycin resistance did not ensure the 
emergence of linezolid resistance, nor did linezolid resistance emerge quicker in those strains 
that had lost erythromycin determinants. There was a tendency for erm(C) determinants to be 
lost more readily than erm(B) determinants. There did not appear to be a correlation between 
the loss of resistance and the type of mutation selected. Growing erythromycin-resistant 
strains in the presence of erythromycin and increasing concentrations of linezolid slowed the 
emergence of linezolid resistance in two of three strains, but not with the hypermutable control 
strain. These results imply treating with linezolid and erythromycin might delay the 
emergence of resistance even if the isolate is erythromycin-resistant.
• Pre-existing hypermutability increased the ability of a strain to develop linezolid resistance. 
However, little evidence was found to suggest hypermutability is a prerequisite in the 
emergence of linezolid resistance either in vitro or in the clinic. Likewise there was little 
evidence for the co-selection of hypermutability and linezolid resistance in either laboratory 
mutants or clinical isolates. Seven of nine linezolid-resistant isolates from the clinic were 
isolated from patients with cystic fibrosis and although transient hypermutability could have 
played a role in the emergence of linezolid resistance, so too could the dosing regimens and 
the variability of linezolid levels in the lung. There was little evidence for hypermutability in 
teicoplanin-resistant isolates from the clinic.
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5.2 Prospects for future studies
The finding that linezolid resistance is often unstable in vitro warrants further research. It would 
be interesting to investigate whether the emergence of stable linezolid resistance is dependent on 
one key 23S rRNA gene copy being mutated, anchoring resistance. The absence of mutations in 
such a stabilising copy might explain unstable resistance, such as that encountered in this work. 
Investigation as to how easy it is to select for a mutation in this stabilising copy in the laboratory 
would be intriguing. Furthermore, defining whether certain copies mutated before others or 
whether there is a sequence order by which proliferation of a mutation occurred would shed more 
light on linezolid resistance.
The finding that 23S rRNA gene copy number commonly changes upon exposure to linezolid 
provides another avenue for continuing research. It would be interesting to determine which gene 
copies are increased in the presence of linezolid. Duplication of the key gene copy could give 
maximum flexibility. However, if the regions flanking the 23S rRNA genes were identical, it 
would be problematic for detection as sequencing of the five published gene copies would lead to 
amplification of more than one copy, and unless a polymorphism was present, distinguishing 
identical copies would be impossible. If there were identical 23 S rRNA gene copies present in 
resistant isolates sequencing only the five published copies would provide a misleading picture of 
the number of copies mutated. Furthermore, if the 23 S rRNA genes and their flanking regions 
were identical, hybridization (to detect 23 S rRNA gene copy number) would not be able to 
distinguish between identical copies, merely a darker area would be present after detection.
The finding of this study and others that it is possible to generate linezolid-resistant isolates with 
more than one type of mutation in the 23S rRNA genes provides another avenue for research. It 
would be interesting to determine whether two different mutations could reside on the same 23 S 
rRNA gene copy or whether this would prove detrimental to the fitness of the mutant.
From the linezolid-resistant mutants selected in this work it is evident that mutations outside the 
23S rRNA genes may be conferring resistance. Some linezolid-resistant strains from the clinic and 
from the laboratory had no mutations known to confer linezolid resistance. There is the possibility
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that mutations in the ribosomal proteins may confer resistance. It would be intriguing to 
investigate the mechanisms of resistance in these mutants.
\
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Table 40. Media used in this study and supplier
Media Supplier
Brain heart infusion agar Oxoid Ltd., Basingstoke, UK
Brain heart infusion broth Oxoid Ltd., Basingstoke, UK
Columbia blood agar Oxoid Ltd., Basingstoke, UK
IsoSensitest agar Oxoid Ltd., Basingstoke, UK
IsoSensitest broth Oxoid Ltd., Basingstoke, UK
Nutrient agar Oxoid Ltd., Basingstoke, UK
Nutrient broth Oxoid Ltd., Basingstoke, UK
Mueller-Hinton agar Oxoid Ltd., Basingstoke, UK
Phosphate-buffered saline (0.01 M, pH 7.4) HPA Media Department, London, UK
CHROMagar™ Staph aureus CHROMagar Microbiology, Paris, France
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Table 41. List of chemicals and materials used in this study and their suppliers.
Chemicals, reagents or materials Supplier
X DNA concatamer ladder Bio-Rad, Hemel Hempstead, UK
123 bp DNA ladder Invitrogen BV, Renfrew, UK
1Kb DNA ladder Invitrogen BV, Renfrew, UK
Agarose (low gelling temperature) FMC BioProducts, Rockland, USA
Agarose for gel electrophoresis Helena Biosciences, Sunderland, UK
Ammonium acetate Sigma-Aldrich, Poole, UK
Annealing buffer Biotage AB, Uppsala, Sweden
Antibiotic discs Oxoid, Basingstoke, UK
Anti-digoxigenin-alkaline phosphate-conjugate 
antibody
Roche Applied Science, Lewes, UK
Binding buffer (pyrosequencing) Biotage AB, Uppsala, Sweden
Brij® 58-P Sigma-Aldrich, Poole, UK
Bromophenol blue BDH, VWR International, Poole, UK
Chloroform BDH, VWR International, Poole, UK
dATP, dTTP, dCTP, dGTP Invitrogen BV, Renfrew, UK
Denaturation solution (pyrosequencing) Biotage AB, Uppsala, Sweden
Deoxycholic acid Sigma-Aldrich, Poole, UK
DIG wash and block buffers Roche Applied Science, Lewes, UK
DTCS quick start kit Beckman Coulter, High Wycombe, UK
DIG-11-dUTP Roche Applied Science, Lewes, UK
DIG-labelled DNA size marker II Roche Applied Science, Lewes, UK
Disodium ethylene diaminotetra-acetic acid Sigma-Aldrich, Poole, UK
Double-processed tissue culture water (PCR- 
quality water)
Sigma-Aldrich, Poole, UK
E test strips BioStat, Stockport, UK
Ethanol BDH, VWR International, Poole, UK
Ethidium bromide Sigma-Aldrich, Poole, UK
Expand long template PCR system Roche Applied Science, Lewes, UK
Ficoll 400 Sigma-Aldrich, Poole, UK
Glucose-6-phosphate Sigma-Aldrich, Poole, UK
Guanidium thiocyanate Sigma-Aldrich, Poole, UK
Hybond N blotting membrane Amersham Biosciences, Little Chalfont, 
UK
Cont.
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Table 41. List of chemicals and materials used in this study and their suppliers (cont.).
Chemicals, reagents or materials Supplier
Hydrochloric acid BDH, VWR International, Poole, UK
Lysostaphin Sigma-Aldrich, Poole, UK
Lysozyme Sigma-Aldrich, Poole, UK
Magnesium chloride Sigma-Aldrich, Poole, UK
Methanol BDH, VWR International, Poole, UK
Microfuge tubes Eppendorf, Anachem, Luton, UK
Mineral oil Sigma-Aldrich, Poole, UK
Nitroblue tetrazolium chloride/5-bromo-4-chloro- 
3-indolylphosphate (NBT/BCIP)
Roche Applied Science, Lewes, UK
N-laurylsarcosine (Sarkosyl NL30) BDH, VWR International, Poole, UK
PCR and sequencing primers Sigma-Genosys, Haverhill, UK
PCR plates Abgene, Epsom, UK
Phenol:chloroform:isoamyl alcohol Sigma-Aldrich Aldrich, Poole, UK
Proteinase K Sigma-Aldrich, Poole, UK
Pulsed-field certified agarose Bio-Rad, Hemel Hempstead, UK
Pyro gold reagents Biotage AB, Uppsala, Sweden
Pyrosequencing plates Biotage AB, Uppsala, Sweden
Q-BIOgene geneclean turbo for PCR kit Q-BIOgene, Cambridge, UK
Reagent cartridge (pyrosequencing) Biotage AB, Uppsala, Sweden
Restriction endonucleases Roche Applied Science, Lewes, UK 
Fermentas, Helena Biosciences, 
Sunderland, UK
Ribonuclease (RNase) Sigma-Aldrich, Poole, UK
Sequencing kit (CEQTM DTCS-Quick Start) Beckman-Coulter, High Wycombe, UK
Sodium acetate Sigma-Aldrich, Poole, UK
Sodium chloride Sigma-Aldrich, Poole, UK
Sodium dodecyl sulphate Sigma-Aldrich, Poole, UK
Sodium hydroxide Sigma-Aldrich, Poole, UK
Storage plates Abgene, Epsom, UK
Streptavidin sepharose HP Amersham Biosciences, Little Chalfont, 
UK
Taq polymerase PCR kit Invitrogen BV, Renfrew, UK
Tris BDH, VWR International, Poole, UK
Tri-sodium citrate Sigma-Aldrich, Poole, UK
Washing buffer (pyrosequencing) Biotage AB, Uppsala, Sweden
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Table 42. List of apparatus used in this study and their suppliers.
Apparatus Supplier and Manufacturers.
ADP 1200/L balance Adam Equip. Co. Ltd., Milton Keynes, 
UK
Beckman CEQ8000 automated sequencer Beckman-Coulter, High Wycombe, UK
Beckman plate centrifuge Beckman-Coulter, High Wycombe, UK
CHEF DR®II apparatus pulsed field systems Bio-Rad, Hemel Hempstead, UK
Cyclone vortex mixer CM1 Nickel-Electro LTD., Weston-super- 
Mare, UK.
DNA subcell® GT agarose gel electrophoresis 
system
Bio-Rad, Hemel Hempstead, UK
Dri-block™ (DB-2D) Techme Ltd., Cambridge, UK.
Echotherm™ chilling/heating plate Torrey Pines Scientific, San Marcos, USA
Electrophoresis constant power supply for agarose 
gel electrophoresis
Amersham Biosciences, Little Chalfont, 
UK
Electrophoresis constant power supply (EPS 500- 
400)
Amersham Biosciences, Little Chalfont, 
UK
Electrophoresis constant power supply BioRad 
power pack 250
Bio-Rad, Hemel Hempstead, UK
Finnpipette micropipettes Thermo Life Sciences, Basingstoke, UK
Finnpipette multichannel pipettes Thermo Life Sciences, Basingstoke, UK
Gilson Pipetteman Anachem, Luton, UK.
Grant SBB6 steamer Grant Instruments, Cambridge, UK
H4 gel electrophoresis tank Bethesda Research Laboratories, Paisley, 
UK
Hybridisation oven ‘Shake and Stack’ Thermo Life Sciences, Basingstoke, UK
IEC micromax centrifuge Thermo Life Sciences, Basingstoke, UK
Mettler AE 240 balance Mettler-Toledo, Beaumont Leys, UK
Mini-sub™ DNA electrophoresis cell Bio-Rad, Hemel Hempstead, UK
Multipoint inoculator Mast Diagnostics, Merseyside, UK
P x 2 thermocycler Thermo Electron Corporation, 
Cambridge, UK
Pharmacia LKB vacugene XL Amersham Biosciences, Little Chalfont, 
UK
pH meter (Corning model 240) Corning Science Products, Corning, USA
Cont.
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Table 42. List of apparatus used in this study and their suppliers (cont.).
Apparatus Supplier and Manufacturers.
PSQ™ 96MA pyrosequencer Biotage AB, Uppsala, Sweden.
Rainin pipette lite LTS multichannel Anachem, Luton, UK.
Spectrophotometer (Densimat) Biomerieux, Basingstoke, UK
Thermomixer comfort MTP Eppendorf, Cambridge, UK
UV stratalinker 2400 Stratagene, California, USA.
Vacuum prep tool and workstation Biotage AB, Uppsala, Sweden.
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Table 43. Antibiotics used and their suppliers.
Antibiotic Supplier
Chloramphenicol Sigma
Ciprofloxacin Bayer
Clindamycin Sigma
Erythromycin Sigma
Fusidic acid Sigma
Linezolid Pfizer
Oxacillin Sigma
Quinupristin/dalfopristin Aventis
Rifampicin Sigma
Teicoplanin Aventis
Vancomycin Aventis
Fosfomycin Sigma
312
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